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 Characterization of GPI-specific antibody responses with carbohydrate microarrays. 
Plasmodium falciparum malaria affects about 500 million people worldwide and is responsible for 
approximately 2.5 million deaths per year. Drug resistance is a growing problem at a time when 
there is still no effective vaccine. Glycosylphosphatidylinositol (GPI) is the major anchor for 
membrane-associated proteins of P. falciparum and there is growing evidence that this glycolipid 
plays a major role as a toxin in the pathology of malaria. It has been postulated that antibodies 
against plasmodial GPI mediate anti-toxic and anti-disease immunity against malaria and that GPI 
could be a suitable component of a malaria vaccine. Lack of a reliable method for the 
characterization of anti-GPI antibodies has made it difficult to generate strong supportive data for 
this hypothesis. We have established carbohydrate microarrays based on synthetic P. falciparum 
GPI glycans to study antibody responses to different structural elements of this complex antigen. 
Results demonstrated, that only part of the total anti-GPI response in individuals from malaria 
endemic regions is associated with exposure to malaria. Microarray-based epitope analyses with 
truncated GPIs demonstrated differences in the fine specificity of anti-GPI antibodies in malaria-
exposed and non-exposed populations and showed evidence for a correlation between the presence 
of anti-GPI antibodies with a certain fine specificity and resistance to severe malaria. The GPI 
microarray was also a valuable screening platform for the selection of GPI specific B cell 
hybridomas. The monoclonal antibodies (mAbs) generated were used to evaluate biological 
activities of anti-GPI antibodies in functional assays. These unique mAbs represent new research 
tools that will facilitate characterisation of the GPI-anchored proteome of protozoan parasites. 
 Use of synthetic oligosaccharide to elicit Bacillus anthracis specific antibodies. Anthrax is 
an acute zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The recent use 
of B. anthracis spores as a biological weapon has stressed the need for efficient vaccines and 
detection systems. The similarity of spore cell surface antigens to other bacteria of the B. cereus 
group has made it difficult to create selective antibody-based detection systems. On the surface of 
B. anthracis spores a tetrasaccharide containing a novel monosaccharide (anthrose) has been 
discovered recently. Since anthrose was not found in spores of related strains of bacteria, we 
envisioned the detection of B. anthracis spores based on antibodies against anthrose-containing 
polysaccharides. Carbohydrate-protein conjugates containing the synthetic tetrasaccharide, an 
anthrose-rhamnose disaccharide or anthrose alone were employed to immunize mice. All three 
formulations were immunogenic and elicited IgG responses with different fine specificities. All sera 
and mAbs derived from tetrasaccharide immunized mice cross-reacted with spores of a panel of 
virulent B. anthracis strains, but also with some of the B. cereus strains tested. Although not strictly 
specific for B. anthracis spores, antibodies against the tetrasaccharide may have potential as 
immuno-capturing components for a highly sensitive spore detection system. 
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 Charakterisierung von GPI-spezifischen Antikörper-Antworten mit Kohlenhydrat-
Microarrays. Plasmodium falciparum Malaria betrifft weltweit etwa 500 Millionen Menschen und 
ist verantwortlich für zirka 2.5 Millionen Todesfälle pro Jahr. Medikamentenresistenz ist ein 
wachsendes Problem und derzeit gibt es noch keine wirksame Impfung. Membranassoziierte 
Proteine von P. falciparum werden hauptsächlich durch Glykosylphosphatidylinositol (GPI) 
verankert und vieles deutet darauf hin, dass dieses Glykolipid eine bedeutende Rolle als Toxin in 
der Malariapathologie spielt. Es wurde postuliert, dass GPI-spezifische Antikörper antitoxische- 
und antikrankheits- Immunität gegen Malaria vermitteln und dass GPI eine geeignete Komponente 
eines Malaria Impfstoffes sein könnte. Das Fehlen einer verlässlichen Methode zur 
Charakterisierung von anti-GPI Antikörpern hat die Validierung dieser Hypothese erschwert. Wir 
haben Kohlenhydrat-Microarrays basierend auf synthetischen P. falciparum GPI Glykanen 
etabliert, um Antikörperantworten gegen die verschiedenen strukturellen Elemente dieses 
komplexen Antigens zu untersuchen. Die Resultate zeigten, dass nur ein Teil der gesamten Anti-
GPI Antwort von Individuen aus Malaria endemischen Regionen mit Malariaexposition assoziiert 
ist. Microarray basierte Epitopanalysen mit verkürzten GPIs demonstrierten Unterschiede in der 
Feinspezifität von anti-GPI Antikörpern bei malariaexponierten und nicht exponierten 
Populationen. Die Analysen lieferten Evidenz für eine Korrelation zwischen der Präsenz von anti-
GPI Antikörpern einer bestimmten Feinspezifität und Resistenz gegen schwere Malaria. Der GPI 
Microarray fungierte auch als Plattform für die Selektion von GPI-spezifischen B Zell Hybridomen. 
Die generierten monoklonalen Antikörper (mAk) wurden verwendet um biologische Aktivitäten 
von anti-GPI Antikörpern in funktionellen Untersuchungen zu evaluieren. Diese mAk 
repräsentieren neue Forschungsinstrumente, welche die Charakterisierung des GPI verankerten 
Proteoms von parasitären Protozoen erleichtern werden.  
 Anwendung von synthetischen Oligosacchariden zur Herstellung von Bacillus anthracis 
spezifischen Antikörpern. Anthrax ist eine akute Zoonose verursacht durch sporenbildende B. 
anthracis Bakterien. Da B. anthracis Sporen als biologische Waffe benutzt wurden, werden 
effiziente Vakzine und Detektionsmethoden dringend benötigt. Die Ähnlichkeit von 
Sporenoberflächenantigenen zu anderen Bakterien der B. cereus Gruppe hat die Entwicklung von 
selektiven antikörperbasierenden Detektionssystemen erschwert. An der Oberfläche von B. 
anthracis Sporen wurde kürzlich ein Tetrasaccharid mit einem neuen Monosaccharid (Anthrose) 
entdeckt. Da Anthrose in Sporen von eng verwandten Bakterien nicht gefunden wurde, haben wir 
die Detektion von B. anthracis Sporen basierend auf Antikörpern gegen synthetische, 
anthrosehaltige Polysaccharide anvisiert. Kohlenhydrat-Protein Konjugate mit dem Tetrasaccharid, 
einem Anthrose-Rhamnose Disaccharid und Anthrose alleine wurden verwendet, um Mäuse zu 
immunisieren. Alle drei Formulierungen waren immunogen und induzierten IgG Antworten mit 
unterschiedlichen Feinspezifitäten. Alle Seren und mAk, abgeleitet von einer Tetrasaccharid 
immunisierten Maus, kreuzreagierten mit Sporen von virulenten B. anthracis Stämmen, aber auch 
mit einigen getesteten B. cereus Stämmen. Obwohl Antikörper gegen das Tetrasaccharid nicht strikt 
spezifisch für B. anthracis Sporen sind, haben sie Potenzial als immunologische Komponente für 
ein hoch sensitives Sporen-Detektionssystems.  
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1.1 Synthetic Oligosaccharides for Medical Applications 
 
 While nucleic acids and proteins are linear assemblies, carbohydrates are a highly complex 
and diverse class of biopolymers commonly found in nature as glycoconjugates such as 
glycoproteins and glycolipids (1). Oligosaccharide chains (glycans) are known to mediate many 
important biological functions. These include viral entry, signal transduction, inflammation, cell-
cell interactions, pathogen-host interactions, fertility, and development (2-9). All cells in nature are 
covered with a dense coating of glycans that is important for biological processes, but also for the 
binding of pathogens. Glycans may undergo cycles of evolutionary changes in which long-lived 
hosts may evade the more rapidly evolving pathogens that infect them by changing their glycan 
expression pattern, without compromising their own survival (10-12). This may explain the large 
structural variations of glycans in nature, which contribute to biological diversity and perhaps even 
speciation (12).    
 Our understanding of glycoconjugates is lagging behind advances in genomics and 
proteomics. Rapid advances in the field of glycomics have been hindered by the lack of general 
sequencing methods and difficulties in the isolation of oligosaccharides in pure form. But recently 
improved protocols for solution-phase oligosaccharide synthesis (13-15), as well as the use of 
automated carbohydrate assembly methods (1), have provided access to quantities of pure 
oligosaccharides sufficient for research applications. Synthetic carbohydrates allowed the 
development of novel tools that provide a molecular picture of biological processes involving 
carbohydrates. These tools include: monovalent fluorescent conjugates, neoglycoproteins, 
multivalent quantum-dot conjugates, affinitytagged saccharides, derivatized magnetic particles and 
latex microspheres, sepharose affinity resins, carbohydrate microarrays, and surface-plasmon 
resonance to probe carbohydrate–protein interactions (9). These techniques are now being applied 
for the development of carbohydrate-based diagnostics, vaccines and therapeutics.  
 Glycan microarrays, for example, are a low-cost platform to screen interactions involving 
carbohydrates in a high throughput manner. The chip-based format offers important advantages 
over conventional methods. These include the ability to screen several thousand binding events in 
parallel and the fact that a minimal amount of analyte and ligand are required. Assay 
miniaturization is particularly suitable for glycomics, as access to pure oligosaccharides is often the 
limiting factor (1, 9). The first carbohydrate arrays consisted of a variety of sugars deposited on a 
slide and were used to profile the glycan-binding specificity of fluorescently-labelled anti-
carbohydrate monoclonal antibodies, lectins and bacterial toxins (16-21). Carbohydrate arrays also 
found applications in diagnostics; the GloboH hexsaccharide cancer marker and analogs were 
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arrayed and used to test monoclonal antibodies and patient sera for GoboH-specific binding (22). A 
potently neutralizing antibody, 2G12, protects against viral challenge in animal models of HIV 
infection, by binding terminal Man α1-2Man residues on gp120 (23). Carbohydrate arrays have 
been developed to characterize the affinity and structural specificity of 2G12 mannose recognition 
compared with other mannose-binding or gp120-binding proteins to develop a carbohydrate 
template for HIV vaccine design (18, 24-25).  
 In addition to serving as tools, carbohydrates also hold great potential as vaccines. The cell 
surfaces of pathogens exhibit oligosaccharides that are often distinct from those of their hosts. 
Specific types of glycoconjugate are often more highly expressed on the surface of tumours than on 
normal cells (26). Such cell-surface carbohydrate structures may serve as basis for carbohydrate-
based detection systems and vaccines (27). Several antibacterial vaccines based on purified capsular 
polysaccharides or on neoglycoconjugates are now commercially available, such as vaccines against 
Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenza type b and Salmonella 
typhi (28). Synthetic access to oligosaccharides of infectious agents that are difficult to culture and 
isolate (such as Plasmodium falciparum and Bacillus anthracis) may lead to the development of 
new synthetic carbohydrate vaccines.   
 Glycomics has just gone beyond the initial proof-of-principle studies for diagnostics and 
therapeutic candidates. The knowledge gained from glycomics will become as important as a basis 
for the pharmaceutical industry as that discovered in the fields of genomics and proteomics (27).  
 
1.2 Glycosylphosphatidylinositol (GPI) Anchors in Malaria Pathogenesis and Immunity 
 
1.2.1 Plasmodium and Malaria 
 
 Malaria is transmitted to vertebrate hosts, such as rodents, monkeys and humans, by the bite 
of female Anopheles mosquitoes that are infected with protozoan parasites of the genus 
Plasmodium. Plasmodium belongs to the phylum of the Apicomplexa that contains other human and 
veterinary pathogens like Toxoplasma, Cryptosporidium, Eimeria, Babesia and Theileria. The 
inoculated sporozoite stage is transient and causes no pathology. Within a few minutes, sporozoites 
infect liver cells and undergo a period of intracellular replication, which is also clinically silent. 
After schizogony the parasite initiates blood-stage infection, which is responsible for the major 
symptoms and pathology of malaria, the most serious being anaemia and cerebral malaria (Fig. 1) 
(29). Four different species cause human malaria, Plasmodium falciparum and Plasmodium vivax 
accounting for the majority of morbidity and mortality (30). In areas of high malaria transmission, 
the burden of disease is borne by infants and young children. Overall patterns of disease depend 
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markedly on the age and the previous immunological experience of the host (31). Adaptive immune 
responses in the host limit the clinical impact of infection and provide partial, but incomplete, 
protection against pathogen replication; however, these complex immunological reactions can also 
contribute to disease and fatalities (29). 
 Malaria is possibly the most serious infectious disease of humans, infecting 5–10% of the 
world’s population, with 300–600 million clinical cases and more than 2 million deaths annually. 
Moreover, malaria is a major social and economic burden in endemic areas. There are multiple 
channels by which malaria impedes development, including effects on fertility, population growth, 
saving and investment, worker productivity, absence, premature mortality and medical costs (32). 
Widespread and increasing drug and insecticide resistance has exacerbated the situation, 
undermining the effectiveness of malaria control methods that depend on chemotherapy and vector 
control, respectively (33). Therefore, new approaches to combat malaria, such as vaccine 
development and/or discovery of novel therapeutic agents, are urgently needed (34-35). 
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Figure 1. The life cycle of Plasmodium falciparum. The complex live cycle of P. falciparum 
alternating between a female mosquito and the human host starts when sporozoites are injected 
during the bite of an infected mosquito. The sporozoites invade within a few minutes hepatocytes 
and after schizogony thousands of merozoites capable of invading red blood cells are released into 
the blood stream. Ring, trophozoite, schizont and merozoite stages are distinguished during the 
asexual blood stage developmental cycle. Maturating parasites produce adherent ligands allowing 
binding to receptors expressed by endothelial cells of blood vessels in organs such as the brain, 
lungs and placenta. After 48 hours, the parasitized red blood cells (PRBCs) rupture and release 
more merozoites. The presence of the parasite and the invasion of red blood cells might not be 
sufficient to account for disease; instead, the release of bioactive parasite molecules and an 
inappropriately regulated host immune response could be the main causes of fatal pathogenesis, 
which occurs in only a minority of patients. Some merozoites differentiate into gametocytes, which, 
when taken up by another feeding mosquito, perpetuate the sexual cycle in the insect (29). 
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1.2.2 Role of GPI in Malaria Pathogenesis 
 
 Binding of diverse endothelial cell-expressed receptors by P. falciparum Erythrocyte 
membrane protein 1 (EMP1) sequesters parasites in certain sites so that they are removed from the 
circulation and, consequently, do not travel to the spleen. This immunological effector organ 
efficiently filters PRBCs from the bloodstream (36). Although sequestration is advantageous for the 
survival of the parasite, this strategy has the pathological consequence of concentrating parasites in 
various vital organs. As sequestered parasites mature, they produce a variety of bioactive molecules 
that either upregulate or downregulate pathogenic processes. Immune responses to infectious insults 
are mainly initiated by the interaction of pathogen-associated molecular patterns (PAMPs) with 
receptors expressed by host cells. Many studies implicate glycosylphosphatidylinositol (GPI) of P. 
falciparum as a malaria PAMP and as a toxin (29).  
 It has long been recognized that factors endogenously produced by the host in response to 
parasite components contribute to the development of pathological conditions. Following his 
demonstration that malarial fever is synchronous with the developmental cycle of the blood-stage 
parasites, Camillo Golgi suggested already in 1886 that a toxin causes the malarial paroxysm. In 
1899 Robert Koch also deduced the existence of a toxin and proposed the development of anti-toxic 
or clinical immunity (37). Maegraith proposed that both fever and other pathological processes in 
malaria were the result of a parasite toxin. He further exemplified the toxic basis of severe malaria 
by reference to the clinical similarities to bacterial sepsis, understood to be caused by endotoxin, 
and suggested that malaria toxin exerts similar effects through the induction of endogenous 
mediators of host origin (38). 
 P. falciparum GPIs elicit a wide range of activities, which resemble those produced during 
malaria infection. The observed in vitro effects of GPIs include: production of acute-phase 
cytokines such as TNF and IL-1; insulin-like activity, causing hypoglycemia and triglyceride 
lipogenesis in adipocytes; expression of inducible nitric oxide synthase in macrophages and 
endothelial cells; and upregulation of surface expression of intercellular-adhesion molecule 1, 
vascular cell-adhesion molecule 1 and E-selectin in leukocytes and endothelial cells (37, 39, 40). 
Consistent with these findings, specific antibodies could efficiently block the bioactivities of GPIs 
(41). GPI-induced cellular activation is mediated mainly by TLR2, initiating the MAPK and NF-κB 
signaling pathways (40). These findings have been extended to other pathogens, e.g. Trypanosoma 
brucei, Trypanosoma cruzi and Trypanosoma gondii, confirming that GPIs act widely as pro-
inflammatory toxins in eukaryotic parasitism (42). The culmination of these studies was the recent 
demonstration that murine antibodies raised through immunization with a P. falciparum GPI glycan 
analogue completely abolished parasite lysate-induced TNF-α release from mouse macrophages 
(43). To extend that the in vitro model matches the clinical situation in humans, this is the most 
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suggestive evidence to date that GPIs are the predominant pro-inflammatory toxins of P. 
falciparum. However, at present, the evidence that P. falciparum GPIs act as toxins in humans in 
vivo is circumstantial (44).  
 
1.2.3 Structure, Recognition and Processing of P. falciparum GPIs 
 
 GPIs are a group of glycolipids that are expressed ubiquitously by eukaryotic cells (45). The 
primary role of GPIs is anchoring functionally important proteins onto cell surfaces, comprising 
molecules that provide barriers against immune attack and proteases, membrane property 
regulators, receptors, cell adhesion molecules, and cell surface hydrolases (46). In mammalian cells, 
GPI occurs in low abundance and is predominantly found in the protein-anchored form. In 
protozoan parasites, however, GPIs occur at relatively high levels both as moieties that anchor 
proteins and as glycolipids not attached to proteins (free GPIs). It is possible, although not yet 
proven, that it is the free GPIs released at the time of schizont rupture that are predominantly 
responsible for toxin-mediated effects. The glycan part of the GPI glycolipid consists of a 
conserved, linear 6-O-(ethanolamine-PO4)-a-Man-(1-2)-a-Man-(1-6)-a-Man-(1-4)-a-GlcNH2-(1-6)-
myo-inositol-1-PO4 core structure. GPIs from different organisms, species or cell types vary widely 
in the type of lipid moieties, inositol acylation, the extent of additional ethanolamine phosphate 
groups and sugar residues attached to the conserved glycan core (Fig. 2). These variations confer 
broad structural diversity and might impart a wide range of functional roles to GPIs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. GPI-anchor structure and possible modifications to Man3-GlucN oligosaccharide core. R1 
= Manα-(1-2); R2 = Phosphoethanolamine; R3 = Phosphoethanolamine; R4 = Gal4; R5 = GalNAcβ-
(1-4); R6 = Fatty acid at C2 or C3 of inositol. 
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 The GPI anchor is linked with the carboxy-terminus of proteins via the ethanolamine head. 
Biosynthesis of GPI precursors and posttranslational protein modification with GPI proceed in the 
endoplasmatic reticulum. After post-translational removal of the carboxy-terminal signal peptide 
the resulting new terminal carboxyl group is combined with the amino group of the ethanolamine 
residue of a GPI precursor molecule. Then the GPI-anchored proteins are transported to the Golgi 
complex and are finally inserted into the plasma membrane (47).  
 P. falciparum synthesizes two mature GPIs at the mid to late trophozoite stages, which were 
shown to be Man4-GlcN-PI and Man3-GlcN-PI (48-49). The structures of P. falciparum GPIs are 
heterogeneous with respect to fatty acid substitution on the glycerol and inositol residues (Fig. 3). 
Plasmodial GPIs from human and rodent malaria species demonstrate a high level of conservation 
in structure, which is also seen in widely dispersed geographical isolates of P. falciparum. To date, 
the GPIs of the other human malaria parasites have not been described. The structures of parasite 
GPI differ considerably from those of human GPIs and therefore, P. falciparum GPIs comprise 
epitopes that can be recognized by the mammalian immune system and their biosynthetic pathway 
might offer a specific target for the development of novel drugs against malaria.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The structures of P. falciparum GPIs: A) Man3-GlcN-PI and B) Man4-GlcN-PI (46, 48). 
 
 Initiation of immune responses to P. falciparum GPIs likely occurs during schizogony, 
when merozoites with GPI-linked surface proteins and free GPI are released. GPIs may activate 
antigen presenting cells (APC) and macrophages by TLR2 (40). Parasite material is internalized by 
APCs and after processing through the endosomal/lysosomal pathway, peptides are presented in 
association with MHC class II to T cells. Given the absence of peptide epitopes for T cells, antibody 
responses to free GPIs are likely to be T-cell-independent during a primary infection. During a 
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secondary response, activated GPI-specific B cells may internalise and process GPI-linked proteins 
and present peptides derived from these GPI-linked proteins to CD4+ T cells in the context of 
MHC-II. It is probable that T-cell help for GPI-specific B cells is provided by T cells recognizing 
peptide epitopes that are physically linked to GPI, leading to immunoglobulin class switching, 
somatic mutation and affinity maturation of the BCR and the generation of plasma cells and 
memory B cells. Alternatively, GPIs could also be presented to NK T cells by CD1 molecules, 
which are MHC-like molecules expressed on the surface of APCs (44).  
 
1.2.4 GPI-anchored proteins of P. falciparum 
 
 In addition to their putative roles as toxins, GPIs may indirectly contribute to malaria 
pathogenesis by anchoring protein determinants of parasite virulence. The surfaces of the various 
extra-cellular forms of the malaria parasite, the merozoite, gamete, ookinete, and sporozoite, are 
coated by different proteins that are either known or presumed to be GPI-anchored. Some of these 
proteins are well characterised including MSP-1 and MSP-2 on merozoites (50, 51), Pfs48/45 on 
gametes (52), Pfs25 and Pfs28 on ookinetes (53, 54), and CSP on sporozoites (55, 56). Most known 
blood-stage GPI-anchored proteins appear to be essential for growth as attempts to generate parasite 
“knock-out” mutants have failed (57) and several of them are prominent vaccine candidate antigens. 
 Genomic and proteomic studies suggest that only a minority of GPI-anchored surface 
proteins of P. falciparum has been discovered so far (58-60). The C-terminal sequences of known 
GPI-anchored proteins share the general characteristics of eukaryotic GPI anchor signals, namely a 
C-terminal stretch of 13-18 non-charged amino acids enriched with hydrophobic amino acids. The 
cleavage sites of three P. falciparum GPI anchor signal sequences are known (MSP-1, -2, and -4) 
(61). Despite this knowledge, very few P. falciparum proteins have been confirmed as possessing 
GPI anchors. Due to fatty acid acylation of inositol in the glycolipid structure, GPI-anchored 
Plasmodium proteins are resistant to cleavage by phosphatidylinositol-specific phospholipase C, 
thereby preventing the use of this common enzymatic identification method (48). To identify more 
GPI-anchored proteins of P. falciparum a combination of proteomic and computational approaches 
has been used. Focusing on the blood stages, proteomic analysis of proteins labelled with 
radioactive glucosamine identified GPI anchoring on 11 proteins ((MSP)-1, -2, -4, -5, -10, rhoptry-
associated membrane antigen, apical sushi protein, Pf92, Pf38, Pf12, and Pf34). Another nine lower 
abundance [3H]-glucosamine-labelled GPI-anchored proteins were also apparent at this life stage, 
but these remained unidentified. To predict the identity of these proteins as well as those present at 
other life stages, bioinformatic approaches were developed and predicted that the P. falciparum 
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genome encodes 30 GPI-anchored proteins (62). Since sporozoites cannot be cultivated in vitro, this 
approach cannot be applied for this development stage.  
 Analysis of the GPI-anchored proteome of different life stages of P. falciparum will form an 
important basis for further elucidation of the complex host-pathogen interactions in malaria. 
Characterisation of newly identified GPI-anchored proteins will contribute both to the 
understanding of host cell invasion mechanisms and the nature of anti-parasite immunity.  
 
1.2.5 Immunity to P. falciparum GPIs 
 
 Epidemiological studies show that, after the initial period in which children are susceptible 
to severe malaria, protective immunity to malaria develops in three sequential phases: first, 
immunity to life-threatening disease which operates despite high prevalence of parasitaemias; 
second, immunity to symptomatic infection which also occurs in the face of relatively high 
prevalence, incidence and density of infection; and only then, third, partial immunity to 
parasitization that limits parasite numbers, replication and burden within the host (29). Natural 
immunity to malaria is therefore thought to be a combination of anti-toxic and anti-parasitic 
immune responses. It appears that anti-toxic immunity, or anti-disease immunity may be distinct 
processes from anti-parasite immunity (63). The former are acquired both earlier and more easily. 
Anti-parasite immunity is difficult to achieve and unstable, meaning that ongoing exposure is 
required to maintain immunity (37).  
 One possibility is that anti-toxic immunity results in part from the acquisition of acquired 
immune responses to GPI. Young children are compromised in their ability to mount anti-
carbohydrate responses and this might contribute to their susceptibility to severe disease. In 
populations exposed to P. falciparum the antibody response to purified GPIs is characterised by a 
predominance of IgG over IgM and an increase in the prevalence, level and persistence of responses 
with increasing age (44). This has raised the possibility that these naturally occurring antibodies 
could neutralize GPIs and influence the outcome of human malaria. The relationship between anti-
GPI antibodies and clinical malaria has been evaluated in a number of studies. In children in 
Western Kenya a significant association was found between the presence of anti-GPI antibodies and 
reduced risk of severe anaemia. In contrast, people who were not exposed to the malaria parasite 
completely lacked anti GPI-antibodies (61). Subsequent cross-sectional studies reported no 
association between presence of anti-GPI antibodies and protection against mild clinical malaria 
(64), severe malaria (65) or maternal immunity (66); similarly, a prospective study also found no 
association between anti-GPI antibodies and resistance to clinical malaria (65). Conversely, in a 
recent study from Senegal, anti-GPI antibody concentrations were significantly lower in cerebral 
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malaria patients than in those with mild malaria (67), and anti-GPI antibodies were associated with 
markedly reduced risk of symptomatic infection in children of Javanese migrants to Papua (68).  
 One plausible explanation for the variable results of epidemiological studies resides in the 
fact that GPIs are not readily amplifiable from natural sources, and their purification often yields 
heterogeneous material. In addition, some of the protocols used to measure anti-GPI antibody levels 
may be suboptimal: the extracted GPI material was immobilized non-covalently via unspecific 
interactions to ELISA plates and subsequently washed with detergent-containing buffer. These 
conditions favor an uncontrolled loss of material with resulting loss of sensitivity and specificity of 
the assay. To date, however, there is little evidence to show that the antibody responses measured 
correlate with protection against clinical malaria or disease severity and clearly, this area requires 
considerable further investigation. The use of fully synthetic GPIs will help dispel any doubt that 
the responses measured are specific, and combining clinical studies with functional assays (such as 
toxin neutralisation) will provide the clearest outcomes (44). 
 
1.2.6 Prospects for Anti-GPI Vaccination 
 
 Vaccination is an elegant way to induce an adaptive immune response in non-immune 
individuals by confronting the immune system with crucial antigenic determinants of a pathogen 
without the deleterious effects of disease. Despite decades of research, an effective vaccine against 
malaria has remained elusive. There are, however, several lines of evidence to suggest that 
protective immunity to malaria is possible. Repeated infection of an individual with malaria leads to 
the gradual acquisition of naturally acquired immunity (sect. 1.2.5). Immunization with irradiated 
sporozoites has been shown to result in partial or complete protection in mice (69), monkeys (70) 
and humans (71) from experimental malaria challenge with viable sporozoites. Further, passive 
transfer of purified immunoglobulins from immune individuals can protect children with acute 
infection (72). However, key obstacles to the development of a malaria vaccine include the lack of 
immune correlates of protection, the lack of reliable and predictive animal models, and the 
developmental and antigenic diversity and variability of the parasite.  
 Nevertheless, development of a vaccine against malaria that reduces morbidity and mortality 
has long been seen as an essential component of a sustainable malaria control strategy. The majority 
of subunit-vaccine candidates, whether against sporozoites, liver-stages, gametocytes, merozoites or 
trophozoite blood-stages, target proteins expressed either on the surface or within invasion 
organelles of these life-stage, and would provide clinical protection indirectly, by killing the 
parasite or by reducing replication and hence parasite burden. All these strategies face similar 
problems, e.g. redundancy in invasion pathways, antigenic diversity, antigenic variation, 
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immunosuppression, immune evasion strategies and problems of MHC-linked genetic restriction in 
the immune response to these antigens (37). A multivalent multi-stage approach may thus be 
required. 
 The use of vaccines against the disease aims to reduce morbidity and mortality directly, by 
immunizing individuals with parasite products that contribute to host pathology. In this case, the 
death of the parasite is not a necessary objective in fulfilling of the aims of the vaccine (37). 
Chemical synthesis of the glycan group of P. falciparum GPI has recently provided a means to test 
the hypothesis that this molecule is causally involved in the pathogenesis of P. berghei infection. 
Mice immunized against the GPI glycan were substantially protected against severe malarial 
pathology, including cerebral syndrome, acidosis and pulmonary oedema, and fatality. The noted 
protection was independent of any reduction in parasitaemia (43). These findings indicate that GPI 
is an essential parasite product in the pathogenesis of systemic disease and the lethal syndromes, at 
least in this model. GPI may therefore also contribute to pathogenesis and fatalities in humans. This 
data provide pre-clinical proof-of-principle for the development of an anti-toxic vaccine against 
malaria. However, vaccination targeted at GPIs in humans raises safety concerns that vaccinated 
individuals with malaria would feel less sick and thus present to hospital later and with high levels 
of parasitaemia, with the attendant risks of severe anaemia and organ failure. Inhibition of GPI-
mediated early pro-inflammatory cytokine responses that limit parasite growth may also favour 
rapid raises in parasitaemia in vaccinated individuals (73). Thus, although the preclinical data 
indicate a role for GPI in severe pathogenesis, it still remains to be determined whether anti-toxic 
vaccines can be deployed alone (where they may prevent or delay severe pathology) or whether the 
vaccine needs to be given in combination with an effective anti-parasite vaccine (in order to prevent 
the possibility that, if acute clinical symptoms are effectively suppressed, cases may take longer to 
present for treatment) (74).  
 
1.3 Anthrose for Anthrax Detection 
 
1.3.1 Bacillus anthracis and Anthrax 
 
 The fifth and sixth plagues in the Bible’s book of Exodus may have been outbreaks of 
anthrax, caused by Bacillus anthracis. B. anthracis is derived from the Greek word for coal, 
anthrakis, because of the black skin lesions it causes. This obligate pathogen exists in two forms, 
the vegetative form and the spore. The vegetative form is a facultatively anaerobic, large, Gram-
positive bacillus, which, under adverse growth conditions, forms a single endospore. The spores are 
remarkably resistant to a range of adverse environmental conditions, e.g. temperature, desiccation, 
pH, chemicals, or irradiation, thus ensuring long-term survival (75). Anthrax is a zoonosis whose 
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natural reservoir may be considered to be the soil. There is no animal reservoir, because infected 
animals rapidly die. Anthrax is a disease largely of mammalian herbivores, which acquire their 
infection through ingestion of contaminated soils. Secondary spread may occur directly to 
scavenger animals, via flies contaminating vegetation, or via biting flies (Fig 4). If spores are 
ingested, disease begins in the intestinal tract, with subsequent development of septicemia. In the 
case of scavenger animals that eat dead animals, the disease results from infection by vegetative 
organisms. Illness in animals progresses rapidly, and often the first sign of anthrax is the discovery 
of dead animals (76).  
 
 
Figure 4. Cycle of infection in anthrax. The spore is central to the cycle, although infection can also 
be acquired through uptake of the vegetative forms when humans or carnivores eat meat from an 
animal that died of anthrax or when biting flies transmit the disease (75). 
 
 Outbreaks in animal populations are prevalent and widespread. An outbreak in Iran caused 
the death of 1 million sheep in 1945; an epidemic in South Africa and Namibia between 1984 and 
1989 killed thousands of wild animals; 19 outbreaks in 1996 in Nepal affected 222 animals; 1.570 
cases of anthrax in cattle in China were reported in 1996; the death of 204 livestock in Australia 
was reported in 1997; and 1.612 outbreaks occurred between 1991 and 1996 in India. Cattle and 
sheep are the usual victims and have a mortality rate of 80%, though horses and swine are also 
affected. Wild animals, including deer, many rodents, toads, and cat species are at risk, while frogs, 
rats and adult dogs are largely resistant (77, 78). 
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 Once in the host, spores are phagocytized by macrophages and are carried to the lymph 
nodes, during which time they germinate and multiply. As the capacity of the lymph nodes is 
exceeded, the bacteria then enter the blood stream and eventually cause septicemia. The principal 
virulence factors of B. anthracis are its capsule and two exotoxins, all of which are coded on one of 
two plasmids, the pX01 and pX02 plasmids. Both plasmids are necessary for full virulence; loss of 
either results in an attenuated strain. Sterne, such an attenuated strain, carries pX01 and therefore 
can synthesise exotoxin, but does not have a capsule. The poly-D-glutamic acid capsule inhibits 
phagocytosis of vegetative cells and is also poorly recognized by the host’s immune system. The 
anthrax toxin is composed of three proteins known as protective antigen (PA), lethal factor (LF), 
and edema factor (EF). These proteins must act cooperatively, with PA containing the cell-binding 
domain, and either LF or EF causing cell toxicity. PA binds to receptors on the surface of most cell 
types, though macrophages are typically most affected. PA is then activated by proteolytic cleavage 
which leaves a 63-kDa fragment (PA63) attached to the receptor. The loss of the 20-kDa fragment 
(PA20) triggers heptamer formation by receptor-bound PA63 and exposes a hydrophobic patch on 
each monomer of PA63, which can then bind to either EF or LF in a competitive manner. The 
formation of the PA63 heptamer induces endocytosis and concurrent transport of EF or LF into the 
cell. Edema toxin produces tissue edema, inhibits neutrophil activity, and interferes with production 
of TNF and IL-6 by monocytes. Lethal toxin interferes with intracellular signaling by inactivating 
mitogen-activated protein kinase. Lethal toxin also stimulates the release of TNF and Il-1 from 
macrophages, which may contribute to death in anthrax toxemia (78-80).  
 
1.3.2 Anthrax in Humans 
 
 The major sources of human anthrax infection are direct or indirect contact with infected 
animals, or occupational exposure to infected or contaminated animal products. Accidental human 
infection by B. anthracis is rare; in the 1980s, there were only 2.000 estimated annual worldwide 
cases (77, 78). It is believed that approximately 80% of reported cases of anthrax infection were due 
to industrial exposure, with the majority of the remaining cases being caused by agricultural 
exposure. Widespread use of vaccines in high risk populations of animals and humans, as well as 
improvements in industrial hygiene have minimized such occurrences in industrialized nations (78, 
81, 82).  
 Anthrax is classified as a disease by the route of exposure, as exposure to spores via 
cutaneous, inhalation, or oral ingestion has different pathological consequences. Cutaneous anthrax 
is the most common type, with an estimated 2.000 cases reported annually worldwide. The largest 
epidemic occurred in Zimbabwe in 1979-1985, when more than 10.000 human cases were reported 
(83). Cutaneous anthrax occurs at the site of inoculation of spores into the skin via an abrasion, cut 
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or possible insect bite. Cutaneous anthrax causes mortality in approximately 20% of cases if not 
treated, but is entirely treatable with appropriate antibiotics. Cutaneous anthrax begins as a pruritic 
papule that becomes vesicular, and then necrotic, often accompanied by significant edema, 
consistent with the expression of the toxin at the site of infection. A characteristic painless black 
edematous lesion develops, and then resolves in 1 to 2 weeks. Most cases of cutaneous anthrax 
resolve spontaneously. The most deadly form of anthrax is pulmonary anthrax, or inhalational 
anthrax, which results from the inhalation of airborne spores (78). Inhalational anthrax develops 
slowly over a period of 1–6 days and causes general malaise, coughing, and fatigue followed by 
more serious respiratory distress. Death is reported to occur within 24-36 h after respiratory distress 
begins (78, 79). Even with early intervention, the prognosis of patients with inhalational anthrax is 
poor: inhalational anthrax has a mortality rate nearing 100%. Gastrointestinal anthrax is the rarest 
form of natural anthrax and outbreaks are continually reported mostly in Africa and Asia, following 
ingestion of insufficiently cooked contaminated meat. Gastrointestinal anthrax causes initial 
gastroenteritis with progressively worsening abdominal complications including severe diarrhoea, 
abdominal pain, and vomiting of blood. Late-stage gastrointestinal anthrax leads to bowel 
perforation and toxemia resulting in death within 2–5 days. Gastrointestinal anthrax has been 
reported to cause fatalities in 25–60% of cases. Fortunately, B. anthracis is sensitive to a variety of 
antimicrobials. The effectiveness of treatment depends on the route of exposure and the time of 
diagnosis. Antibiotic treatment is highly effective in cases of cutaneous anthrax resulting in 
sterilization of the lesions within 24 hours and resolution within a few weeks. Typical antibiotics 
include ciprofloxacin, doxycycline, and penicillin. However, once the infection is established, 
successful medical intervention is difficult as the infection becomes refractory to treatment (78).  
 Although anthrax is susceptible to antibiotics, vaccination would be the most efficient and 
cost effective form of mass protection. An attenuated B. anthracis strain, isolated by L. Pasteur in 
1881, was used successfully in animals as the first live bacterial vaccine (84, 85). The Sterne 
attenuated spore vaccine, based on an avirulent non-encapsulated 34F2 strain is still used as a live 
veterinary vaccine (86). In contrast to the former USSR and China, live spore vaccines have not 
been adopted for human use in Western countries due to fears concerning residual pathogenicity 
(86, 87). The current U. S. vaccine for anthrax has been licensed since 1972 and was developed 
based on the outcome of human trials conducted in the 1950s (88). This vaccine, known as anthrax 
vaccine adsorbed (AVA), consists of a culture filtrate from an attenuated strain of B. anthracis 
(V770-NP1-R) adsorbed to aluminum salts as an adjuvant. The principal antigenic component of 
AVA is PA antigen, with smaller amounts of EF and LF. A similar culture supernatant-derived 
human vaccine is produced in the United Kingdom. The UK vaccine is from the animal vaccine 
Sterne strain (89). The vaccine is licensed to be given in a six dose series over an 18-month period. 
Chapter 1: Introduction 
 15 
In a study, using a monkey model, inoculation with this vaccine at zero and two weeks was 
completely protective against an aerosol challenge at eight and 38 weeks and 88% effective at 100 
weeks (90). Although the current vaccines available provide effective protection, they do suffer 
from several problems, namely: lack of standardisation, the relatively high expense of production, 
the requirement for repeated dosing, and the associated transient side effects (91). Much of the work 
on generating a second generation vaccine is based on the observation that antibodies to PA are 
crucial in the protection against exposure to virulent anthrax spores. Antibodies to PA are thought to 
prevent binding to its cellular receptor and subsequent binding of LF and EF, which are required 
events for the action of the two toxins. Protective immunity in key animal models can be generated 
by vaccination with recombinant PA, as well as spores and DNA plasmids that express PA. 
Although antibodies to PA address the toxemia component of anthrax disease, antibodies to 
additional virulence factors, including the capsule or somatic antigens in the spore, may be critical 
in development of complete, sterilizing immunity to anthrax exposure (92).  
 
1.3.3 Anthrax as Biological Weapon: Need for Rapid-Detection Methods 
 
 Bioterrorism is defined by the intentional or threatened use of microorganisms or toxins 
derived from living organisms to cause death or disease in humans, animals or plants on which we 
depend. The other major point is to generate fear in the population (93). Many such agents are 
zoonotic and could have a considerable impact on agriculture as well as on human health. Anthrax 
is seen as one of the most likely biological agents for use as a weapon. B. anthracis spores are quite 
stable in the environment, can be transmitted by aerosolisation and cause inhalational anthrax that 
has a high mortality rate. It has been estimated that 50 kg of B. anthracis spores released over an 
urban population of 5 million would sicken 250.000 and kill 100.000 (94). This would almost 
certainly lead to a rapid total breakdown in medical resources and civilian infrastructures.   
 Its applicability for use in biological warfare has been proven throughout the 20th century. 
During World War I, Germany used B. anthracis to infect livestock during transhipment. In 1941 
the British Government began testing the effect of anthrax on sheep on the Scottish island of 
Gruinard. Due to the durability of the spores the island was declared safe only in 1990 after 
decontamination using formaldehyde (83). Japan infected prisoners and contaminated the 
waterways and food supplies of various Chinese cities with B. anthracis between 1932 and 1945 
(95). The United States has weaponised anthrax spores, as did other countries in the 1950s and 
1960s. This was evidenced by the accidental aerosol release of B. anthracis spores from a Soviet 
military microbiology facility in Sverdlovsk in the former Soviet Union in April 1979. This was the 
largest known outbreak of inhalational anthrax in the 20th century: 68 of the 79 patients with 
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inhalational anthrax died (96). In more recent times, B. anthracis has also become a threat from 
terrorist groups. The cult of Aum Shinrikyo in Japan tried on several occasions to disperse anthrax 
unsuccessfully in Tokyo in the mid 1990s, but they used an attenuated vaccine strain (83). The most 
recent biological warfare attack was the deliberate release of B. anthracis in the United States 
shortly after the terrorist attacks of 11 September 2001. This terrorist act caused 22 cases of anthrax, 
including 5 deaths. To prevent future attacks B. anthracis biology and pathogenesis has been 
studied in search for improved vaccines and detection methods (93).  
 Due to the potential of B. anthracis for use as an agent of bioterrorism, its occupational 
exposure, and the persistence of spores in the environment, the development of rapid and accurate 
detection methods are needed. Aside from these exposure factors, rapid diagnosis of anthrax is 
necessary since the infection is difficult to diagnose (78). Specific detection of B. anthracis is 
challenging, due to its genetic similarity to other bacteria of the B. cereus group, which comprises 
B. cereus, B. anthracis, B. thuringiensis, and B. mycoides (97). Genomic studies on strains of B. 
anthracis, B. cereus and B. thuringiensis have suggested that B. anthracis and B. thuringiensis are 
sub-species of the species B. cereus. The main difference between these sub-species is the presence 
of plasmids coding for insecticidal toxins in B. thuringiensis and the presence of the capsule and 
toxin plasmids in B. anthracis (78). Although it is not possible to discriminate between species by 
16S rRNA sequencing, B. anthracis can be clearly distinguished using a range of DNA-based 
approaches such as amplified fragment length polymorphism, variable number tandem repeat 
(VNTR) and multilocus sequence typing (MLST) (98, 99). In addition, although B. anthracis is one 
of the most molecular monomorphic bacteria known, all known strains have been separated into 
five categories (allowing for geographical identification) on the basis of variable numbers of 
tandem repeats in the variable region of the VrrA gene (100). Individual isolates can now be typed 
on the basis of single-nucleotide polymorphisms (101). These PCR-based assays and traditional 
phenotyping of bacteria are the most accurate detection systems but are also complex, expensive, 
and slow. Therefore, there is a pressing need to develop novel methods for rapid, simple, and 
precise detection of B. anthracis. Currently, anthrax detection research is mainly based on nucleic 
acid detection, immunoassays and mass spectrometry.  
 
1.3.4 Unique Anthrose carried by the Exosporium Glycoprotein BclA   
 
 All members of the Bacillus genus produce endospores as part of their life cycle. It is not 
possible to determine the identity of spores by casual or morphological examination and therefore, 
identification and classification of spore species have focused on the vegetative form of these 
organisms (sect. 1.3.3). The mature B. anthracis spore contains a central, genome-containing 
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compartment called the core and three prominent protective layers called the cortex, coat, and 
exosporium (102). The cortex, which is adjacent to the core, is composed of a thick layer of 
peptidoglycan (103). The cortex is covered by the spore coat, which contains approximately 30 
different proteins (104). The exosporium consists of a paracrystalline basal layer and an external 
hair-like nap. As the outermost layer, the exosporium serves as the primary permeability barrier of 
the spore and as the source of spore surface antigens (102, 105). In addition, the exosporium 
interacts with the soil environment, with spore-binding cells in the mammalian host, and with host 
defenses. The formation of the exosporium during sporulation is a complex and energy-consuming 
process. As such, it is unlikely that this structure would be maintained by the bacterium unless it 
was important for survival. The pressure to maintain the exosporium is probably related to some 
aspect of infection because most non-pathogenic Bacillus spores do not possess a well-developed 
exosporium (106).  
 The glycoprotein Bacillus collagen-like protein of anthracis (BclA) is the structural 
component of the hair-like nap and has been shown to be an immunodominant protein suggesting a 
role for this protein in spore-host interactions (105). BclA has conserved amino- and carboxy-
termini and a long, central collagen-like region that is similar to mammalian collagen proteins (107, 
108). This polymorphic collagen-like region consists of GXX repeats, including a large proportion 
of GPT triplets, and (GPT)5GDTGTT repeats. The latter 21-amino-acid repeat has been named 
BclA repeat (107) and appears to be an essential feature of the BclA protein important for the 
structural organization of BclA on the spore surface. The number of GXX repeats in the collagen-
like region found in different naturally occurring B. anthracis strains varies from 17 to 91 (105, 
107, 108). The length of this region is proportional to the length of the hair-like nap, which varies 
from 140 to 608 Å (108). The bcla gene is also present in the genome of B. cereus and B. 
thuringiensis (109).  
 The BclA protein is extensively glycosylated with two O-linked carbohydrates, a 715-Da 
tetrasaccharide and a 324-Da disaccharide (110). Multiple copies of the tetrasaccharide are linked to 
the collagen-like region of BclA, whereas the disaccharide may be attached outside of this region. 
Most of the collagen-like region repeating units contain a threonine residue that provides sites for 
potential glycosylation via a GalNAc linker. It was assumed that BclA glycosylation plays an 
important role, since glycosylation requires many genes and enzymes and it occurs when the cell is 
starved for nutrients. For other prokaryotic glycoproteins, several different functions for 
glycosylation have been proposed, including the maintenance of protein conformation, heat 
stability, surface recognition, resistance to proteolysis, enzymatic activity, cell adhesion, 
agglutination, and immune evasion (110). Using NMR, mass spectrometry, and other analytical 
techniques, the structure of the tetrasaccharide was recently elucidated as 2-O-methyl-4-(3-
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hydroxy-3-methylbutamido)-4,6-dideoxy-β-D-glucopyranosyl-(1→3)-α-L-rhamnopyranosyl-
(1→3)-α-L-rhamnopyranosyl-(1→2)-L-rhamnopyranose. A unique characteristic of this glycan is 
the previously undescribed terminal sugar (i.e. 2-O-methyl-4-(3-hydroxy-3-methylbutamido)-4,6-
dideoxy-D-glucose), the so called anthrose. Since anthrose was not found in spores of the B. cereus 
T strain and a B. thuringiensis ssp. kurstaki strain, anthrose may be useful for species-specific 
detection of B. anthracis spores or as a new target for therapeutic intervention (110). 
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2.1 Goal 
 
 To contribute to the development and evaluation of synthetically produced carbohydrate 
antigens of infectious agents as vaccine components and tools in biomedical research.  
 
2.2 Objectives  
 
1. To develop a novel carbohydrate microarray based on synthetic Plasmodium 
falciparum GPI glycans 
 
2. To assess levels and fine specificities of anti-GPI antibodies in healthy and malaria 
exposed cohorts with the carbohydrate microarray 
 
3. To select GPI specific B-cell hybridomas with the carbohydrate microarray 
 
4. To evaluate biological activities of the produced monoclonal anti-GPI antibodies 
 
5. To use synthetically produced Bacillus anthracis spore glycan antigens to produce 
monoclonal antibodies that allow spore detection 
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Abstract 
 
 Parasite glycosylphosphatidylinositol (GPI) is an important toxin in malaria disease, 
and people living in malaria-endemic regions often produce high levels of anti-GPI 
antibodies. The natural anti-GPI antibody response needs to be understood to aid the design 
of an efficient carbohydrate-based antitoxin vaccine. We present a versatile approach based 
on a synthetic GPI glycan array to correlate anti-GPI antibody levels and protection from 
severe malaria. 
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 Malaria kills more than two million humans every year, most of them African infants under 
the age of two. While children living in malaria-endemic regions seem to develop immunity to 
severe malaria after only a few infections1, immunity to infection is acquired much later2. Natural 
immunity is therefore thought to be a combination of antitoxic and antiparasitic immune responses, 
and lack of antitoxic immunity may represent a key factor responsible for the vulnerability of 
infants to severe malaria. GPI has emerged as a central toxin that induces the expression of many 
host genes implicated in malaria pathogenesis2. As for other parasitic diseases, such as 
trypanosomiasis and toxoplasmosis, certain pathogenic features may be caused by parasite GPI 
glycans3,4. 
 GPIs anchor proteins in the membranes of all eukaryotic cells5 and constitute up to 90% of 
protein glycosylation in protozoan parasites6. A considerable fraction of GPI appears at the plasma 
membrane without protein attachment as free GPI (ref. 7). The glycan part of the GPI glycolipid 
consists of a conserved, linear 6-O-(ethanolamine-PO4)-Man-α(1-2)-Man-α(1-6)-Man-α(1-4)-
GlcNH2-α(1-6)-myo-inositol-1-PO4 core structure. Serological studies using GPIs purified from 
Plasmodium falciparum have indicated that sera from malaria-endemic regions contain naturally 
occurring anti-GPI antibodies5,8,9,10. However, it is not clear to what extent the development of anti-
GPI immune responses is related to malaria exposure, and there is a growing interest to assess the 
relevance of the anti-GPI immune response for protection against malaria disease. A recent study 
with a rodent malaria model showed that a GPI-based vaccine candidate substantially reduces 
malaria mortality11. However, evidence for a correlation of anti-GPI antibody levels and antitoxic 
immunity against severe malaria in humans is missing. One explanation for this lack of data resides 
in the fact that GPIs are not readily amplifiable from natural sources, and their purification often 
yields heterogeneous material. Several studies using bulk-purified GPIs from cultured parasites in 
ELISA experiments have yielded contradictory results5,8,9,10. Moreover, some technical aspects of 
those studies remain questionable. GPIs are amphiphilic molecules and therefore are poorly soluble 
in pure alcohol. However, lyophilized GPI-containing fractions from the studies mentioned 
above5,8,9,10 were resolubilized in pure methanol. In addition, the GPI material was immobilized 
noncovalently via unspecific interactions to ELISA plates and subsequently washed with detergent-
containing buffer. These conditions favor an uncontrolled loss of material and might in part explain 
the inconsistency of the results obtained. Here, we present a versatile method based on microarrays 
of covalently attached synthetic GPI glycans for parallel screening of multiple sera on a single slide. 
 We developed a high-throughput screening platform by spotting picomolar amounts of 
synthetic GPI glycan fragments of different lengths on the surface of glass slides (Fig. 1). Each 
synthetic molecule was spotted in quadruplicate in order to ensure reproducibility of the results. In 
addition, the molecules were arrayed to create 64 identical screening units on a single glass slide. 
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The printed glass slides were then assembled to a 64-well screening platform with an adhesive 
gasket on the surface of the slide (Supplementary Methods and Supplementary Fig. 1 online). The 
amount of synthetic molecule immobilized (5–10 pg) and the volume of the test sample (5 µl) make 
this platform an excellent tool for screening large numbers of serum samples. To validate the 
printing of carbohydrates on the microarray, we immobilized decreasing concentrations of 
oligosaccharide 6 on microarray slides and incubated the slides with fluorescein isothiocyanate 
(FITC)-labeled ConA. We observed a linear correlation between the concentration of GPI 6 and 
binding to ConA. This confirms the direct relation between the concentration of the sample and the 
amount of immobilized carbohydrate (Supplementary Methods and Supplementary Fig. 2 online). 
 Analysis of synthetic P. falciparum–related GPI glycans of different lengths revealed a 
length-dependent binding of the GPI glycan to paired serum samples collected from healthy 
subjects in a malaria-endemic region in both wet and dry seasons (Fig. 2a–f). Glycan fragments 
containing less than five carbohydrate units (1, 2, 3) showed virtually no binding to the serum 
samples tested, whereas longer glycans (4, 5, 6, 7) all showed substantial bindings (Fig. 2a–f). This 
result suggests that a pentasaccharide likely represents the minimal epitope for naturally elicited 
anti-GPI antibodies. 
 Sera taken from individual subjects living in the same malaria-endemic area diverged 
substantially in the fine specificity of anti-GPI antibodies, as illustrated by some examples (Fig. 2a–
f). Though some sera contained antibodies that only recognized the GPIs with a phosphate 
ethanolamine group on the third mannose (Fig. 2b,e), most other sera reacted with all Man3- and 
Man4-GPIs (4, 5, 6, 7). Paired samples taken in a 6-month interval from the same donors revealed a 
notable stability of individual anti-GPI antibody response patterns, irrespective of overall antibody 
level increase (Fig. 2a–e) or decrease (Fig. 2e,f). To validate the microarray method, we performed 
comparative serum titration experiments in ELISA versus microarray-based analysis with 12 
selected sera and found good correspondence of results (Supplementary Methods and 
Supplementary Fig. 3 online). 
 In a more detailed analysis, we assessed the antibody levels of serum samples collected from 
malaria-exposed and non-exposed populations to the two structurally distinct GPI glycans with or 
without the ethanolamine phosphate group (Man4-GPIs 6 and 7, and Man3-GPIs 4 and 5) of P. 
falciparum. Sera from malaria-exposed adult Africans had high IgG levels against Man4-GPIs 6 and 
7, and substantial reactivity was observed against the Man3-GPIs 4 and 5, although the mean 
antibody level was lower than that observed against the Man4-GPIs (Fig. 2g). Thus, the fourth 
mannose was identified as a key recognition element for many GPI-reactive antibodies. The 
phosphate ethanolamine group on the third mannose generally does not have an important role in 
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binding. Mean antibody levels against GPI glycans 4 and 6, which lack this appendage, were only 
slightly lower than those against compounds 5 and 7, respectively. 
 Surprisingly, most sera of malaria-unexposed Caucasian adults also contained IgG that bind 
to the Man4-GPIs 6 and 7 (Fig. 2h). In contrast to sera from malaria-exposed Africans, no 
significant reactivity with the Man3-GPIs 4 and 5 was observed (Fig. 2h). Both Man3-GPI 5 and 
Man4-GPI 7 have been found on P. falciparum blood-stage parasites12,13. The ratio of the two 
structurally distinct molecules may vary during intra-erythrocytic development14. Only Man4-GPI 
serves as anchor for surface proteins such as MSP-1 and MSP-2 (ref. 13). P. falciparum Man3-GPI, 
like some Toxoplasma gondii GPIs, may primarily exist as the free glycolipid on the parasite cell 
surface. Screening with microarrays of structurally defined synthetic GPIs demonstrates that both 
structures comprise epitopes that can be recognized by the human immune system. This finding 
indicates that the Man4-GPI response represents a broader anti-GPI response probably also 
involving some nonmalarial species, whereas the Man3-GPI response might represent a more 
specific antimalarial GPI response. 
 The difference in the anti-Man3-GPI response between African and European sera may 
represent a response to nonmalarial parasites found only in Africa. To address this point, we 
hypothesized that if anti-Man3-GPI responses are primarily elicited by malaria parasites, whereas 
anti-Man4-GPI antibodies arise from exposure to a variety of pathogens, a malaria infection in 
previously unexposed individuals should boost a pre-existing anti-Man4-GPI B-cell response and 
should also elicit a de novo anti-Man3-GPI response. In support of this hypothesis we observed an 
increase in pre-existing anti-Man4-GPI (6 and 7) IgG levels and the development of a substantial 
anti-Man3-GPI (4 and 5) antibody response in Caucasian volunteers involved in a sporozoite 
challenge vaccine trial (Fig. 2i). This finding is even more noteworthy when considering that 
antimalaria chemotherapy started immediately after the first microscopic detection of blood-stage 
parasites. These results demonstrate that even one subclinical malaria infection can have a profound 
effect on the overall anti-GPI antibody level and on the reactivity pattern. 
 Our approach provides more detailed insights than those obtained with antigens extracted 
from parasite preparations. Anti-GPI fine specificity patterns likely reflect exposure to a variety of 
pathogens and mirror the general epidemiological situation of a population. Therefore, anti-GPI 
antibody levels measured with GPI isolated from P. falciparum parasites critically depend on the 
ratio of Man3- and Man4-GPI in the antigen preparations. The ratio of mean anti-Man3-GPI and 
anti-Man4-GPI antibody levels may represent a marker for the relative intensity of malaria 
exposure. 
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 The immune system of children under two years of age is unable to produce antibodies to 
many carbohydrate antigens unless the sugars are conjugated to a carrier protein15. Lack of 
antibodies to GPI in small children may stem from the fact that a free glycolipid (rather than the 
protein-GPI conjugates) is predominantly responsible for induction of anti-GPI antibodies9. We 
observed that a specific response against the Man3-GPI, presumably the free form of GPI in P. 
falciparum, was built up after host contact with the malaria parasite. The observation that European 
control subjects also showed a substantial anti-Man4 response poses an important question, as the 
origin of that response could be of major importance for the design of a GPI-based antitoxin malaria 
vaccine. A possible explanation is that the anti-Man4-GPI response in malaria-unexposed subjects 
may arise as a result of an infection with nonmalarial parasites or even fungi rather than 
representing autoimmune response. The question of whether an antitoxic immune response to 
malarial GPI provides protection against malaria remains open. However, the novel microarray-
based approach reported here addresses most technical challenges that have hampered previous 
work and allows for a more accurate analysis of samples. 
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Figures 
 
Figure 1. Synthetic GPI glycans for microarray construction. Seven synthetic GPI glycans (1-7) 
were arrayed as quadruplicates in 64 identical screening units on a glass slide coated with bovine 
serum albumin to build a GPI glycan microarray. 
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Figure 2. Analysis of serum samples using synthetic GPI glycan microarray. (a–f) Temporal 
stability of individual anti-GPI IgG response patterns in donors living in a malaria hyperendemic 
region of Ghana. Representative results from six donors are shown to demonstrate the diversity and 
temporal stability of the fine specificity of individual anti-GPI responses. Paired samples from 
blood donations of the same donor taken at the end of the low-transmission dry season (dry) or at 
the end of the high-transmission wet season (wet) are compared. (g,h) IgG levels against synthetic 
GPI compounds 1-7 in sera from cohorts of African donors living in a malaria-endemic area (g) and 
from malaria non-exposed Europeans (h). Each data point represents one serum; bars indicate the 
mean antibody level. (i) Increase in mean serum IgG levels against synthetic GPI compounds after 
experimental P. falciparum sporozoite challenge of malaria non-exposed Europeans. Sera were 
taken before (Pre) or after (Post) experimental challenge. Each data point represents one serum; 
bars indicate the mean level. 
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Supporting Information 
 
SI-Fig. 1: An adhesive gasket containing 64 chambers was adapted to the printed glass slide to 
build a 64-well screening device where the bottom of each well contains a single screening unit. 
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SI-Fig. 2: Validation of array printing. Binding of FITC-labeled ConA to a series of decreasing GPI 
6 concentrations.  Error bars represent standard deviations from paired data. 
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SI-Fig. 3: Validation of the microarray data by comparative serum titration experiments in ELISA 
versus microarray-based analysis. Shown are results obtained with serial dilutions of human sera 
(1:100; 1:300; 1:900; 1:2700) from three selected malaria-exposed donors  (D1: low responder; D2: 
high responder; D3: non responder) that were analysed in parallel in GPI 7 immobilized ELISA 
plates and on a microarray slide. 
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Supplementary Subjects, Materials & Methods Section     
 
 Carbohydrate synthesis: Carbohydrates with a terminal sulfhydryl-containing linker were 
prepared as previously described1. The terminal sulfhydryl-containing linker provided a handle for 
covalent immobilization of the structures to a maleimide-modified surface.     
 
 Functionalization of slides: Microarray slides were functionalized as previously 
described2, briefly aldehyde slides (Genetix) were immersed in phosphate buffered saline (1xPBS, 
50 mL) containing 1% BSA (w/v) and incubated overnight at room temperature.  The slides were 
rinsed twice with distilled water (100 mL) and twice with 95% ethanol  (50 mL), then dried under a 
stream of dry argon. Subsequently, the slides were immersed in anhydrous DMF (45 mL; Aldrich) 
containing 6-Maleimidohexanoic acid Nhydosuccinimide ester (40 mg; Aldrich) and N, N-
diisopropylethylamine (100 mM; Fluka). The slides were incubated in this solution for 24 h at room 
temperature, washed four times with 95% ethanol (50 mL), and stored in a vacuum dessicator until 
use.     
 
 Printing and validation of slides: A volume of 3 nL of a 10 mM solution of synthetic GPI-
glycan in PBS were deposited on the surface of the slide to form each microarray spot using a 
Genetix array printer (Genetix). The slides were subsequently incubated in a humid chamber for 
24h before being quenched with 1mM b-mercaptoethanol for 2h at room temperature. The slides 
were then washed three times with water and stored in a dessicator. Stored slides were stable for at 
least two months without changes in the reproducibility of the experiments.  
 To validate the printing of carbohydrates on the microarray, decreasing concentrations of 7 
were immobilized and subsequently incubated with FITC-labelled ConA. A linear correlation 
between the concentration of GPI-Man4 (7) and binding to ConA was observed to confirm the 
immobilization (see SI-Fig. 2). Comparative serum titration experiments in ELISA versus 
microarray-based analysis, performed with 12 selected sera, validated the microarray data (see SI-
Fig. 3:  for prototypical data).     
 
 Enzyme-linked immunosorbent assay (ELISA): Reacti-BindTM maleimide activated clear 
strip plates (PIERCE; Rockford, USA) were coated with l00 mL of a 50 mM solution of synthetic 
GPI. Wells were then blocked with 5% milk powder in PBS for 1 h at room temperature followed 
by three washings with PBS containing 0.05% Tween-20.  Plates were then incubated with three-
fold serial dilutions of human serum in PBS containing 0.05% Tween-20 and 0.5% milk powder for 
2 h at room temperature. After washing, the plates were incubated with alkaline phosphatase-
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conjugated F(ab')2 fragment goat anti-human IgG (γ-chain specific) antibodies (Jackson 
ImmunoResearch  Laboratories, West Grove, USA) for 1 h at room temperature and then washed.  
Phosphatase substrate (1 mg mL -1 p-nitrophenyl phosphate (Sigma)) in buffer (0.14% Na2CO3, 
0.3% NaHCO3, 0.02% MgCl2, pH 9.6) was added and incubated at room temperature. The optical 
density (OD) of the reaction product was recorded after appropriate time at 405 nm using a 
microplate reader (Titertek Multiscan MCC/340, Labsystems, Finland).     
 
 Subjects: Control (pre-immune) sera from malaria naive individuals were obtained from 
healthy adult Caucasian volunteers aged 18-45 years from the Basel area participating in a Phase I 
clinical trial approved by the Basel Research Ethics Committee (Genton et al, in press). The effect 
of sporozoite challenge was analyzed with sera from healthy malaria naive adult Caucasian subjects 
aged 18–50 years from the Oxford area recruited for a vaccine trial (Thompson, FM et al., 
submitted). Volunteers underwent experimental challenge with the chloroquine-sensitive 3D7 strain 
of P. falciparum through bites by infected laboratory-reared Anopheles stephensi mosquitoes. The 
study received ethical approval from the Oxfordshire Research Ethics Committee. Serum samples 
from malariaexposed individuals were taken from adult African volunteers aged 18-50 years and 
serial serum samples came from 9–22 years old volunteers from the Kassena Nankana District of 
northern Ghana.      
 
 Analysis of sera: Spotted microarray slides were covered with FlexWell-64 (GRACE BIO-
LABS) layers. Wells were then blocked with 5% milk powder in PBS for 1 h at room temperature 
followed by three washings with PBS containing 0.05% Tween-20.  The wells were subsequently 
incubated with human serum diluted 1:100 in PBS containing 0.05% Tween-20 and 0.5% milk 
powder for 2 h at room temperature. After washing, the slides were incubated with CyTM3-
conjugated affinity-pure F(ab`)2 fragment goat anti-human IgG (Fcγ-fragment specific) antibodies 
(MILAN ANALYTICA AG) for  1 h at room temperature and then washed. Dried slides were read 
on a GenePixTM Personal 4100A (Axon Instruments) Microarray-scanner at a wavelength of 
532nm. The resulting picture was quantitative analysed with GenePixTM Pro 6 software. 
Background fluorescence intensity from spotted buffer without carbohydrates was subtracted to GPI 
signals for each individual microarray slide. 
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Abstract 
 
 Glycosylphosphatidylinositol (GPI) glycolipids abound on the cell surface at the merozoite 
stage of Plasmodium falciparum life cycle and are a central toxin in malaria. The level at which the 
host adaptive immune response to GPI contributes to protection against malaria pathology remains 
unclear. Attempts to correlate anti-GPI antibody levels and pathology yielded contradictory results. 
Here, we present the application of a novel carbohydrate microarray based on synthetic PfGPI 
glycans to assess levels and fine specificities of anti-GPI responses in healthy and malaria diseased 
individuals as well as the age dependent development of anti-GPI responses in malaria exposed 
children. Anti-GPI antibodies were only rarely found in children under the age of 18 months. Sera 
from subjects with severe malaria and healthy children contained antibodies that recognized 
predominantly synthetic Man3-GPI and Man4-GPIs. In contrast, an inverted length-dependent fine 
specificity of antibodies to GPI-glycans was observed in children with mild malaria. These sera also 
recognized substantially the most truncated GPIs included in the analysis, glycans comprising 
glucosamine-inositol moieties without or with one or two coupled mannose residues. This sub-
population of anti-GPI antibodies may be involved in protection against the development of severe 
malaria pathology. 
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Introduction 
 
 Glycosylphosphatidylinositols are evolutionary conserved glycolipids found in the outer cell 
membranes of virtually all eukaryotic cells from vertebrates to protozoa (1) and constitute up to 
90% of protein glycosylation in protozoan parasites (2). The glycan part of the GPI glycolipid 
consists of a conserved, linear 6-O-(ethanolamine-PO4)-a-Man-(1-2)-a-Man-(1-6)-a-Man-(1-4)-a-
GlcNH2-(1-6)-myo-inositol-1-PO4 core structure. Although evolutionarily conserved, species-
dependent branching of the GPI core structure results in unique GPI molecules comprising epitopes 
that can be recognised by the mammalian immune system (3). GPIs anchor a diverse range of 
proteins to the surface of Plasmodium falciparum, but may also exist free of protein attachment (4-
6). As for other parasitic diseases, such as trypanosomiasis and toxoplasmosis, certain pathogenic 
features may be caused by parasite GPI-glycans (7, 8). In vitro and in vivo studies have established 
plasmodial GPI as potent activator of the host immune system and as inducer of pro-inflammatory 
cytokines (9-11). Although inflammatory cytokines are beneficial in controlling and eliminating 
parasites, excessive production of these cytokines, particularly TNF-α, is thought to play a 
significant role in aggravating clinical symptoms which may lead to severe malaria. 
 In populations exposed to P. falciparum, the antibody response to purified GPIs is 
characterized by an age-dependent development that correlates with the acquisition of immunity to 
severe malaria (12). Therefore it has been postulated that antibodies against plasmodial GPI mediate 
anti-toxic and anti-disease immunity against malaria and that GPI could be a suitable component of 
a malaria vaccine. In the present report we show the application of a novel carbohydrate microarray 
based on synthetic PfGPI glycans to assess levels and fine specificities of anti-GPI responses in 
healthy and malaria diseased individuals as well as the age dependent development of anti-GPI 
responses in Tanzanian children. 
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Material and Methods 
 
 Subjects. The study was conducted in Ifakara, Tanzania from June to September 2003 as 
described in (13). Samples were collected from children (aged 3 to 60 months) presenting with 
malaria at the hospital. Severe malaria cases were defined according to the World Health 
Organization criteria for severe malaria (14). Uncomplicated malaria was defined as the presence of 
asexual P. falciparum, an axillary temperature of >37.5°C, or symptoms of headache or myalgia but 
no other signs of severe malaria. Exclusion criteria were confirmed coinfection, malnutrition (mid-
upper-arm circumference [MUAC] of <12 cm), or antimalarial treatment during the last 14 days. 
Asymptomatic children (presence of P. falciparum, axillary temperature of <37.5°C, and no other 
symptoms) were age-matched as closely as possible to patients by convenience sampling in the 
same area in 2006. Ethical clearance was obtained from the Ifakara Health Research and 
Development Centre's scientific review board and the Medical Research Coordinating Committee 
of the National Institute for Medical Research in Tanzania. 
 
 Synthetic GPI microarray. Carbohydrates with a terminal sulfhydryl-containing linker were 
prepared as previously described (15). The terminal sulfhydryl-containing linker provided a handle 
for covalent immobilization of the structures to a maleimide-modified surface. Functionalization 
and printing of slides were performed as previously described (3). Briefly aldehyde slides (Genetix 
Ltd, Hampshire, UK) were immersed in PBS containing 1% BSA (w/v) and incubated overnight at 
room temperature. The slides were rinsed twice with distilled water and twice with 95% ethanol, 
then dried under a stream of anhydrous argon. Subsequently, the slides were immersed in anhydrous 
DMF (Aldrich, St. Louis, Mo.) containing 1mg/mL 6-Maleimidohexanoic acid N-hydosuccinimide 
ester (Aldrich, St. Louis, Mo.) and N,N-diisopropylethylamine (100 mM; Fluka, St. Louis, Mo.). 
The slides were incubated in this solution for 24 h at room temperature and washed four times with 
95% ethanol. A volume of 3 nL of a 10 µM solution of synthetic GPI-glycan in PBS were deposited 
on the surface of the slide to form each microarray spot using a Genetix array printer (Genetix Ltd, 
Hampshire, UK). The slides were subsequently incubated in a humid chamber for 24h before being 
quenched with 1mM β-mercaptoethanol for 2h at room temperature. The slides were then washed 
three times with water and stored in a dessicator. Microarrays were validated with FITC-labelled 
ConA and comparative serum titration experiments in ELISA versus microarray-based analysis, 
yielding good correspondence of results (9). Stored slides were stable over two months without 
alteration in the reproducibility of the experiments. 
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 Microarray-based immunoassay. Spotted microarray slides were covered with FlexWell-64 
(GRACE BIO-LABS, Bend, OR) layers. Microarray wells were blocked with 0.5% milk powder in 
PBS for one hour at room temperature followed by three washings with PBS containing 0.01% 
Tween-20. Afterwards wells were incubated with human serum diluted 1:100 for two hours at room 
temperature. After washing, slides were incubated with indocarbocyanine dye-conjugated affinity-
pure F(ab')2 fragment goat anti-human IgG (Fcγ-fragment specific) antibodies (MILAN 
ANALYTICA AG) for one hour at room temperature and washed again. Dried slides were read on 
a GenePixTM Personal 4100A (Axon Instruments, Sunnyvale, CA) Microarray-scanner at a 
wavelength of 532nm. The resulting picture was quantitatively analysed with GenePixTM Pro 6 
software. Background fluorescence intensity from spotted buffer without carbohydrates was 
subtracted to GPI signals for each individual microarray slide. 
 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting. Aliquots of lysed P. falciparum blood stage parasites were mixed with loading 
buffer (1.7 ml of 0.5 M Tris-HCl [pH 6.8], 2 ml of glycerol, 4.5 ml of 10% sodium dodecyl sulfate, 
1 ml of β-mercaptoethanol, 0.8 ml of bromophenol blue [0.3%, wt/vol]) and heated 10 min at 95°C 
before loading on SDS-10% PAGE minigels. As a molecular weight marker, SeeBluePlus 
(Invitrogen) was used. Separated proteins were transferred electrophoretically to nitrocellulose filter 
(Protean Nitrocellulose, BA 85; Schleicher & Schuell) by semidry blotting. Blots were blocked with 
PBS containing 5% milk powder and 0.1% Tween 20 overnight at 4°C and then incubated with 
human serum diluted 1:200 for 2 h. After several washing steps, blots were incubated with goat 
anti-human IgG horseradish peroxidase conjugated Ig (Bio-Rad Laboratories, Hercules, Calif.) for 1 
h. Blots were developed using the ECL system according to manufacturer's instructions. 
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Results 
 
 Effect of age on the acquisition of high anti-GPI IgG responses. Serum samples collected in 
Ifakara (Tanzania) from children aged 3-60 months (Table 1) with uncomplicated or severe malaria 
or healthy controls were analysed on synthetic GPI microarrays spotted with seven PfGPI analogues 
(Fig. 1). Fluorescence values for the samples from small children aged 3-18 months (for GPI 6: 
median = 1708; range = 0-12531) were significantly lower than those for the samples from children 
aged 19-60 months (for GPI 6: median = 3700; range = 0-61301) (Mann-Whitney U, P < 0.0001) 
(Fig. 2). In addition, high anti-GPI IgG responses to all synthetic glycans were only rarely found in 
children under the age of 18 months, even in those with acute malaria infection. Regression analysis 
including all ages demonstrated a modest correlation between anti-GPI 6 and 7 antibodies and age 
in children with severe malaria (r2 = 0.125, P = 0.010 for GPI 6; r2 = 0.096, P = 0.026 for GPI 7) but 
not for the shorter glycans.  
 In accordance, while serum samples from healthy Tanzanian infants involved in a vaccine trial 
had no significant anti-GPI IgG antibody levels, sera from their mothers contained antibodies that 
bound to Man3- and Man4-GPIs (Fig. 3). In immunoblotting experiments with lysates of P. 
falciparum blood stage parasites, serum samples of healthy mothers stained series of protein bands 
over a broad range of molecular weights, indicating the presence of a strong anti-protein antibody 
response (Fig. 4A). In comparison to their mothers the infants showed low antibody levels to P. 
falciparum proteins.  
 Sera of a GPI seropositive mother and her GPI seronegative child taken at 2.5 months of age 
showed a comparable binding pattern in Western blot analysis (Fig. 4B). Five months later the 
humoral immune response of the child to P. falciparum lysates changed considerably to a novel 
response pattern. These results suggest that although the mother possessed naturally acquired anti-
protein and anti-GPI antibodies, maternally transmitted P. falciparum-specific antibodies were 
predominantly directed against protein antigens. 
 
 Levels and fine specificities of anti-GPI responses in healthy and malaria diseased 
individuals. In microarray analysis sera from subjects with severe malaria and healthy children 
contained antibodies that recognized predominantly the GPIs 5, 6 and 7 (Fig. 5). Only for GPI 7 the 
mean level of IgG antibody was significantly higher in children with severe malaria than in healthy 
controls (P = 0.0041). In contrast, an inverted length-dependent fine specificity of antibodies to P. 
falciparum-related GPI-glycans was observed in children with mild malaria, since these sera also 
recognized substantially the most truncated GPIs (GPIs 1 to 4) without a phosphate ethanolamine 
group. While the mean level of IgG antibody to GPIs 1, 2, 3 and 4 was significantly (see Table 1 for 
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P values) higher in children with mild malaria than in children of the two other cohorts, the mean 
fluorescence values to GPIs 5, 6 and 7 were significantly (see Table 1 for P values) higher for 
samples from children with severe malaria than for samples from subjects with uncomplicated 
malaria.      
 Selected GPI positive and negative serum samples from the three categories of individuals 
were analysed in Western blot analysis with total lysates of unsynchronized P. falciparum blood 
stage parasites. Serum samples that had microarray fluorescence signals less than 2000 for all 
synthetic GPI glycans were considered as GPI seronegative. All tested GPI seropositive samples 
yielded person-specific multiple band staining patterns independent of their clinical condition (Fig. 
6). Reactivity and patterns obtained with serum samples from healthy GPI seronegative children 
were comparable to those of GPI responder. In contrast, mild and severe malaria diseased GPI 
seronegative children had lower antibody levels to P. falciparum lysates, especially children with 
uncomplicated malaria showed a markedly reduced anti-protein response.        
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Discussion 
 
 GPI of P. falciparum may be involved in the pathogenesis of malaria. Attempts to correlate 
anti-GPI antibody levels and pathology using purified GPI from cultured parasites have yielded 
contradictory results (12, 16, 17). Assuming that the preparations used were pure and free from 
contaminants, this inconsistency in results may reside in the fact that GPIs are heterogeneous and 
difficult to isolate from their natural sources. Therefore, anti-GPI antibody levels measured with 
extracted GPI critically depend on the ratio of Man3- and Man4-GPI in the antigen preparations. 
Concerns over the purity of GPI preparations derived from P. falciparum can be effectively 
abolished using fully synthetic GPIs for a more accurate analysis of serum samples. We are 
applying carbohydrate microarrays based on synthetic P. falciparum GPI to study antibody 
responses to different structural elements of this complex antigen. In a previous study, microarray-
based serological analyses with synthetic GPIs demonstrated differences in the fine specificity of 
anti-GPI antibodies in malaria-exposed and non-exposed adult populations, indicating that anti-
Man3 GPI responses are primarily elicited by malaria parasites, while anti-Man4 GPI antibodies 
may arise in response to exposure to a variety of pathogens (3).  
 In this study we applied the novel and validated carbohydrate microarray to assess levels and 
fine specificities of anti-GPI responses in healthy and malaria diseased individuals. Sera from 
Tanzanian subjects with severe malaria and healthy children contained antibodies that recognized 
predominantly Man4-GPIs and Man3-GPI with a phosphate ethanolamine group. Strikingly, a 
significant different antibody response was found in patients with mild malaria, since these sera 
recognized substantially the most truncated GPIs without a phosphate ethanolamine group. Presence 
of these antibodies in a proportion of subjects with mild malaria and lack in children with severe 
disease may suggest that this sub-population of anti-GPI antibodies is involved in protection against 
the development of severe malaria pathology. Anti-Man4 antibodies are present in malaria 
unexposed as well as exposed populations and it is possible that these antibodies recognize 
functionally irrelevant epitopes, predominantly protein-bound sub-population of parasite GPI 
molecules.  
 P. falciparum GPIs occur at relatively high levels both as moieties that anchor proteins and as 
glycolipids not attached to proteins (free GPI) (6). The fine specificity of monoclonal antibodies 
(mAbs) produced against synthetic GPI and their reactivity with parasite expressed GPI in 
immunfluorescence analysis (IFA) and with GPI anchors of parasite protein in Western blotting 
correlated (18). Intense staining of P. falciparum and Trypanosoma brucei parasites in IFA and 
Western blotting analysis was only obtained with mAbs that also bound strongly to the most 
truncated GPI-1, the glycan comprising glucosamine-inositol moieties without mannose residues. 
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GPI-specific mAbs recognising more complex epitopes with mannose sugars coupled to the 
glucosamine-inositol moiety showed reduced binding to parasite-derived GPI in IFA and Western 
blotting, probably due to sterical hindrance. Thus, naturally occurring antibodies cross-reactive with 
truncated GPIs found only in children with uncomplicated acute malaria may have better access to 
parasite GPIs, resulting in more effective anti-GPI neutralizing activity.       
 Acquired immunity to malaria relates also to IgG responses against protection-associated 
protein antigens. Therefore selected serum samples of the three categories of individuals in the 
same age range were analysed in Western blot analysis with lysates of P. falciparum blood stage 
parasites. Interestingly, GPI seropositive samples independent of their clinical condition correlated 
with a substantial anti-protein IgG response. In contrast to GPI seronegative healthy children, 
seronegative mild and severe malaria diseased individuals had lower antibody levels to P. 
falciparum lysates. These results indicate, that an acute malaria infection decreases at some stage 
serum antibody levels due to binding of parasite-specific immunoglobulins to their antigens.  
 Although regression analysis demonstrated only modest correlations between GPI specific IgG 
levels and age, high anti-GPI antibody responses were only rarely found in children under the age 
of 18 months, even in those with acute malaria infection. It is well known that the immune system 
of children under two years of age has a reduced capacity to produce antibodies to certain 
carbohydrate antigens. In humans IgG molecules of all subclasses, but with different efficiencies, 
cross the placenta and confer passive immunity to the newborn (19, 20). In malaria endemic areas, 
young children are thought to be protected against malaria attack during the first few weeks of life 
partially by transplacentally acquired antibodies (19). Our results indicate that GPI specific IgGs are 
less effective maternally transmitted than anti-protein antibodies, which may contribute to the 
relative protection by killing the parasite or by reducing replication and hence parasite burden. 
 The synthetic GPI microarray-based approach allowed more differentiated insights than could 
be obtained with extracted GPI for the role of anti-GPI antibodies in antitoxic immunity to malaria. 
Our results argue for a protection-associated role of a sub-population of anti-GPI IgGs cross-
reactive with truncated PfGPI glycans against the manifestations of severe malaria. Thus, 
glucosamine-inositol moieties coupled with one or two mannose sugars may be the functional 
relevant epitopes accessible for protective anti-GPI antibodies. However, a direct role for anti-GPI 
antibodies of the same or another fine specificity in neutralizing parasite toxins involved in malaria 
pathogenesis remains to be demonstrated. The observations summarized here are of major 
significance for the design of a GPI-based anti-toxic malaria vaccine candidate aiming to reduce 
childhood mortality in malaria endemic regions.  
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Figures 
 
Fig. 1. A: Structures of the seven synthetic GPI-glycans (1-7) that were printed on a BSA-coated 
glass slide to build a GPI-glycan microarray. B: Example microarray image after incubation with 
human serum diluted 1:100. C: Spotting order of the seven GPI-glycans that were arrayed as 
quadruplicates in 64 identical screening units on a single slide. 
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Fig. 2. Effect of age on the acquisition of high anti-GPI IgG responses. Shown are anti-GPI-6 IgG 
levels from Tanzanian children with severe or mild malaria or healthy controls. Data are expressed 
as absolute fluorescence at 532 nm for samples at s serum dilution of 1:100.   
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Fig.3. Anti-GPI-6 responses of healthy Tanzanian infants and mothers. Shown are IgG levels 
expressed as fluorescence at 532 nm in serial serum samples from infants aged 2.5, 7.5, and 9 
months and mothers diluted 1:100. Horizontal lines indicate mean levels of anti-GPI response.  
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Fig. 4. A: Western blotting analysis with serum samples from healthy Tanzanian infants aged 2.5, 
7.5, and 9 months and mothers using parasite lysates of P. falciparum blood stage cultures. Each 
lane represents serum from one individual donor at a dilution of 1:200. B: Immunoblotting analysis 
of sera of a mother and her child at 2.5 and 7.5 months of age.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Anti-PfGPI antibodies in antitoxic immunity to malaria 
 54 
Fig. 5 Anti-GPI IgG levels and fine specificities of children with severe or uncomplicated malaria 
or healthy controls. Shown are IgG responses to each synthetic GPI compound expressed as 
fluorescence at 532 nm in serum samples diluted 1:100 from Tanzanian children with severe (s) or 
uncomplicated (m) malaria or healthy (h) controls. Horizontal lines indicate mean levels of anti-GPI 
response.  
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Fig. 6. Western blot analysis of the reactivity of sera from children with severe or mild malaria or 
healthy controls with P. falciparum K1 blood stage lysates. Each lane represents serum from one 
individual GPI seronegative or seropositive donor. All serum samples were used at a dilution of 
1:200. 
 
 
 
 
 
 
 
Chapter 4: Anti-PfGPI antibodies in antitoxic immunity to malaria 
 56 
Table 1. Anti-GPI IgG responses of Tanzanian children with severe or uncomplicated malaria or healthy 
controls 
 
Condition No. of Median age in anti-GPI IgG antibodies1    comparisons2   
  children mths (range) GPI  mean  median range h-vs-m h-vs-s m-vs-s 
 
healthy 50  24 (4-60)  GPI-1 2267  2177  0-4742 0.0008 
mild  87  26 (3-60)  GPI-1 8929  2855  0-57708   n.d. 
severe 52  29 (6-60)   GPI-1 1545  1333  0-13364     0.0002 
 
healthy      GPI-2 1770  1743  0-4339 0.0001 
mild       GPI-2 9095  1952  0-48747   n.d. 
severe      GPI-2 628  427  0-5214     0.0001 
       
healthy      GPI-3 1944  1345  0-19379 0.0067 
mild       GPI-3 6706  1920  0-58944   0.4989 
severe      GPI-3 2741  738  0-43579     0.0361 
       
healthy      GPI-4 2591  1506  0-35195 0.0224 
mild       GPI-4 7924  1676  0-60086   0.7259 
severe      GPI-4 3052  1046  0-55193     0.0408 
 
healthy      GPI-5 5124  1736  0-56585 0.4429 
mild       GPI-5 3723  458  0-55705   0.0968 
severe      GPI-5 10112 1348  0-61930     0.0116 
 
healthy      GPI-6 10219 3739  0-60994 0.0531 
mild       GPI-6 5480  1690  0-60553   0.539 
severe      GPI-6 12265 3929  0-61301     0.0082 
 
healthy      GPI-7 5286  2156  0-39710 0.8095 
mild       GPI-7 4820  764  0-58363   0.0041 
severe      GPI-7 13731 3648  0-58389     0.0008 
 
1 Antibody responses are expressed in fluorescence at 532nm 
2 Two-sided t-test (P < 0.05) between healthy (h) children or children with mild (m) or severe (s) malaria; grey 
 shaded when means are significant different  
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Abstract 
 
 Glycosylphosphatidylinositol (GPI) glycolipids of plasmodial parasites are involved in 
malaria pathogenesis and there is evidence that anti-GPI antibodies can protect against severe 
malaria. We are using synthetic GPIs to characterise humoral immune responses against this 
dominant malaria toxin. Here we have generated GPI-specific B-cell hybridomas from mice 
immunized with a synthetic GPI glycan conjugated to a carrier protein. When hybridoma cell 
culture supernatants were screened with microarrays spotted with seven complete or truncated 
versions of synthetic P. falciparum GPI, monoclonal anti-GPI antibodies (mAbs) with different 
antigen binding patterns were identified. In immunofluorescence assays intense staining of P. 
falciparum and Trypanosoma brucei parasites was only obtained with antibodies that also bound 
strongly to the most truncated structure included in the analysis, a glycan comprising glucosamine-
inositol moieties without mannose residues. Cross-reactivity of the anti-GPI mAbs with GPI 
anchors of proteins of plasmodial and trypanosomal parasites was demonstrated by Western blotting 
analysis. In P. berghei and T. brucei rhodesiense mouse infection models passive immunisation 
with anti-GPI mAbs did not reduce parasite in vivo multiplication and no delay of fatalities was 
observed. This is the first detailed description of the properties of anti-GPI mAbs. These new 
research tools will facilitate characterisation of the GPI-anchored proteome of protozoan parasites. 
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Introduction 
 
 Malaria is a debilitating and frequently fatal disease of the tropics caused by parasites of the 
genus Plasmodium. P. falciparum is responsible for the vast majority of deaths from malaria.[1] The 
complex live cycle of P. falciparum alternating between a female mosquito and the human host 
starts when sporozoites are injected during the bite of an infected mosquito. The sporozoites invade 
hepatocytes and after schizogony thousands of merozoites capable of invading red blood cells are 
released into the blood stream. Ring, trophozoite, schizont and merozoite stages are distinguished 
during the asexual blood stage developmental cycle. This stage is responsible for the major 
symptoms and pathology of malaria, the most serious being anaemia and cerebral malaria. In recent 
years, malaria has spread at an alarming rate owing to the increasing resistance of the parasite to 
drugs, and the resistance of mosquitoes to insecticides. Therefore, new approaches to combat 
malaria, such as vaccine development and/or discovery of novel therapeutic agents, are urgently 
needed.[2-4] 
 Glycosylphosphatidylinositols (GPIs) are ubiquitous molecules that anchor proteins in the 
membrane of virtually all eukaryotic cells from protozoa to vertebrates[5-8] and constitute up to 90% 
of protein glycosylation in protozoan parasites. The glycan part of the GPI glycolipid consists of a 
conserved, linear 6-O-(ethanolamine-PO4)-Man-α(1-2)-Man-α(1-6)-Man-α(1-4)-GlcNH2-α(1-6)-
myo-inositol-1-PO4 core structure. Although evolutionarily conserved, species-dependent branching 
of the GPI core structure results in unique GPI molecules comprising epitopes that can be 
recognised by the mammalian immune system.[9] 
 The most prevalent form of protein glycosylation in malaria parasites is the C-terminal 
addition of a GPI membrane anchor.[10] The surfaces of the various extra-cellular forms of the 
malaria parasite, the merozoite, gamete, ookinete, and sporozoite, are coated by different proteins 
that are either known or presumed to be GPI-anchored. Some of these proteins are well 
characterised including MSP-1 and MSP-2 on merozoites,[11,12] Pfs48/45 on gametes,[13] Pfs25 and 
Pfs28 on ookinetes,[14,15] and CSP on sporozoites.[16,17] Genomic and proteomic studies suggest that 
only a minority of the GPI-anchored surface proteins of this parasite have been identified so far.[18-
20] GPI-anchored proteins are crucially involved in host-parasite interactions and several of them are 
regarded as key candidate antigens for a multi-valent subunit malaria vaccine.  
 There is growing evidence that the GPIs of protozoan parasites display diverse biological 
activity and contribute to parasite-associated pathogenesis. Among the bioactive molecules 
produced by the P. falciparum parasites, GPI has emerged as a central toxin that induces the 
expression of many host genes implicated in malaria pathogenesis. In particular the induction of 
pro-inflammatory cytokines by GPIs appears to be an important element in the development of 
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severe malaria.[21-23] Natural semi-immunity developed by individuals living in areas of high 
malaria transmission is thought to be a combination of anti-toxic and anti-parasitic immune 
responses and lack of anti-toxic immunity may represent a key factor responsible for the 
vulnerability of infants to severe malaria. Anti-GPI antibodies have been proposed as mediators of 
malaria “anti-disease” immunity since the age-dependence of their development correlates with the 
acquisition of immunity to severe malaria.[24] Toxin-neutralisation assays using anti-GPI antibodies 
have yielded controversial results.[25-27] However, the proof of concept for GPI as an anti-toxic 
component for a malaria vaccine was demonstrated with a vaccination strategy using fully synthetic 
GPI analogues that delayed malaria in a lethal rodent model.[28] 
 In the present report we show the application of carbohydrate microarrays based on 
synthetic PfGPI for the selection of GPI specific B-cell hybridomas. The monoclonal anti-GPI 
glycan antibodies produced represent a new research tool to evaluate biological activities of anti-
GPI antibodies and to characterise the GPI proteome of P. falciparum and other apicomplexan 
parasites.  
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Results 
 
 Generation of PfGPI specific monoclonal antibodies. Mice were immunized three times 
with 10µg of ImmunEasyTM (QIAGEN) formulated synthetic GPI 6 (Fig. 1) conjugated to KLH as 
carrier protein. Blood samples were taken pre-immune, three weeks after the second and third 
immunization, and analysed on microarrays spotted with seven synthetic PfGPI analogues (Fig. 1). 
High anti-GPI IgG titers could be detected in all immunized mice after the second immunization for 
the compounds GPI 2 to 7 whereas reactivity of the immune sera with GPI 1 was lower (Fig. 2A). A 
major titer increase was measured after the third vaccination only for GPI 1. Preimmune serum 
samples showed no significant reactivity with the spotted PfGPIs analogues. 
 Six hybridoma cell lines secreting GPI-specific IgG were identified by screening of culture 
supernatants with the synthetic-GPI based microarray (Fig. 2B). The mAbs MTG2, MTG3, MTG5 
and MTG6 reacted in microarray analysis with comparable fine specificity. These mAbs showed 
strong binding to all GPI-glycans, indicating that the glucosamine-inositol moieties include the 
most essential parts of their epitopes. Reactivity of the mAb MTG4 was low for the GPI 1 
compound, indicating that the first mannose sugar coupled to the glucosamine-inositol moieties is 
needed in addition for a strong binding. The fine-specificity of the mAb MTG1 was unique, since 
stronger binding to PfGPI 5 when compared to the other glycans was measured. 
 
 Anti-GPI mAbs bind to native GPI of Plasmodium and Trypanosoma parasites. All six 
anti-GPI mAbs were tested for parasite binding using an indirect immunofluorescence assay (IFA). 
The mAbs MTG2, MTG3, MTG5 and MTG6 showed strong binding to P. falciparum blood stage 
parasites in IFA, while mAbs MTG1 and MTG4 yielded only weak signals (Fig. 3). None of the 
anti-GPI mAbs showed binding to uninfected erythrocytes (not shown). In accordance, mAbs 
MTG2, MTG3, MTG5 and MTG6, but not mAbs MTG1 and MTG4, cross-reacted also strongly 
with in vitro cultivated T. brucei rhodesiense parasites (Fig. 3). As expected, an evenly distributed 
staining of the cells was observed, indicating a membrane-localised expression of the GPI-antigens 
accessible to the mAbs.  
 Expression of GPI-anchored proteins during blood stage development was analyzed by 
Western blotting with lysates of highly synchronised in vitro cultivated P. falciparum blood stage 
parasites harvested at different time-points. Individual samples thus represented ring, trophozoite or 
schizont stages. The anti-GPI mAbs MTG2, MTG3 and MTG6 but not mAbs MTG1, MTG4 and 
MTG5 (not shown) stained series of bands over a broad range of molecular weights (Fig. 4A, lanes 
1-8). While a few bands dominated in the ring stage, new bands emerged in the trophozoite stage 
and the relative signal abundances of bands increased considerably, demonstrating specificity of the 
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anti-GPI mAbs for developmentally regulated GPI-anchored proteins. Uninfected erythrocytes 
yielded no detectable signal (not shown). Less complex band pattern were obtained with sporozoite 
lysates (Fig. 4A, lane 9). The same P. falciparum Western positive anti-synthetic-GPI mAbs stained 
multiple bands with cell lysates of P. berghei and P. chabaudi asexual blood stages harvested from 
infected mice (Fig 4B). With lysates of bloodstream-form trypanosomes cultivated in host-cell free 
medium a few distinct bands were stained with the anti-GPI mAbs (Fig. 4C).  
 
 Evaluation of parasite inhibiting activity of GPI specific mAbs. In vitro growth 
inhibition assays in absence of phagocytes and an active complement system were performed to 
assess parasite inhibitory activity of the anti-GPI mAbs with blood stage P. falciparum and with T. 
brucei rhodesiense parasites. Even at final antibody concentrations as high as 500 µg/mL the anti-
synthetic-GPI mAbs showed no significant growth inhibitory effects in five independent 
experiments conducted with two different batches of antibody preparations (data not shown). 
 In vivo activity of the anti-GPI mAbs was assessed in outbreed NMRI mice infected with 
either a GFP expressing P. berghei ANKA strain or with the human T. brucei rhodesiense strain 
STIB 900. mAbs (200µg) formulated in PBS were administered intravenously 24 h before and 72 h 
after infection. Parasitemia levels were not significantly different between test and control groups 
(Fig. 5A and 5C), and no delay of fatalities was observed in three independent experiments 
conducted with different batches of anti-GPI antibody preparations (Fig. 5B and 5D).  
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Discussion 
 
 Glycosylphosphatidylinositols are evolutionary conserved glycolipids found in the outer cell 
membranes of all eukaryotes. GPIs anchor a diverse range of proteins to the surface of P. 
falciparum, but may also exist free of protein attachment.[29-31] As for other parasitic diseases, such 
as trypanosomiasis and toxoplasmosis, certain pathogenic features of malaria may be caused by 
parasite GPI-glycans.[32,33] In vitro and in vivo studies have established plasmodial GPI as a potent 
activator of the host immune system and as inducer of pro-inflammatory cytokines.[21-23] These 
responses seem to play a critical role in the pathogenesis of severe malaria. In populations exposed 
to P. falciparum, the antibody response to purified GPIs is characterized by an age-dependent 
development that correlates with the acquisition of immunity to severe malaria.[24] Therefore, it has 
been postulated that antibodies against plasmodial GPI mediate anti-toxic and anti-disease 
immunity against malaria and that GPI could be a suitable component of a malaria vaccine.  
 The lack of a reliable method for the characterization of anti-GPI antibodies in large 
numbers of serum samples has made it difficult to generate strong supportive data for this 
hypothesis. Moreover many studies on GPI have been criticized, since incompletely characterised 
antigen preparations extracted from cultured parasites were used. Polysaccharides are often 
heterogeneous and difficult to isolate from their natural sources. Concerns over the purity of GPI 
preparations derived from P. falciparum can be effectively abolished if results can be repeated 
using fully synthetic GPIs. The use of pure fully characterized synthetic material allows for a direct 
correlation of the antibody signal to a specific glycan structure. We are applying carbohydrate 
microarrays based on synthetic P. falciparum GPI to study antibody responses to different structural 
elements of this complex antigen. Microarray-based serological analyses with synthetic GPIs 
demonstrated differences in the fine specificity of anti-GPI antibodies in malaria-exposed and non-
exposed populations, indicating that anti-Man3 GPI responses are primarily elicited by malaria 
parasites, while anti-Man4 GPI antibodies may arise in response to exposure to a variety of 
pathogens.[9]  
 Monoclonal antibodies to PfGPIs are important tools to study the role of GPIs in the 
pathophysiology of malaria. Although the generation of monoclonal antibodies to purified GPIs was 
reported more than a decade ago,[34] the details of this work have not been published. In the present 
report we show the application of the novel carbohydrate microarray based on synthetic PfGPI for 
the selection of GPI specific B-cell hybridomas from mice immunized with pure synthetic GPI 
glycan. 
 The adjuvanted GPI 6 KLH conjugate was immunogenic in mice and elicited IgGs cross-
reactive with all spotted synthetic GPI analogues. The fine specificity of the vaccine-induced 
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humoral immune response was different from naturally elicited anti-GPI IgGs, since serum 
antibodies reactive with the shortest GPI oligosaccharides 1 - 3 were only sporadically detected.[9]  
 To investigate the role of GPI in malaria pathogenesis and for a detailed analysis of the 
humoral immune response, six GPI-specific mouse B-cell hybridomas with variable fine 
specificities were generated by screening hybridoma cell supernatants for GPI-crossreactivity in 
synthetic-GPI microarray analysis. The fine specificity of the anti-GPI mAbs and their reactivity to 
native antigen correlated. mAbs MTG2, MTG3, MTG5 and MTG6, in contrast to the mAbs MTG1 
and MTG4, showed strong binding to P. falciparum blood stage parasites in IFA. While the IFA 
positive mAbs showed strong binding to the glucosamine-inositol moieties of the highly truncated 
GPI 1, mAbs MTG1 and MTG4 recognising more complex epitopes with mannose sugars coupled 
to the glucosamine-inositol moiety yielded only weak IFA signals. Sterical hindrance may result in 
reduced binding to native GPI. It is not clear whether free GPI and protein bound GPI are both 
accessible for the anti-GPI mAbs on the parasite cell surface. Notably, the same Plasmodium IFA 
positive mAbs cross-reacted also with in vitro cultivated T. brucei bloodstream forms, which 
express a dense surface coat of GPI-anchored variant surface glycoprotein (VSG). Binding to native 
GPI occurred even though T. brucei VSG-GPIs have a strain dependent addition of branching 
oligogalactose side chain to the conserved core glycan.[4]   
 The produced monoclonal anti-GPI antibodies represent a new research tool to characterise 
the GPI proteome of P. falciparum and other apicomplexan parasites and may help to identify new 
GPI-anchored proteins. Reactivity of the anti-synthetic-GPI mAbs for parasite-encoded GPI 
anchored antigens was demonstrated in Western blotting analysis for P. falciparum blood stages 
and sporozoites, P. berghei and P. chabaudi blood stages and T. brucei bloodstream forms. In these 
immunoblots the mAbs detected multiple protein bands supporting genomic and proteomic studies, 
which predicted that only a minority of GPI-anchored surface proteins of P. falciparum has been 
discovered so far.[18-20] Focusing on the blood stages, proteomic analysis of proteins labelled with 
radioactive glucosamine identified GPI anchoring on 11 known proteins.[35] Another nine lower 
abundance [3H]-glucosamine-labelled GPI-anchored proteins were also apparent at this life stage, 
but these remained unidentified. To predict the identity of these proteins as well as those present at 
other life stages a hidden Markov model, trained on P. falciparum sequences has been developed. 
This bioinformatics approach predicted that the P. falciparum genome encodes 30 GPI-anchored 
proteins.[35] Since sporozoites cannot be cultivated in vitro, this approach cannot be applied for this 
development stage.  
 The ability of the generated anti-GPI mAbs to bind to parasite GPI raises to possibility that 
these reagents may eventually be used immunotherapeutically in malaria to inhibit parasite growth 
or to neutralize the toxic activities of GPI in vivo. To evaluate biological activities of our anti-GPI 
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mAbs, we performed functional analysis, including in vitro parasite growth inhibition assays and 
passive protection experiments in animal infection models. Despite binding to the protozoan 
parasite species, the anti-GPI mAbs had no effect on parasite replication in vitro. Currently, the 
correlation of in vitro growth inhibitory activities of antibodies with their potential protective 
capacity in vivo is incompletely understood. Therefore, we performed passive immunization studies 
in mice infected with either P. berghei or with T. brucei rhodesiense. The administrated anti-GPI 
glycan mAbs had no effect on parasitemia levels and no delay of fatalities was observed.  
 
Conclusions 
 
 These results do not rule out that anti-GPI antibodies of the same or another fine specificity 
have the potential to modulate pathomechanisms in severe forms of the disease, such as cerebral 
malaria. In a P. berghei rodent model of severe malaria active immunization with synthetic GPI 
glycan resulted in substantial protection against malarial acidosis, pulmonary oedema, cerebral 
syndrome and fatality, without reducing parasite levels.[28] Synthetic GPI may thus represent a 
suitable component for a malaria vaccine aiming to reduce childhood mortality in malaria endemic 
regions.  
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Experimental Section 
 
 Mouse immunogenicity studies. Three mice carrying human immunoglobulin Cγ1 heavy and 
Cκ light chain gene segments[36] were immunized subcutaneously and intraperitoneal with synthetic 
GPI 6 antigen (Fig. 1) conjugated to keyhole-limpet-hemocyanine (KLH) formulated in 
ImmunEasyTM adjuvant (QIAGEN, Hombrechtikon, Switzerland). Starting on day 0, they received 
at three-weekly intervals three doses of 10µg conjugate.  
 
 Generation of anti-GPI monoclonal antibodies (mAbs). Three days before cell fusion an 
immunized animal received an intravenous booster injection with 10µg of GPI-KLH conjugate in 
phosphate-buffered saline (PBS). From the killed mouse the spleen was aseptically removed and a 
spleen cell suspension in IMDM was mixed with PAI mouse myeloma cells as a fusion partner. 
Spleen and myeloma cells in a ratio of 1:1 were centrifuged; after the supernatant was discarded, 
the pellet was mixed with 1 mL pre-warmed polyethylene glycol 1500 sterile solution. After 60s 
10mL of culture medium were added. After 10 min cells were suspended in IMDM containing 
hypoxanthine, aminopterin, thymidine, and 20% fetal bovine serum (HAT) and cultured in 96-well 
tissue culture plates. Cells were cultured at 37°C with 5% CO2 and fed five days later with 100 mL 
of HAT- medium. Cells secreting GPI-specific IgG were identified by screening culture 
supernatants with a synthetic GPI microarray-based immunoassay. Six hybridoma cell lines 
producing GPI specific mAbs were identified and cloned twice by limiting dilution. The mAbs, 
named MTG1, MTG2, MTG3, MTG4, MTG5 and MTG6, were purified from spent culture 
supernatant of the hybridoma clones by protein A affinity chromatography (HiTrap rProtein A FF, 
Amersham Biosciences, Piscataway, USA). Purified MAbs were dialyzed against PBS with Slide-
A-Lyzer Dialysis Cassette (PIERCE, Rockford, USA), aliquoted, and stored at -80°C. 
 
 Synthetic GPI microarray. Carbohydrates with a terminal sulfhydryl-containing linker 
were prepared as previously described.[37] The terminal sulfhydryl-containing linker provided a 
handle for covalent immobilization of the structures to a maleimide-modified surface. 
Functionalization and printing of slides were performed as previously described.[9] Briefly aldehyde 
slides (Genetix Ltd, Hampshire, UK) were immersed in PBS containing 1% BSA (w/v) and 
incubated overnight at room temperature. The slides were rinsed twice with distilled water and 
twice with 95% ethanol, then dried under a stream of anhydrous argon. Subsequently, the slides 
were immersed in anhydrous DMF (Aldrich, St. Louis, Mo.) containing 1mg/mL 6-
Maleimidohexanoic acid N-hydosuccinimide ester (Aldrich, St. Louis, Mo.) and N,N-
diisopropylethylamine (100 mM; Fluka, St. Louis, Mo.). The slides were incubated in this solution 
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for 24 h at room temperature and washed four times with 95% ethanol. A volume of 3 nL of a 10 
µM solution of synthetic GPI-glycan in PBS were deposited on the surface of the slide to form each 
microarray spot using a Genetix array printer (Genetix Ltd, Hampshire, UK). The slides were 
subsequently incubated in a humid chamber for 24h before being quenched with 1mM β-
mercaptoethanol for 2h at room temperature. The slides were then washed three times with water 
and stored in a dessicator. Microarrays were validated with FITC-labelled ConA and comparative 
serum titration experiments in ELISA versus microarray-based analysis, yielding good 
correspondence of results.[9] Stored slides were stable over two months without alteration in the 
reproducibility of the experiments. 
 
 Microarray-based immunoassay. Spotted microarray slides were covered with FlexWell-
64 (GRACE BIO-LABS, Bend, OR) layers. Microarray wells were blocked with 0.5% milk powder 
in PBS for one hour at room temperature followed by three washings with PBS containing 0.01% 
Tween-20. Afterwards wells were incubated with appropriate dilutions of mouse sera or hybridoma 
supernatants for two hours at room temperature. After washing, slides were incubated with 
indocarbocyanine dye-conjugated affinity-pure F(ab')2 fragment goat anti-mouse IgG heavy-chain 
antibodies (Jackson ImmunoResearch Laboratories, West Grove, Pa.) for one hour at room 
temperature and washed again. Dried slides were read on a GenePixTM Personal 4100A (Axon 
Instruments, Sunnyvale, CA) Microarray-scanner at a wavelength of 532nm. The resulting picture 
was quantitatively analysed with GenePixTM Pro 6 software. Background fluorescence intensity 
from spotted buffer without carbohydrates was subtracted to GPI signals for each individual 
microarray slide. 
 
 mAbs Isotyping. The isotypes of the generated mAbs were determined by sandwich 
enzyme-linked immunosorbent assay (ELISA). ELISA microtiter plates Immunolon 4 (Dynex 
Technologies Inc., Chantilly, Va.) were coated with unconjugated sheep anti-human kappa (Serotec, 
Raleigh, NC) or goat anti-mouse lambda (Southern Biotech, Birmingham, Ala.) antibodies at 4°C 
overnight. Wells were blocked with 5% milk powder in PBS followed by three washings with PBS 
containing 0.05% Tween-20; then 100 µL of tested supernatants were added to different wells, 
which were incubated and washed again. Plates were incubated for one hour with alkaline 
phosphatase-conjugated goat anti-mouse antibodies specific for IgG (Sigma, St. Louis, Mo.); IgG1; 
IgG2b; IgG3; IgM (Southern Biotech, Birmingham, Ala.) and with alkaline phosphatase-conjugated 
mouse anti-human antibodies specific for IgG1 (Southern Biotech, Birmingham, Ala.). After 
washing, phosphatase substrate was added and incubated at room temperature. The optical density 
of the reaction product was recorded at 405 nm. 
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 Indirect immunofluorescence assay (IFA). In vitro cultivated P. falciparum or T. brucei 
rhodesiense parasites were washed and mixed with two volumes of a solution containing 4% 
paraformaldehyde and 0.1% Triton X-100. Droplets of 40 µL of cell suspension were added to each 
well of a diagnostic microscope slide (Flow Laboratories, Baar, Switzerland) and incubated for 30 
min at room temperature. Cells were blocked with blocking solution containing 100 mg/mL fatty 
acid-free bovine serum albumin in PBS. Immunostaining was performed by incubating the wells 
with 25 µL of an appropriate hybridoma supernatant or purified mAbs dilution in blocking solution 
in a humid chamber for one hour at room temperature. After five washes with blocking solution, 25 
µL of 5-µg/mL indocarbocyanine dye-conjugated affinity-pure F(ab')2 fragment goat anti-mouse 
IgG heavy-chain antibodies (Jackson ImmunoResearch Laboratories, West Grove, Pa.), diluted in 
blocking solution containing 0.01 mg of Hoechst dye no. 33256 (Sigma, St. Louis, Mo.) per mL, 
were added to the wells and incubated for one hour at room temperature. Finally, the wells were 
washed five times, mounted with mounting solution (90% [vol/vol] glycerol containing 0.1 M Tris-
Cl [pH 8.0] and 2 mg of o-phenylenediamine per mL) and covered with a coverslip. Antibody 
binding and DNA staining were assessed by fluorescence microscopy on a Leitz Dialux 20 
fluorescence microscope and documented with a Leica DC200 digital camera system. 
 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting. For time course analyses, aliquots of synchronous cultures of P. falciparum-
infected erythrocytes were harvested at 6-h intervals and washed with PBS. Pelleted infected red 
blood cells were lysed by mixing with a large volume (adjusted to 5% hematocrit) of 0.015% 
(wt/vol) saponin in 150 mM NaCl and 15 mM sodium citrate and incubated on ice. Finally, the 
pelleted parasites were resuspended in PBS buffer and stored at -80°C until further use. Aliquots of 
lysed P. falciparum blood stage parasites, Anopheles stephansi salivary gland lysate containing P. 
falciparum sporozoites, P. berghei (ANKA) and P. chabaudi blood stages harvested from infected 
mice, and T. brucei parasites were mixed with loading buffer (1.7 mL of 0.5 M Tris-HCl [pH 6.8], 2 
mL of glycerol, 4.5 mL of 10% sodium dodecyl sulfate, 1 mL of β-mercaptoethanol, 0.8 mL of 
bromophenol blue [0.3%, wt/vol]) and heated 10 min at 95°C before loading on SDS-10% PAGE 
minigels. As a molecular weight marker, SeeBluePlus (Invitrogen, Basel, Switzerland) was used. 
Separated proteins were transferred electrophoretically to nitrocellulose filter (Protean 
Nitrocellulose, BA 85; Schleicher & Schuell) by semidry blotting. Blots were blocked with PBS 
containing 5% milk powder and 0.1% Tween 20 overnight at 4°C and then incubated with 
hybridoma supernatant or purified mAbs for 2 h. After several washing steps, blots were incubated 
with goat anti-mouse IgG horseradish peroxidase conjugated Ig (Bio-Rad Laboratories, Hercules, 
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Calif.) for 1 h. Blots were developed using the ECL system (PIERCE, Rockford, USA) according to 
manufacturer's instructions. 
 
 Parasite culture and in vitro growth inhibition assay. P. falciparum strain K1 was 
cultured essentially as described previously.[38] The culture medium was supplemented with 0.5% 
AlbuMAX (Gibco, Paisley, Scotland) as a substitute for human serum.[39] Synchronization of 
cultures was achieved by sorbitol treatment as described previously.[40] Serogroup 0+ or A+ 
erythrocytes for passages were obtained from the Swiss Red Cross (Basel, Switzerland). 
 For in vitro growth inhibition assays, synchronous late trophozoites were diluted with fresh 
red blood cells to result in 0.5% parasitemia and mixed with purified mAb. The final hematocrit in 
cultures was adjusted to 0.5%. Each culture was set up in sextuplicate in 96-well flat-bottomed 
culture plates. After 96 h, the plates were centrifuged at 180 × g for 5 min, and the culture 
supernatants were discarded. Pelleted erythrocytes were resuspended in 200 µL of PBS 
supplemented with 15 µg of hydroethidine fluorescent vital stain (Polysciences Inc., Warrington, 
Pa.) per mL and incubated at 37°C for 30 min. The erythrocytes were washed with PBS and 
analyzed in a FACSscan flow cytometer (Becton Dickinson, San Jose, Calif.) with CellQuest 3.2.1fl 
software. The hydroethidine emission was detected in the FL2 channel by logarithmic 
amplification, and the erythrocytes were gated on the basis of their forward and side scatters. A total 
of 30,000 cells per sample were analyzed. Percent inhibition was calculated from the geometric 
mean parasitemias of sextuplicate test and control wells as 100 × [(control - test)/control]. Statistical 
significance was calculated by a two-sided t test. Confidence intervals (P < 95%) were calculated 
by antilogging the confidence limits calculated on the log scale. 
 Bloodstream form trypanosomes were cultivated in Minimum Essential Medium (MEM) 
with Earle's salts (GIBCO/BRL No 072-01100 P), supplemented with 25 mM HEPES, 1 g/L 
additional glucose, 2.2 g/L NaHCO3, 10 ml/L MEM nonessential amino acids (100 ?) and heat 
inactivated horse serum (15%). The medium was further supplemented according to,[41] with 0.2 
mM 2-mercaptoethanol, 2 mM Na-pyruvate, 0.1 mM hypoxanthine and 0.016 mM thymidine. 
Cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 in air. 
 For in vitro growth inhibition assays, bloodstream form trypanosomes were inoculated into 
96-well flat-bottomed microtiter plates (Costar, USA) at a density of 200 trypanosomes/100µL 
culture medium. The trypanosomes were incubated in the presence of purified mAbs for 72 h. Wells 
without antibodies served as controls and background fluorescence and absorbance of the mAbs 
containing medium were determined for each mAb. After incubation for 68 h, 10µL of the Alamar 
blue® dye was added into each well of the plate, which was then incubated under culture conditions 
for an additional 4 h. Fluorescence measurements were performed using a fluorescence plate reader 
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(Cytofluor 2300, Millipore, Bedford, MA) at 530 nm excitation and 590 nm emission wavelength. 
The decrease of fluorescence, as a measure for reduced trypanosome number, was calculated for 
each mAb by subtraction of the measured value from the background fluorescence. The average of 
the fluorescence units of the growth control without antibodies served as the 100% standard. The 
average fluorescence in the presence of a mAb minus average background fluorescence was 
expressed as percentage of the growth control.  
 
 In vivo parasite growth inhibition studies. All animal studies were carried out based on a 
protocol approved by an animal ethics committee. In vivo activity of the anti-GPI mAbs was 
assessed in mice infected with either a GFP expressing P. berghei ANKA strain (1 times 104 
parasitized erythrocytes per mL)[42] or with the T. brucei rhodesiense strain STIB 900 (1 times 104 
bloodstream form trypanosomes). Doses of 200µg antibodies formulated in PBS were administered 
intravenously 24 h before and 72 h after infection to six-week-old NMRI female mice obtained in 
sterile containers from RCC Ltd. (Füllinsdorf, Switzerland). Parasitemia levels were determined on 
several days after infection and the survival time in days was also recorded. For T. brucei 
rhodesiense tail blood smears were prepared and examined under a bright field microscope with a 
200-fold magnification and a counting grid with defined dimensions. The degree of P. berghei 
ANKA infection (parasitaemia expressed as per cent infected erythrocytes) was determined by 
FACSscan flow cytometery (Becton Dickinson, San Jose, Calif.) according to.[42] 
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Figures 
 
Fig. 1. Structures of the seven synthetic GPI-glycans (1-7) that were arrayed on a BSA-coated glass 
slide to build a GPI-glycan microarray. Attachment of GPI 6 to keyhole-limpet-hemocyanine 
(KLH) carrier protein afforded the conjugate used for immunization studies. 
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Fig. 2. A: Development of anti-GPI 1 to 7 IgG responses in mice after immunization with synthetic 
GPI 6 antigen conjugated to KLH formulated in ImmunEasyTM adjuvant. Sera were taken pre-
immune, three weeks after the second and third immunization. Shown are readouts obtained with 
serial dilutions of sera of a representative mouse in synthetic PfGPI microarray analysis. B: Fine 
specificities of the six generated anti-GPI mAbs. Serial dilutions of hybridoma supernatants were 
analysed in the microarray-based immunoassay. C: Prototype microarray images obtained after 
incubation with MTG1 and MTG6 mAbs. Serial four-fold dilutions of the hybridoma supernatants 
started at the upper right screening unit. D: Spotting order of the seven synthetic GPI-glycans (1-7) 
that were arrayed as quadruplicates in 64 identical screening units on a single slide. 
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Fig. 3. Immunofluorescence staining of late trophozoites and schizonts of P. falciparum strain K1 
and bloodstream-forms of T. brucei rhodesiense strain STIB 900. Parasites were stained with 
purified anti-synthetic GPI mAbs (4µg/ml) and a secondary antibody conjugated to Cy3. Nuclei 
were visualized using Hoechst dye no. 33256.   
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Fig. 4. A: Western blotting analysis with anti-synthetic GPI mAb MTG6 using P. falciparum blood 
stage lysates taken 6, 12, 18, 24, 30, 36, 42, and 48 h (lanes 1 to 8) after synchronization and 
salivary gland sporozoites (lane 9). An anti-GAPDH mAb served as a loading control. Western 
blotting analysis with mAb MTG6 with total cell lysates of asexual blood stages of P. chabaudi (B, 
lanes 1) and P. berghei (B, lanes 2) and of in vitro cultivated T. brucei gambiense (C, lane1) and T. 
brucei rhodesiense (C, lane 2) lysates. Blots were developed using the ECL system. Comparable 
results were obtained with the two other Western blotting positive mAbs MTG2 and MTG3.  
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Fig. 5. Passive immunization studies with anti-synthetic GPI mAbs using murine infection models 
with either a GFP expressing P. berghei ANKA strain or with the T. brucei rhodesiense strain STIB 
900. Parasitemia levels (A and C) were determined on several days after infection and the survival 
time in days was also recorded (B and D). Unvaccinated mice served as controls. Two further 
independent experiments with different batches of anti-GPI antibody preparations yielded 
comparable results.  
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Suggestion for the table of contents 
Glycosylphosphatidylinositol (GPI) glycolipids of Plasmodium falciparum may be involved in the 
pathogenesis of malaria. GPIs are heterogeneous and difficult to isolate from their natural sources. 
Carbohydrate microarrays based on pure fully characterized synthetic GPI allowed the selection of 
GPI specific B-cell hybridomas and the first detailed description of the properties of anti-GPI 
monoclonal antibodies. 
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 Spores of Bacillus anthracis have been used as biowarfare agents to terrorize civilian 
populations. Once this durable form of the pathogen has been inhaled it will kill most victims if 
treatment does not commence within 24-48 h.[1] After uptake into the body, the spores germinate 
and vegetative cells multiply and produce toxins, leading to the development of lesions from which 
the infection may disseminate, which is frequently fatal. It is assumed that an effective anthrax-
subunit vaccine should contain multiple antigens. A surface antigen of the spores eliciting 
antibodies that suppress germination and enhance phagocytosis of spores by macrophages would be 
a suitable component for such a vaccine. 
 Several detection systems have been developed to identify B. anthracis[2]-[4] and process the 
large number of samples that have to be tested each year. PCR-based assays or traditional 
phenotyping of bacteria are the most accurate but are also complex, expensive, and slow. Antibody 
binding to spore-surface peptide and protein antigens is less complicated, although it is plagued by 
higher false-positive and false-negative readouts. The similarity of spore-cell-surface antigens of the 
opportunistic human pathogen B. cereus and other bacteria of this group makes it difficult to create 
selective, reliable, antibody-based detection systems. 
 On the surface of B. anthracis spores, a unique tetrasaccharide 1 (Scheme 1) containing an 
entirely novel monosaccharide, named anthrose, was discovered recently.[5] Access to usable 
quantities of pure cell surface oligosaccharides by isolation is often difficult and leaves synthetic 
chemistry as a last resort to procure carbohydrate antigens. We envisioned the detection of B. 
anthracis spores based on antibodies against carbohydrate antigen 1, which is not present on related 
strains of bacteria. 
 The tetrasaccharide was chemically synthesized[6], [7] in the form of the n-pentenyl glycoside 
2.[6] The chemical handle on the reducing end was utilized to introduce a reactive terminal aldehyde 
moiety through ozonolysis. Covalent attachment[8], [9] of synthetic 2 to the keyhole-limpet-
hemocyanine (KLH) carrier protein by reductive amination produced a carbohydrate-protein 
conjugate 3 that was immunogenic in mice (Scheme 1). The conjugation to protein carriers is an 
efficient way to improve the immunogenicity of oligosaccharide antigens. The proteins provide 
peptide units that can be recognized by carrier-specific T cells, thus converting a T-cell-independent 
response against an unconjugated oligosaccharide into a more efficient T-cell-dependent response. 
 Tetrasaccharide-KLH conjugates formulated in ImmunEasy adjuvant (QIAGEN) elicited 
tetrasaccharide binding immunoglobulin G (IgG) antibodies after the third immunization in mice. 
Three B cell hybridoma lines producing tetrasaccharide specific monoclonal IgG antibodies (mAbs) 
were generated from spleen cells of one of the immunized mice. In an indirect immunofluorescence 
assay, all three mAbs bound specifically to native B. anthracis endospores. No binding was found 
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to endospores of B. cereus, B. subtilis, and B. thuringiensis, which are close relatives of B. 
anthracis (Figure 1). 
 These results demonstrate that distinct differences in cell-surface carbohydrate antigens can 
provide the basis for the generation of specific immunological reagents. This was demonstrated 
herein for the synthetic tetrasaccharide antigen 2 of B. anthracis. The tetrasaccharide-specific mAbs 
may be suitable to develop a highly sensitive and specific detection system for B. anthracis 
endospores and contribute to the development of novel therapeutic or preventive approaches. 
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Figures 
 
Scheme 1. Structure of the tetrasaccharide 1 found on the surface of B. anthracis spores and its 
synthetic analogue 2. Attachment through a pentenyl handle to the KLH carrier protein afforded the 
conjugate 3: a) O3, MeOH, -78 °C, 10 min; b) Me2S, MeOH, RT, 2 h; c) KLH carrier protein, PBS 
buffer solution (pH 7.2), NaBH3CN, 37 °C, 48 h. PBS = phosphate-buffered saline. 
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Figure 1. Indirect immunofluorescent staining of B. anthracis and B. cereus endospores by a mAb 
that was generated against the synthetic tetrasaccharide 2. Left column: bright-field microscopy; 
right column: Cy3-specific immunofluorescence staining of a) B. anthracis spores with an isotype-
matched control mAb, b) B. anthracis spores with a 2-specific mAb, and c) B. cereus spores with a 
2-specific mAb. 
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Supporting Information 
 
Figure SI 1. Tetrasaccharide specific IgG ELISA titers after second (2.IMM), third (3.IMM) and 
fourth (4.IMM) immunization of a mouse with KLH conjugate formulated in ImmunEasyTM (IE) or 
in phosphate buffered saline (PBS-4.IMM). Preimmune serum sample (PRE) showed no significant 
reactivity with the immunogen. 
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 Ozonolysis of Tetrasaccharide 2 and Conjugation with Bovine Serum Albumine (BSA) 
and Keyhole Limpet Haemocyanin (KLH).  Tetrasaccharide 2 (5 mg, 0.029 mmol) was dissolved 
in methanol (3 mL) and cooled to -78 °C. Ozone gas was passed through the solution for 10 min 
under vigorous stirring. A pale blue solution was formed. The excess ozone was displaced with 
nitrogen over a period of 10 min. The blue color disappeared. Methylsulfide (0.1 mL) was added 
and the reaction mixture was stirred for 2 h at room temperature. Afterwards, all the volatiles were 
removed under a stream of nitrogen. The resulting white solid was used directly in the subsequent 
conjugation step. MS (ESI) experiments showed the formation of the aldehyde. The solid was 
dissolved in 1 mL of 0.1 M phosphate buffered saline (PBS buffer), pH 7.2. The volume was 
divided into two times 0.5 mL, each of them in a separate flask. In one of them 4.2 mg of BSA was 
added, in the other 4.2 mg of KLH. To each of the two flasks 1 mg of sodium cyanoborohydride 
was added and the mixtures incubated under gentle agitation at 37 °C for 48 h. After 20 h, an 
additional 0.5 mg of sodium cyanoborohydride was added and the incubation continued. Both 
mixtures were diafiltered using a Amicon Centriprep with molecular weight cut-off value of 30 000 
Da with six changes of PBS at 4 °C. Larger volumes (1.0 mL instead of 0.5 mL) of PBS buffer in 
the conjugation step resulted in a smaller number of  tetrasaccharide moieties (three to four) 
attached to the protein. Due to the higher mass of KLH, we do not have comparative data for KLH. 
 
 Mouse Immunogenicity Studies. Mice carrying human immunoglobulin Cγ1 heavy and Cκ 
light chain gene segments (Pluschke et al., 1998) were immunized subcutaneously and 
intraperitoneal with tetrasaccharide–KLH conjugate formulated in ImmunEasyTM adjuvant 
(QIAGEN). Starting on day 0, they received at three-weekly intervals four doses of 20 µg 
conjugate. 
 
 Generation of anti-Tetrasaccharide Monoclonal Antibodies (mAbs). Three days before 
cell fusion, a mouse immunized with the ImmunEasyTM formulation received an intravenous 
booster injection with 20 µg of conjugate in phosphatebuffered saline. From the sacrified mouse the 
spleen was aseptically removed and a spleen cell suspension in IMDM was mixed with PAI mouse 
myeloma cells as a fusion partner. Spleen and myeloma cells in a ratio of 1:1 were centrifuged; after 
the supernatant was discarded, the pellet was mixed with 1 mL pre-warmed polyethylene glycol 
1500 sterile solution. After 60 s 10 mL of culture medium were added. After 10 min cells were 
suspended in IMDM containing hypoxanthine, aminopterin, thymidine, and 20% fetal bovine serum 
(HAT) and cultured in 96-well tissue culture plates. The cells were cultured at 37 °C with 5% CO2 
and fed 5 days later with 100 ml of HAT medium. Cells secreting tetrasaccharide-specific 
immunoglobulin (IgG) were identified by enzyme-linked immunosorbent assay (ELISA) using 
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Immunolon 4 plates (Dynex Technologies Inc., Chantilly, Va.) coated with tetrasaccharide-BSA 
conjugate. Three hybridoma cell lines producing tetrasacchartide specific mAbs were identified and 
cloned twice by limiting dilution. Three mAbs, named MTA1, MTA2 and MTA3, were purified 
from spent culture supernatant of the three hybridoma clones by protein A affinity chromatography 
(HiTrap rProtein A FF, Amersham Biosciences). Purified MAbs were dialyzed against PBS with 
Slide-A-Lyzer Dialysis Cassette (PIERCE), aliquoted, and stored at -80 °C. 
 
 ELISA.  ELISA microtiter plates Immunolon 4 (Dynex Technologies Inc., Chantilly, Va.) 
were coated at 4 °C overnight with 50 µL of a 10 µg/mL solution of tetrasaccharide-BSA conjugate 
in PBS, pH 7.2. Wells were then blocked with 5% milk powder in PBS for 1 h at room temperature 
followed by three washings with PBS containing 0.05% Tween-20. Plates were then incubated with 
two-fold serial dilutions of mouse serum or hybridoma cell supernatants in PBS containing 0.05% 
Tween-20 and 0.5% milk powder for 2 h at room temperature. After washing, the plates were 
incubated with alkaline phosphatase-conjugated goat anti-mouse IgG (γ-chain specific) antibodies 
(Sigma, St. Louis, MO) for 1 h at room temperature and then washed. Phosphatase substrate (1 
mg/mL p-nitrophenyl phosphate (Sigma)) in buffer (0.14% Na2CO3, 0.3% NaHCO3, 0.02% MgCl2, 
pH 9.6) was added and incubated at room temperature. The optical density (OD) of the reaction 
product was recorded after appropriate time at 405 nm using a microplate reader (Titertek Multiscan 
MCC/340, Labsystems, Finland). 
 
 MAb Isotyping. The isotypes of the generated mAbs were determined by ELISA. ELISA 
microtiter plates Immunolon 4 (Dynex Technologies Inc., Chantilly, Va.) were coated at 4 °C 
overnight with 50 µL of a 10 µg/mL solution of tetrasaccharide-BSA conjugate in PBS buffer. 
Wells were then blocked with 5% milk powder in PBS followed by three washings with PBS 
containing 0.05% Tween-20; then 100 µL of tested supernatants were added to different wells, 
which were incubated and washed again. Plates were incubated for 1 h with alkaline phosphatase-
conjugated goat anti-mouse antibodies specific for IgG (Sigma); IgG1; IgG2b; IgG3; IgM;  
(Southern Biotech) and with alkaline phosphatase-conjugated mouse anti-human antibodies specific 
for IgG1 and κ (Southern Biotech). After washing, phosphatase substrate was added and incubated 
at room temperature. The optical density of the reaction product was recorded at 405 nm. 
 
 Immunofluorescence Assays (IFA) for Detection of Bacillus anthracis endospores. 
Endospore suspensions were added to microscope glass slides, air-dried and fixed twice with 
acetone. Slides were incubated in a moist chamber for 30 min at room temperature with either 
mouse serum diluted in PBS, hybridoma supernatants or purified mAbs diluted in PBS. After five 
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washes with PBS, Cy3-conjugated affinity-pure F(ab`)2 fragment goat anti-mouse IgG antibodies 
(Jackson Immuno Research  Laboratories, West Grove, PA), were added to the slides and incubated 
for 30 min at  room temperature. Afterwards, slides were washed five times with PBS and covered 
with a cover slip. Antibody binding was assessed by fluorescence microscopy. The B. anthracis 
strains used for IFA were Pasteur 1, A73202 and Sterne, NCTC8234 and the B. cereus strain was 
JF1887 (ATCC9634). 
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Abstract  
 
Aims: Bacillus anthracis strains of various origins were analysed with the view to describe intrinsic 
and persistent structural components of the Bacillus collagen-like protein of anthracis glycoprotein 
associated anthrose containing tetrasaccharide in the exosporium.  
Methods and Results: The tetrasaccharide consists of three rhamnose residues and an unique 
monosaccharide – anthrose. As anthrose was not found in spores of related strains of bacteria, we 
envisioned the detection of B. anthracis spores based on antibodies against anthrose-containing 
polysaccharides. Carbohydrate–protein conjugates containing the synthetic tetrasaccharide, an 
anthrose–rhamnose disaccharide or anthrose alone were employed to immunize mice. All three 
formulations were immunogenic and elicited IgG responses with different fine specificities. All sera 
and monoclonal antibodies derived from tetrasaccharide immunized mice cross-reacted not only 
with spore lysates of a panel of virulent B. anthracis strains, but also with some of the B. cereus 
strains tested.  
Conclusions: Our results demonstrate that antibodies to synthetic carbohydrates are useful tools for 
epitope analyses of complex carbohydrate antigens and for the detection of particular target 
structures in biological specimens.  
Significance and Impact of the Study: Although not strictly specific for B. anthracis spores, 
antibodies against the tetrasaccharide may have potential as immuno-capturing components for a 
highly sensitive spore detection system. 
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Introduction 
 
 Anthrax is an acute zoonotic disease caused by the spore-forming, rod-shaped bacterium 
Bacillus anthracis that can lie dormant in the soil for decades. Upon ingestion by grazing animals, 
the spores germinate, changing from the resistant form into the growing and toxin producing 
vegetative form. After the bacteria disseminate, they typically kill the infected animal and return to 
the environment converting again to spores. B. anthracis has been described as the ultimate 
biological weapon because of its virulence and persistence when disseminated as spores (Inglesby 
et al. 1999, Borio et al. 2001).  
 Human vaccines for anthrax are available (Turnbull 2000, Pittman et al. 2001) but there has 
been much controversy over the safety and effectiveness of the current vaccines. Research on a 
second-generation vaccine in recent years was based on the observation that antibodies to protective 
antigen (PA) are crucial for protection against exposure to virulent anthrax spores (Brey 2005). 
Since antibodies to PA address the toxemia component of anthrax disease, it is assumed that an 
effective anthrax-subunit vaccine should contain multiple antigens. Inclusion of killed B. anthracis 
spores enhances the protective efficacy of PA-based vaccines in animal models (Brossier 2002). In 
order to generate an immunity that protects from infection with B. anthracis, the capsule or somatic 
antigens in the spore may represent critical vaccine components.  
 The exosporium, the primary permeability barrier of the spore and the source of spore surface 
antigens has been the focus of recent investigations. As the outermost surface of the spore, the 
exosporium is likely to be the most immunological accessible structure of the spore. The 
glycoprotein Bacillus collagen-like protein of anthracis (BclA) was the first exosporium protein that 
was identified and has been shown to be an immunodominant protein suggesting a role for this 
protein in spore-host interactions (Steichen et al. 2003). BclA has conserved amino- and carboxy-
termini and a long, central collagen-like region that is similar to mammalian collagen proteins 
(Sylvestre et al. 2002, Sylvestre et al. 2003). This polymorphic collagen-like region consists of 
GXX repeats, including a large proportion of GPT triplets, and (GPT)5GDTGTT repeats. The latter 
21-amino-acid repeat has been named BclA repeat (Sylvestre et al. 2002) and appears to be an 
essential feature of the BclA protein important for the structural organization of BclA on the spore 
surface. The number of GXX repeats in the collagen-like region varies among strains (Steichen et 
al. 2003, Sylvestre et al. 2003) and is responsible for the different lengths of the exosporium 
filament found on spores of different B. anthracis strains (Sylvestre et al. 2003). Two O-linked 
carbohydrates attached to BclA, a 715-Da tetrasaccharide and a 324-Da disaccharide, have been 
identified (Daubenspeck et al. 2004). Multiple copies of the tetrasaccharide are linked to the 
collagen-like region of BclA, whereas the disaccharide may be attached outside of this region. Most 
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of the collagen-like region repeating units contain a threonine residue that provides sites for 
potential glycosylation via a GalNAc linker. The tetrasaccharide is composed of three rhamnose 
residues and anthrose, an unusual sugar that was not found in spores of strains belonging to the 
phylogenetically most similar species B. cereus and a B. thuringiensis (Daubenspeck et al. 2004, 
Tamborrini et al. 2006). Here, we demonstrate cross-reactivity of antisera and monoclonal 
antibodies raised against the synthetic B. anthracis tetrasaccharide and truncated anthrose 
containing structures using immunoblots with lysed spores of B. anthracis and B. cereus strains. 
 
Chapter 7: Immuno-detection of anthrose in the B. cereus group 
 96 
Material and Methods 
 
 Synthesis of carbohydrates. The tetrasaccharide I was prepared as described before by our 
group (Werz and Seeberger 2005, Werz et al. 2007). Following our initial report, four other groups 
achieved the synthesis of this tetrasaccharide or corresponding sequences (Adamo et al. 2005, 
Saksena et al. 2005, Mehta et al. 2006, Crich and Vinogradova 2007, Guo and O'Doherty 2007, 
Saksena et al. 2006, Saksena et al. 2007). The disaccharide II as well as the anthrose III used for 
further vaccination studies were prepared in an analogous manner by our modular approach (Werz 
and Seeberger 2005, Werz et al. 2007). The experimental details for the preparation of II and III as 
well as their analytical data are described in the supplementary material (Figs S1 and S2). The 
terminal double bonds of II and III were transformed into thiol functionalities suitable for reaction 
with a maleimide-functionalized KLH carrier protein. These KLH-glycoconjugates were used for 
the mouse immunogenicity studies. 
 
 Bacterial strains. B. anthracis strains selected from different genotypes (Maho et al. 2006, 
Pilo et al. 2008) are described in Table 1. B. thuringiensis ATCC 29730; B. cereus ATCC 10876; B. 
cereus ATCC 10876; B. cereus ATCC 13061; B. cereus ATCC 14579: B. cereus ATCC 33019, 
were purchased from the American Type Culture Collection (Rockville, MD, USA.). B. cereus 
F4370/75 (Cereus III lineage, ST-27); B. cereus m1545 (Cereus I lineage; ST-5); B. cereus m1564 
(Cereus I lineage; ST-6); B. cereus m1293 (Cereus II lineage; ST-45); B. cereus F4810/72 (Cereus 
II lineage; ST-26) were obtained from F. G. Priest (Priest et al. 2004).  
 
 Production of spores from Bacillus anthracis. Strains of Bacillus anthracis were cultured 
on tryptone soya agar with 5% sheep blood (Oxoid, Basel, Switzerland) at 37°C for 18 h. Then the 
culture plates were kept at room temperature for 4 weeks until the colonies appeared dry. 
Subsequently colonies were suspended in 1 ml PBS buffer (50 mM Na2HPO4 - NaH2PO4 pH 8.0, 
140 mM NaCl) per culture plate, heated at 80ºC for 10 min. Spores were then collected by 
centrifugation at 4000 x g for 15 min and suspended in PBS at a titer of 109 spores per ml.  
 
 Mouse immunogenicity studies. Mice carrying human immunoglobulin Cγ1 heavy and Cκ 
light chain gene segments (Pluschke et al. 1998) were immunized with synthetic saccharide 
antigens (Fig 1.) conjugated to keyhole-limpet-hemocyanine (KLH) formulated in ImmunEasyTM 
adjuvant (QIAGEN). Starting on day 0, they received at three-weekly intervals three doses of 40µg 
conjugate. Blood was collected before each immunization and 2 weeks after the final injection. The 
production of anti-tetrasaccharide monoclonal antibodies is described in (Tamborrini et al. 2006). 
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Anti- B. thuringiensis antiserum was generated by immunization with strain ATCC 29730 B. 
thuringiensis spores (Raven Biological Laboratories, INC, Omaha, NE). Mice were immunized 
subcutaneously at three-weekly intervals with 106 B. thuringiensis spores formulated in 0.2 ml PBS 
without adjuvant. Two weeks after the third injection, heart blood was collected and serum stored at 
-20° C until use.  
 Animals were housed in temperature-controlled rooms (22°C, ±3°). Conventional laboratory 
feeding and unlimited drinking water were provided to the mice. Approval for animal 
experimentation has been obtained from the responsible authorities and all experiments have been 
performed in strict accordance with the Rules and Regulations for the Protection of Animal Rights 
laid down by the Swiss Bundesamt für Veterinärwesen. All animal manipulations have been 
performed under controlled laboratory conditions by specifically qualified personnel in full 
conformity to Swiss and European regulations. 
 
 Enzyme-linked immunosorbent assay (ELISA). ELISA microtiter plates Immunolon 4 
(Dynex Technologies Inc., Chantilly, Va.) were coated at 4°C overnight with 50µl of a 10µg ml-1 
solution of saccharide-BSA conjugate in PBS, pH 7.2. Wells were then blocked with 5% milk 
powder in PBS for 1 h at room temperature followed by three washings with PBS containing 0.05% 
Tween-20. Plates were then incubated with two-fold serial dilutions of mouse serum or mAbs in 
PBS containing 0.05% Tween-20 and 0.5% milk powder for 2 h at room temperature. After 
washing, the plates were incubated with alkaline phosphatase-conjugated goat anti-mouse IgG (γ-
chain specific) antibodies (Sigma, St. Louis, MO) for 1 h at room temperature and then washed. 
Phosphatase substrate (1 mg ml-1  p-nitrophenyl phosphate (Sigma)) in buffer (0.14% Na2CO3, 
0.3% NaHCO3, 0.02% MgCl2, pH 9.6) was added and incubated at room temperature. The optical 
density (OD) of the reaction product was recorded after appropriate time at 405 nm using a 
microplate reader (Titertek Multiscan MCC/340, Labsystems, Finland).  
 
 PCR and DNA sequencing. PCR was performed using FIREPol (Solis BioDyne, Tartu, 
Estonia) Taq polymerase and synthetic oligonucleotides hybridizing to flanking or internal 
sequences of the bclA gene. A segment including the entire bclA gene was amplified by using the 
primers 5′-CCGTTAGAATCCATTGCAAGATGATAAGGC-3′ and 
5′-CGACCAACCATACTGTGTGCAGCTCTTGGC-3′ (Sylvestre et al. 2003). The sequence 
encoding the BclA variable collagen-like region containing the GXX-repeats was amplified by 
using the primers 5′-CCCTAATCTTGTAGGACCTACATTACCACC-3′ and 
5′-CCCACCGGAGTTAAATGCATATAGTCCTGC-3′ (Sylvestre et al. 2003). 30µl reactions were 
carried out with a GeneAmp 9700 PCR System (Applied Biosystems). Template DNA was 
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denatured at 94 °C for 4 min. Thirty amplification cycles of 30 s of denaturation at 94 °C, 30 s of 
annealing at 58 °C, and 2 min of extension at 72 °C were performed followed by one cycle of 
10 min at 72 °C. The PCR products were analyzed by agarose gel electrophoresis and sequenced by 
using two primers flanking the bclA gene (5′-CGTGTCATTTTCTTTCGGTTTTGCATCTAC-3′ 
and 5′-GTGCCTCCTACGGAATGTCATACAAC-3′) by MACROGEN (Korea).  
 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting. Endospore suspensions were solubilized with 2x loading buffer (1.7 ml of 0.5 M 
Tris-HCl [pH 6.8], 2 ml of glycerol, 4.5 ml of 10% sodium dodecyl sulfate, 1 ml of ß-
mercaptoethanol, 0.8 ml of bromophenol blue [0.3%, wt/vol]) and heated 10 min at 95 °C before 
loading on the 10 % SDS-PAGE. As molecular weight marker SeeBlue®Plus (Invitrogen) was 
used. Separated proteins were electrophoretically transferred to a nitrocellulose filter (Protran 
Nitrocellulose, BA85; Schleicher & Schuell) by semidry blotting. Blots were blocked with PBS 
containing 5% milk powder and 0.1% Tween 20 overnight at 4 °C. Whole blots or cut strips were 
incubated with appropriate dilutions of immune serum or mAbs in blocking buffer for 2 h at room 
temperature. In competition experiments primary antibodies were pre-incubated for 30 min with 
synthetic competitors. After several washing steps, blots were incubated with goat anti-mouse IgG 
horseradish peroxidase conjugated Ig (BioRad Laboratories, CA, USA) or with alkaline 
phosphatase-conjugated goat anti-mouse {gamma} heavy-chain antibodies (Sigma, St. Louis, Mo.) 
for 1 h. Blots were finally developed either using the ECL system according to manufacturer’s 
instructions or with 5-bromo-4-chloro-3-indolylphosphate (BioRad, Reinach, Switzerland) and 
nitroblue tetrazolium (BioRad) to visualize bands. 
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Results 
 
 Fine specificity of antibodies raised against anthrose-containing synthetic 
carbohydrates. Synthetic B. anthracis tetrasaccharide, a rhamnose-anthrose disaccharide and 
anthrose  (Fig. 1) were covalently attached to the keyhole-limpet-hemocyanine (KLH) carrier 
protein by reductive amination to improve their immunogenicity by the recruitment of carrier-
specific T cells. Mice were repeatedly immunized with a CpG based adjuvant (ImmunEasyTM, 
QIAGEN) formulation of the conjugates and the fine specificity of the immune sera was analyzed 
by ELISA and immunoblotting. 
 All anthrose monosaccharide-immunized animals developed high IgG ELISA titers to 
anthrose. Cross-reactivity with the disaccharide and the tetrasaccharide antigen was comparatively 
low (Fig. 2A). Sera from anthrose-rhamnose disaccharide immunized mice reacted best with the 
disaccharide immunogen itself, but also showed cross-reactivity with the anthrose monosaccharide 
and the B. anthracis tetrasaccharide (Fig. 2B). Sera and mAbs from tetrasaccharide immunized 
mice were highly specific for the tetrasaccharide (Fig. 2C and D, respectively). The three 
tetrasaccharide specific mAbs that were generated previously (Tamborrini et al. 2006) shared the 
IgG2b:λ isotype and exhibited similar fine specificity in all analyses.  
 Cross-reactivity of sera raised against the synthetic carbohydrate structures with the 
tetrasaccharide expressed by B. anthracis on the BclA protein was investigated by immunoblotting 
after separation of B. anthracis endospore lysate proteins by SDS-PAGE. With the endospore lysate 
of strain 1 (Table 1), all sera stained a double band with an apparent molecular weight of around 
~250 kDa, corresponding to the BclA glycoprotein (Fig. 3). In competition experiments the binding 
of the anti-tetrasaccharide mAbs (Fig. 3C) and of anti-tetrasaccharide serum IgG (data not shown) 
to the spore antigen of B. anthracis strain 1 was inhibited only by the synthetic tetrasaccharide in a 
concentration dependent manner. Partial structures, such as trirhamnose, rhamnose-anthrose 
disaccharide, monorhamnose (data not shown), anthrose and a variant of anthrose (data not shown) 
missing the 3-hydroxy-3-methylbutamido side chain (Fig. 3D) failed to compete the strong binding 
to the native tetrasaccharide antigen. Antigen binding of anti-disaccharide antiserum (Fig. 3B) was 
blocked by tetrasaccharide and disaccharide, but not by anthrose. All competitors containing 
anthrose blocked antigen binding of anti-anthrose immune serum, whereas the side chain variant of 
anthrose did not inhibit binding (Fig. 3C).  
 
 Diversity of post-translational modification of the BclA protein in different B. 
anthracis strains. Immunoblotting experiments with spore lysates of a set of 11 B. anthracis 
isolates (Table 1) yielded strain-specific multiple band staining patterns characteristic for the BclA 
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protein (Sylvestre et al. 2003), when an anti-B. thuringiensis antiserum was used as primary 
antibody (Fig. 4E). Although the BclA proteins have a calculated molecular-weight of only 20 – 39 
kDa, both high molecular weight bands (>150kDa) and low molecular weight bands (∼50kDa) 
appear, due to glycosylation of the protein (Sylvestre et al. 2003). Patterns obtained with the 
tetrasaccharide specific mAbs (Fig. 4B) and immune sera (data not shown) included high-
molecular-weight (>150kDa) bands for all strains tested. In the case of strains 1 and 2 as well as the 
„Sterne“ (34F2) strain (data not shown), staining of the high molecular weight band was very 
intense and no other bands became visible. Intense staining of low molecular weight bands was 
observed with strains 3 and 4 (∼55kDa) and 5 to 8 (∼50kDa) but not with strains 9 to 11, indicating 
a possible difference between strains in the levels of glycosylation. With disaccharide (Fig. 4C) and 
anthrose (Fig. 4D) specific immune sera comparable staining patterns were observed. However, 
with strains 3 to 11 staining of the high-molecular-mass bands in relation to the low molecular mass 
bands was increased, indicating that accessibility of the different epitopes differs for the high and 
low molecular weight bands.  
 To test whether immunoblot patterns correlated with the size and structure of the 
tetrasaccharide-carrying collagen-like region of the BclA protein, the bclA genes of the 11 B. 
anthracis strains were amplified by PCR and sequenced. While the amino- and carboxy-terminal 
sequence stretches were conserved, a wide variation in size of the central collagen-like regions from 
69 to 219 amino acids was observed (Table 1), as reflected by size differences of the PCR products 
(Fig 4A). The collagen-like regions varied in the numbers of GXX units and the number of BclA 
repeats, defined by (Sylvestre et al. 2003) as the 21-amino-acid sequence (GPT)5GDTGTT. In all 
eleven B. anthracis strains the same sets of four nucleotide sequences coded for the GPT repeats 
and the BclA repeats, respectively (data not shown).  
 Strains 1 and 2 associated with strong staining of the high-molecular-weight (>150kDa) 
bands had much larger collagen-like regions than the other strains (Table 1). The collagen-like 
regions of strains 3 and 4 that exhibited an additional ∼55kDa molecular weight band in 
immunoblotting were slightly larger than those of strains 5 to 8 that showed a slightly smaller 
(∼50kDa) band. The bclA genes of strains 9 to 11 that exhibited no low molecular weight bands 
were identical to those of strains 5 to 8. As indicated by gene exchange experiments (Sylvestre et al. 
2003), variations in the BclA protein banding patterns thus can be caused by posttranslational 
modifications that depend more on the genetic background of the strains than on the sequences of 
the bclA genes.  
 
 Cross-reactivity of antisera with endospores of B. cereus. In immunoblotting experiments 
with spore lysates of nine B. cereus strains covering the Cereus I, II and III lineages from the MLST 
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B. cereus clade 1 (Priest et al. 2004), tetrasaccharide specific mAbs (Fig. 5) as well as tetra-, di- and 
monosaccharide specific immune sera (data not shown) exhibited reactivity with three strains. 
Staining of a high-molecular-weight band with an anti-B. thuringiensis spore antiserum 
demonstrated the expression of the immunodominant BclA protein in all B. cereus strains. 
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Discussion 
 
 Specific detection and phenotypic differentiation of B. anthracis is challenging (Williams et 
al. 2003), due to its genetic similarity to other bacteria of the B. cereus group (Helgason et al. 
2000). Extensive genomic studies on strains of B. anthracis, B. cereus and B. thuringiensis have 
suggested that B. anthracis and B. thuringiensis are sub-species of the species B. cereus. The main 
difference between these sub-species is the presence of plasmids coding for insecticidal toxins in B. 
thuringiensis and the presence of the capsule plasmid pXO2 and the toxin plasmid pXO1 in B. 
anthracis (Edwards et al. 2005). DNA homology studies of different B. anthracis strains revealed 
evanescent small amounts of genomic variation. This significant homogeneity of B. anthracis may 
be the result of the organism surviving the majority of its life as a spore, where it is not exposed to 
DNA-altering events (Henderson et al. 1995, Helgason et al. 2000, Schupp et al. 2000). The BclA 
protein is an immunodominant spore antigen and it has been shown that the BclA protein itself and 
not its carbohydrate constituent directs the dominant immune response (Steichen et al. 2003). 
Identification of a BclA protein-associated tetrasaccharide with a previously undescribed terminal 
sugar anthrose in the animal vaccine strain “Sterne” of B. anthracis (Daubenspeck et al. 2004) had 
raised hope to have identified a B. anthracis specific antigen on the surface of the spore. It was 
proposed to use this antigen to develop a specific oligosaccharide-based detection system for B. 
anthracis spores, since anthrose was not found in spores of the B. cereus T strain and a B. 
thuringiensis ssp. kurstaki strain (Daubenspeck et al. 2004). The structural analysis of the 
tetrasaccharide was confirmed by our finding that monoclonal antibodies raised against the 
synthetic tetrasaccharide are cross-reactive with intact B. anthracis endospores of B. anthracis 
avirulent strain “Sterne” and highly virulent strain Ames in immunofluorescence assay (Tamborrini 
et al. 2006). Here we have tested these monoclonal antibodies and antisera raised against the 
tetrasaccharide, a rhamnose-anthrose disaccharide and anthrose for cross-reactivity with 
immunoblotted spore lysates of panels of B. anthracis and B. cereus strains. In immunoblotting 
experiments mAbs and immune sera cross-reacted with all B. anthracis isolates, but also with some 
of the B. cereus strains tested. The observed cross-reactivity demonstrates a broader presence of 
anthrose in the B. cereus group, supporting the phenotypic argument that B. cereus, B. thuringiensis 
and B. anthracis could be considered as a single bacterial species (Helgason et al. 2000). Recent 
genetic evidence demonstrating the presence of the anthrose biosynthetic operon in some B. cereus 
strains supports our findings (Dong et al. 2008). The collagen like region of the B. cereus BclA 
proteins contains GXX units harboring threonine residues representing sites for attachment of O-
linked oligosaccharides (Castanha et al. 2006).  
Chapter 7: Immuno-detection of anthrose in the B. cereus group 
 103 
 Four different BclA-related multiple-band patterns were observed. The multiplicity of bands 
is also seen when B. anthracis lysates are analyzed with anti-BclA protein antibodies (Sylvestre et 
al. 2003). We investigated whether the size and structure of the bclA genes and the corresponding 
proteins explains the observed differences in the anti-carbohydrate immunoblot patterns. Sequence 
differences were restricted to the polymorphic collagen-like regions of the BclA protein and 
correlations between the size of the collagen-like regions and the relative apparent molecular 
weights on SDS-PAGE gels were observed. However, for the B. anthracis strains 5 to 11, two 
different anti-tetrasaccharide blotting patterns were observed, while their bclA genes are identical. It 
has been demonstrated by gene exchange experiments (Sylvestre et al. 2003), that genetic 
background dependent posttranslational modifications of the BclA protein can cause such variations 
in the banding pattern. It has been suggested that posttranslational modifications, probably 
implicated in the stability or glycosylation of BclA are responsible for the multiple-band Western 
blotting patterns (Sylvestre et al. 2003). Our results with strains 5 to 11 emphasize the role of bclA 
gene-independent genetic factors in this phenomenon.  In contrast to the mono- and disaccharide 
specific sera, the tetrasaccharide specific antibodies, which seem to bind to a complex epitope 
comprising all four sugar residues of the tetrasaccharide, showed preferential binding to the bands 
with low apparent molecular weight. This observation may indicate that the tetrasaccharide as a 
whole is better accessible in the low molecular weight BclA species. While anti-anthrose and anti-
disaccharide antibodies are likely to bind, even if only the terminal residues are easily accessible, 
the anti-tetrasaccharide antibodies are likely to be much more sensitive to shielding of the deeper 
parts of the tetrasaccharide. Alternatively, glycosyl chains associated with high and low molecular 
weight species may slightly differ in their structure. Changes in the tri-rhamnose core structure, 
such as lack or substitution of one of the rhamnose residues are likely to affect the tetrasaccharide-
specific antibodies but not those raised against anthrose or anthrose-rhamnose.  
 Even though the antibodies generated against anthrose-containing structures are not strictly 
specific for B. anthracis, they detect spore lysates of B. anthracis from a broad phylogenetic 
spectrum, thus representing a valuable immuno-capturing component for a highly sensitive spore 
detection system. Such sensitive immunoassays would be plagued by false-positive results but 
would afford a quick exclusion of negative samples from further analysis. Subsequent confirmatory 
expensive and time-consuming diagnostic tests with high specificity, such as real-time PCR or 
standard culture methods that focus on the vegetative form, are therefore minimized. Moreover it 
would be important to detect spores of B. cereus, since it is an opportunistic human pathogen and 
might be used as basis for engineered biological weapons.   
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Tables and Figures 
 
Table 1. Comparative analysis of the CLR composition of BclA from sequenced PCR products 
 
Strains     Cluster Origin    BclA protein of CLR 
     [according to     GPT  BclA repeats GXX repeats 
     Pilo et al. 2008]     repeats  [(GPT)5GDTGTT] [present once]  
 
Nr. 1     A4  Human Anthrax Switzerland 54  6  GAT 
JF3788   from wool factory 1981      GLT 
           GPS 
           GLG 
  
Nr. 2     A3B  Cattle central Switzerland  57  5  GAT 
JF3853   1952        GLT 
           GPS 
           GLG 
           GDT 
           GTT 
 
Nr. 3     B2  Cattle Bern Switzerland  21  1  GAT 
JF3852   1953        GLT 
           GPS 
           GLG 
 
Nr. 4     B2  Cattle central Switzerland   21  1  GAT 
JF3854   1957        GLT 
           GPS 
           GLG 
 
Nr. 5     A4  Human Anthrax Switzerland 17  1  GAT 
JF3783   from wool factory 1981      GLT 
           GPS 
           GLG 
 
Nr. 6     A4  Air filter wool processing   17  1  GAT 
JF3784   factory with outbreak 1981     GLT 
           GPS 
           GLG 
 
Nr. 7     A4  goat hair, wool processing  17  1  GAT 
JF3785   factory with outbreak 1981     GLT 
           GPS 
           GLG 
 
Nr. 8     A4  unknown origin   17  1  GAT 
JF3851           GLT 
           GPS 
           GLG 
 
Nr. 9     A4  goat hair, wool processing  17  1  GAT 
JF3786   factory with outbreak 1981     GLT 
           GPS 
           GLG 
 
Nr. 10     A4  goat hair, wool processing  17  1  GAT 
JF3787   factory with outbreak 1981     GLT 
           GPS 
           GLG 
 
Nr. 11     nd  unknown origin   17  1  GAT 
A73           GLT 
           GPS 
           GLG 
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Fig. 1. Structure of the synthetic tetrasaccharide (1) of the major surface glycoprotein of Bacillus 
anthracis and deletion sequences of it: anthrose-rhamnose (2; disaccharide); anthrose (3; 
monosaccharide). Attachment via a pentenyl handle to KLH carrier protein afforded the conjugates 
for immunological studies. 
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Fig. 2. Development of mouse IgG responses specific for the anthrose-containing tetrasaccharide, 
disaccharide and monosaccharide compounds shown in Fig. 1. Mice were immunized with 
monosaccharide-KLH (A) disaccharide-KLH (B) or tetrasaccharide-KLH (C) formulations. Shown 
are ELISA readouts obtained with serial dilution of mouse sera taken pre-immune (PI) and two 
weeks after the second, third or fourth immunization. Response patterns of individual 
tetrasaccharide specific mAbs (MTA1; MTA2; MTA3) are depicted in D. In (A) and (B) mean 
ELISA readouts ± SD of sera from three mice are shown. 
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Fig. 3. Competition Western blot experiments with a set of overlapping synthetic sugars were used 
for epitope mapping. B. anthracis endospore suspensions were separated by SDS-10% PAGE under 
reducing conditions and blotted onto a nitrocellulose membrane. Anti-monosaccharide mouse sera 
(A), anti-disaccharide mouse sera (B) and mAb MTA1 (C) were pre-incubated with synthetic 
competitors and afterwards added to cut strips. After incubation with an alkaline phosphatase-
conjugate blots were developed with 5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium to visualize bands. (D) Structures of different competitors used. Anthrose* = anthrose 
without the 3-hydroxy-3-methylbutamido chain. k = no competitor. a = 100 µg/ml competitor. b = 1 
µg/ml competitor. Immune sera were used at a dilution of 1:2000 and mAb MTA1 at a 
concentration of 1 µg/ml.  
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Fig. 4. (A) Differences in the size of the bclA gene in 11 B. anthracis strains (lanes 1 to 11; see also 
table 1). The sequences encoding the collagen-like regions were amplified by PCR and analyzed by 
2% agarose gel electrophoresis. Molecular size markers are indicated in base pairs (bp). (B - E) 
Western blot analysis with spore lysates of the 11 B. anthracis strains. Endospore lysates were 
separated by SDS-10% PAGE and blotted onto a nitrocellulose membrane. Blots were incubated 
with anti-tetrasaccharide mAb MTA1 [0.01µg/ml] (B), with disaccharide- (C), anthrose- (D) and B. 
thuringiensis-antisera (E). All immune sera were used at a dilution of 1:1000 and blots were 
developed using the ECL system. The sizes of the molecular weight markers are given in kDa. (F) 
EZBlueTM (Sigma) protein staining of the 11 B. anthracis separated endospore lysates on a SDS-
10% gel.  
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Fig. 5. Western blot analysis of the reactivity of anti-tetrasaccharide mAb MTA1 (A) and anti-B. 
thuringiensis antiserum (B) with spore lysates. Total spore-lysates of B. anthracis strain 1 (lane 1), 
B. cereus F4370/75 (lane 2), B. cereus m1545 (lane 3), B. cereus m1564 (lane 4), B. cereus m1293 
(lane 5), B. cereus F4810/72 (lane 6), B. cereus ATCC 10876 (lane 7), B. cereus ATCC 13061 (lane 
8), B. cereus ATCC 14579 (lane 9), B. cereus ATCC 33019 (lane 10) and B. thuringiensis ATCC 
29730 (lane 11) were separated by SDS-10% PAGE and blotted onto a nitrocellulose membrane. 
Anti-B. thuringiensis antiserum was used at a dilution of 1:1000 and the mAb at a concentration of 
0.01µg/ml. (C) EZBlueTM (Sigma) protein staining of the 11 Bacillus species separated on a SDS-
10% gel. The sizes of the molecular mass markers are given in kDa. 
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Supplementary material 
 
 General Methods: All chemicals used were reagent grade and used as supplied except 
where noted. Dichloromethane (CH2Cl2) was purchased from JT Baker and purified by a Cycle-
Tainer Solvent Delivery System. Pyridine and acetonitrile were refluxed over calcium hydride and 
distilled prior to use. Analytical thin-layer chromatography was performed on E. Merck silica gel 
60 F254 plates (0.25 mm). Compounds were visualized by dipping the plates in a cerium sulfate 
ammonium molybdate solution or a sulphuric acid/methanol solution (for fully deprotected 
compounds) followed by heating. Liquid chromatography was performed using forced flow of the 
indicated solvent on Sigma H-type silica (10–40 mm). HPLC purifications were performed by a 
Waters system 2420, using a reversed-phase C18 column. 1H NMR spectra were obtained on a 
Varian VXR-300 (300 MHz), Bruker-600 (600 MHz), and are reported in parts per million (δ) 
relative to CHCl3 (δ = 7.26 ppm) or in the case of CD3OD as solvent relative to TMS (δ = 0.00 
ppm). Coupling constants (J) are reported in Hertz (Hz). 13C NMR spectra were obtained on a 
Varian VXR-300 (75 MHz), Bruker-600 (150 MHz) and are reported in δ relative to CDCl3 (δ = 
77.0 ppm) as an internal reference or to TMS (δ = 0.00 ppm). For α/β mixtures we abstained from 
measuring [α]D values. 
 
 Pent-4-enyl 4-Azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-β-D-glucopyranoside (2): 
4-Azido-3-O-benzyl-4,6-dideoxy-2-O-levulinoyl-β-D-glucopyranosyl Trichloroacetimidate1 1 (310 
mg, 0.594 mmol , 1.0 equiv.) was azeotroped three times with toluene and dried in vacuo for 30 
min. CH2Cl2 (7 mL) was added as well as 4-pentenol (205 mg, 2.380 mmol, 4.0 equiv.) . The 
solution was cooled to −35 °C. TMSOTf (13 mg, 11 µL, 0.059 mmol, 0.1 equiv.) was added and the 
reaction mixture stirred for 40 min. Then, the reaction was quenched by addition of pyridine (0.1 
mL). Column chromatography on silica gel (cyclohexane/EtOAc, 3:1) yielded 225 mg (85%) as a 
colorless solid: [α]D = 109.1 (c = 1.0, CHCl3). IR (thin film, CHCl3): 3005, 2933, 2872, 2103, 1744, 
1713, 1415, 1359, 1154, 1072 cm−1. 1H NMR (CDCl3, 300 MHz): δ = 1.35 (d, J = 5.7 Hz, 3H), 
1.61−1.73 (m, 2H), 2.03−2.18 (m, 2H), 2.15 (s, 3H), 2.48−2.53 (m, 2H), 2.67−2.72 (m, 2H), 
3.16−3.26 (m, 2H), 3.39−3.56 (m, 2H), 3.78−3.85 (m, 1H), 4.29 (d, J = 7.8 Hz, 1H), 4.69 (d, J = 
11.1 Hz, 1H), 4.78 (d, J = 11.4 Hz, 1H), 4.94−5-03 (m, 3H), 5.74−5.83 (m, 1H), 7.26−7.35 (m, 5H) 
ppm. 13C NMR (CDCl3, 75 MHz): δ = 18.6, 28.1, 28.9, 30.1, 30.1, 38.0, 67.9, 69.3, 70.9, 73.9, 75.0, 
81.4, 101.0, 115.1, 128.1, 128.4, 128.6, 137.8, 138.2, 171.5, 206.3 ppm. MALDI-HRMS: m/z [M + 
Na]+ calc.468.2105, obsd. 468.2097. 
 
                                                
1 D.B. Werz, P.H. Seeberger, Angew. Chem. Int. Ed. 2005, 44, 6315-6318. 
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 Pent-4-enyl 4-Azido-3-O-benzyl-4,6-dideoxy-β-D-glucopyranoside (3): The glycoside 2 
(225 mg, 0.505 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (5 mL), pyridine (133 µL), AcOH (66 
µL) , and hydrazine monohydrate (3.5 µL, 1.010 mmol, 2.0 equiv.) were added. The reaction 
mixture was stirred for 1 h at room temperature. The reaction was quenched by addition of acetone 
(1 mL) and concentrated. Column chromatography on silica gel (cyclohexane/EtOAc 5:1) yielded 
121 mg (69 %) of a colorless oil; [α]D = 39.6 (c = 0.5, CHCl3). IR (thin film, CHCl3): 3008, 2936, 
2110, 1454, 1354, 1065 cm−1. 1H NMR (CDCl3, 300 MHz): δ = 1.35 (d, J = 6.0 Hz, 3H), 1.67−1.79 
(m, 2H), 2.11−2.18 (m, 2H), 2.48 (s, 1H), 3.11−3.3.72 (m, 2H), 3.41−3.58 (m, 3H), 3.87−3.94 (m, 
1H), 4.19 (d, J = 7.5 Hz, 1H), 4.84 (d, J = 11.1 Hz, 1H), 4.95−5.07 (m, 3H), 5.77−5.87 (m, 1H), 
7.30−7.44 (m, 5H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 18.6, 29.0, 30.2, 60.6, 67.4, 69.3, 70.3, 
75.4, 82.7, 84.2, 103.2, 114.9, 127.8, 128.2, 128.3, 137.9 ppm. MALDI-HRMS: m/z [M + Na]+ 
calc. 347.1840, obsd. 347.1834. 
 
 Pent-4-enyl 4-Azido-3-O-benzyl-4,6-dideoxy-2-O-methyl-β-D-glucopyranoside (4): The 
glycoside 3 (120 mg, 0.345 mmol, 1.0 equiv.) was dissolved in DMF (6 mL) and cooled to 0 °C. 
Sodium hydride (23 mg, 0.575 mmol, 1.6 equiv.) was added, then methyl iodide (125 mg, 39 µL, 
0.881 mmol, 2.6 equiv.) was added and the mixture was stirred over night. The reaction mixture 
was poured into water and extracted twice with EtOAc. The combined organic phases were washed 
with brine, dried over MgSO4 and concentrated. Column chromatography on silica gel 
(cyclohexane/EtOAc 10:1) was performed to yield 119 mg (95 %) as a colorless oil: [α]D = 37.4 (c 
= 0.5, CHCl3). IR (thin film, CHCl3): 2928, 2110, 1454, 1354, 1261, 1088, 1029 cm−1. 1H NMR 
(CDCl3, 300 MHz): δ = 1.33 (d, J = 5.7 Hz, 3H), 1.71−1.77 (m, 2H), 2.14−2.21 (m, 2H), 3.09−3.22 
(m, 3H), 3.40 (t, J = 9.1 Hz, 1H), 3.47−3.55 (m, 1H), 3.62 (s, 3H), 3.88−3.93 (m, 1H), 4.23 (d, J = 
8.1 Hz, 1H), 4.80 (d, J = 10.5 Hz, 1H), 4.91 (d, J = 10.5 Hz, 1H), 4.98−5.08 (m, 2H), 5.76−5.87 (m, 
1H), 7.31−7.44 (m, 5H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 18.6, 29.0, 30.2, 60.6, 60.6, 67.5, 
69.3, 70.3, 75.4, 82.7, 84.2, 103.2, 114.9, 127.8, 128.2, 128.3, 137.9 ppm. MALDI-HRMS: m/z [M 
+ Na]+ calc. 384.1894, obsd. 384.1895. 
 
 Pent-4-enyl 4-Amino-4,6-dideoxy-2-O-methyl-β-D-glucopyranoside (5): The glucoside 4 
(118 mg, 0.326 mmol, 1.0 equiv.) was dissolved under an Ar atmosphere in THF (7 mL) and 
ammonia was condensed into the reaction vessel at -78 °C until the mixture reached a volume of 
about 20 mL. Small pieces of carefully washed sodium were added to the reaction vessel affording 
a solution with a deep blue color. After 30 min the reaction was quenched by adding some drops of 
methanol. Again, small pieces of sodium were added until the blue color persists for at least 30 min. 
The reaction was quenched by adding several mL of methanol. The dry ice bath was removed, the 
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reaction mixture was allowed to warm to room temperature in order to evaporate the ammonia. 
Amberlite IR-120 acidic resin (washed) was added until pH 7 was reached. The mixture was 
filtered, rinsed and concentrated. The crude product was purified by column chromatography using 
a reverse phase column C 18 silica gel (MeOH/H2O). The product containing fractions were 
combined and concentrated affording 36 mg (44%) of a colorless solid; [α]D = −30.4 (c = 0.5, 
CHCl3). IR (thin film, CHCl3): 3596, 3008, 1602, 1373, 1173, 1078, 910 cm−1. 1H NMR (CDCl3, 
300 MHz): δ = 1.27 (d, J = 6.0 Hz, 3H), 1.67−1.77 (m, 3H), 2.10−2.18 (m, 2H), 2.48 (t, J = 9.6 Hz, 
1H), 2.96 (d, J = 7.8 Hz, 1H), 3.15−3.26 (m, 2H), 3.42−3.58 (m, 2H), 3.60 (s, 3H), 3.87−3.94 (m, 
1H), 4.25 (d, J = 8.1 Hz, 1H), 4.94−5.05 (m, 2H), 5.76−5.86 (m, 1H) ppm. 13C NMR (CDCl3, 75 
MHz): δ = 17.7, 28.8, 30.1, 58.2, 60.5, 69.0, 72.9, 75.7, 83.6, 103.2, 114.8, 138.0 ppm. MALDI-
HRMS: m/z [M + H]+ calc. 246.1700, obsd. 246.1698. 
 
 n-Pentenyl 4,6-Dideoxy-4-(3-hydroxy-3-methylbutanamido)-2-O-methyl-β-D-
glucopyranoside (6): The glucoside 5 (30 mg, 0.122 mmol) was dissolved in DMF (4 mL) and 
3-hydroxy-3-methylbutyric acid (29 mg, 0.245 mmol) in 0.5 mL of DMF were added. HATU 
(88 mg, 0.232 mmol), followed by N,N,-diisopropylethylamine (63 mg, 81.0 µL, 0.489 mmol) was 
added yielding a slightly yellow solution. The mixture is stirred at room temperature for 2 h. All 
volatiles were removed in vacuo. The residue was purified by column chromatography using silica 
gel (dichloromethane/methanol 4:1) and further purified by using a reverse phase column C18 silica 
gel (MeOH/H2O). The product containing fractions were combined and concentrated affording 32 
mg (76%) of a colorless solid; [α]D = −26.8 (c = 0.5, CHCl3). IR (thin film, CHCl3): 3430, 3008, 
2934, 1731, 1664, 1251, 1374, 1076 cm−1. 1H NMR (CDCl3, 300 MHz): δ = 1.25−1.31 (m, 9H), 
1.70−1.78 (m, 2H), 2.11−2.19 (m, 2H), 2.38 (s, 2H), 3.00 (t, J = 8.1 Hz, 1H), 3.27 (s, 1H), 
3.43−3.53 (m, 3H), 3.61 (s, 3H), 3.65 (d, J = 9.0 Hz, 1H), 3.73 (s, 1H), 3.87−3.95 (m, 1H), 4.25 (d, 
J = 7.8 Hz, 1H), 4.95−5.06 (m, 2H), 5.75−5.86 (m, 1H), 6.15 (d, J = 8.7 Hz, 1H) ppm. 13C NMR 
(CDCl3, 75 MHz): δ = 18.1, 29.0, 29.3, 29.8, 30.3, 48.7, 57.0, 60.7, 69.1, 69.9, 70.7, 74.0, 83.9, 
103.0, 114.9, 137.9, 172.8 ppm. MALDI-HRMS: m/z [M + Na]+ calc. 368.2049, obsd. 368.2038. 
 
 Pent-4-enyl 4-Azido-3-O-benzyl-6-desoxy-2-O-methyl-β-D-glucopyranosyl-(1→3)-2-O-
benzoyl-4-O-benzyl-α-L-rhamnopyranoside (8): 4-Azido-3-O-benzyl-6-desoxy-2-O-methyl-β-D-
glucopyranosyl-(1→3)-2-O-benzoyl-4-O-benzyl-α-L-rhamnopyranosyl Trichloroacetimidate 7 (85 
mg, 0.109 mmol , 1.0 equiv.) was azeotroped three times with toluene and dried in vacuo for 30 
min. CH2Cl2 (2.5 mL) was added as well as 4-pentenol (38 mg, 0.441 mmol, 4.0 equiv.). The 
solution was cooled to −30 °C . TMSOTf ( 2.5 mg, 2.0 µL, 0.011 mmol, 0.1 equiv.) was added and 
the reaction mixture stirred for 30 min. Then, the reaction was quenched by addition of pyridine 
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(0.1 mL). Column chromatography on silica gel (cyclohexane/EtOAc, 10:1) yielded 48 mg (63%) 
as a colorless solid: [α]D = 48.4 (c = 0.5, CHCl3). IR (thin film, CHCl3): 2936, 2110, 1720, 1270, 
1069 cm−1. 1H NMR (CDCl3, 300 MHz): δ = 1.23 (d, J = 5.9 Hz, 3H), 1.38 (d, J = 6.2 Hz, 3H), 
1.65−1.75 (m, 2H), 2.10−2.18 (m, 2H), 3.00−3.20 (m, 3H), 3.28−3.44 (m, 2H), 3.52 (s, 3H), 
3.58−3.71 (m, 2H), 3.80−3.86 (m, 1H), 4.28 (dd, J = 3.5, 9.4 Hz, 1H), 4.60 (d, J = 7.8 Hz, 1H), 4.70 
(d, J = 10.4 Hz, 1H), 4.78 (d, J = 10.8 Hz, 1H), 4.82 (d, J = 12.5 Hz, 1H), 4.86 (d, J = 13.0 Hz, 1H), 
4.96−5.08 (m, 3H), 5.36 (dd, J = 1.8, 3.4 Hz, 1H), 5.75−5.89 (m, 1H), 7.26−7.49 (m, 12H), 
7.56−7.61 (m, 1H), 8.07 (d, J = 7.2 Hz, 2H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 18.1, 18.4, 28.7, 
30.3, 60.5, 67.2, 67.4, 67.6, 70.4, 73.3, 75.0, 75.3, 76.4, 80.9, 82.7, 84.4, 97.2, 102.9, 114.9, 127.7, 
127.8, 128.1, 128.1, 128.2, 128.3, 128.4, 129.6, 130.2, 132.9, 137.8, 137.9, 138.0, 165.7 ppm. 
MALDI-HRMS: m/z [M + Na]+ calc.724.3205, obsd. 724.3218. 
 
 Pent-4-enyl 4-Azido-3-O-benzyl-6-desoxy-2-O-methyl-?-D-glucopyranosyl-(1?3)-O-
benzyl-?-L-rhamnopyranoside (9): Disaccharide 8 48 mg, (68.4 µmol) was dissolved in MeOH 
(8 mL) and NaOMe (0.6 mL, 0.5 M in MeOH) was added. The mixture was stirred over night. The 
solution was neutralized by treating with Amberlite IR-120, filtered and washed. The solvent was 
removed under reduced pressure, the residue was purified by flash chromatography 
(cyclohexane/EtOAc 4:1) to afford: 41 mg (68 µmol, quant.) as a colorless oil: [α]D = 5.2 (c = 0.5, 
CHCl3). IR (thin film, CHCl3): 3008, 2911, 2111, 1453, 1384, 1093, 1064 cm−1. 1H NMR (CDCl3, 
300 MHz): δ = 1.30−1.34 (m, 6H), 1.62−1.72 (m, 2H), 2.05−2.15 (m, 2H), 2.81 (s, 1H), 3.09−3.26 
(m, 3H), 3.37−3.44 (m, 2H), 3.48−3.52 (m, 1H), 3.57 (s, 3H), 3.64−3.78 (m, 2H), 3.99−4.01 (m, 
2H), 4.54 (d, J = 7.8 Hz, 1H), 4.61 (d, J = 10.8 Hz, 1H), 4.78−4.93 (m, 4H), 4.96−5.05 (m, 2H), 
5.74−5.85 (m, 1H), 7.26−7.43 (m, 10H) ppm. 13C NMR (CDCl3, 75 MHz): δ = 18.1, 18.7, 28.7, 
30.4, 60.8, 66.9, 67.2, 67.3, 70.5, 70.6, 74.9, 75.5, 79.8, 81.2, 82.9, 84.2, 99.0, 102.9, 114.9, 127.7, 
127.8, 128.0, 128.3, 128.4, 137.7, 137.9, 138.2 ppm. MALDI-HRMS: m/z [M + Na]+ 
calc.620.2942, obsd. 620.2942. 
 
 Pent-4-enyl 4-Amino-4,6-dideoxy-2-O-methyl-β-D-glucopyranosyl-(1?3)-?-L-
rhamnopyranoside (10): The glucoside 9 (40 mg, 66.9 µmol) was dissolved under an Ar 
atmosphere in THF (7 mL) and ammonia was condensed into the reaction vessel at -78 °C until the 
mixture reached a volume of about 20 mL. Small pieces of carefully washed sodium were added to 
the reaction vessel affording a solution with a deep blue color. After 30 min the reaction was 
quenched by adding some drops of methanol. Again, small pieces of sodium were added until the 
blue color persists for at least 30 min. The reaction was quenched by adding several mL of 
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methanol. The dry ice bath was removed, the reaction mixture was allowed to warm to room 
temperature in order to evaporate the ammonia. Amberlite acidic resin (washed) was added until pH 
7 was reached. The mixture was filtered, rinsed and concentrated. The crude product was purified 
by column chromatography using a reverse phase column C 18 silica gel (MeOH/H2O). The 
product containing fractions were combined and concentrated affording 21 mg (80%) of a colorless 
solid; [α]D = −51.6 (c = 0.5, CHCl3). IR (thin film, CHCl3): 3590, 3008, 2927, 1449, 1382, 1056 
cm−1. 1H NMR (CD3OD, 300 MHz): δ = 1.25 (d, J = 6.3 Hz, 6H), 1.66−1.73 (m, 3H), 2.11−2.18 
(m, 2H), 2.36 (t, J = 9.6 Hz, 1H), 2.96 (t, J = 8.4 Hz, 1H), 3.16−3.33 (m, 2H), 3.35−3.44 (m, 1H), 
3.47−3.76 (m, 7H), 3.98−3.99 (m, 1H), 4.58 (d, J = 7.8 Hz, 1H), 4.65 (s, 1H), 4.94−5.06 (m, 2H), 
5.78−5.88 (m, 1H) ppm. 13C NMR (CD3OD, 75 MHz): δ = 17.8, 18.2, 29.6, 31.2, 59.5, 60.7, 67.6, 
69.6, 71.7, 72.7, 73.2, 76.7, 81.4, 85.0, 101.0, 105.4, 114.9, 138.9 ppm. MALDI-HRMS: m/z [M + 
H]+ calc. 414.2098, obsd. 414.2097. 
 
 n-Penteny l4,6-Dideoxy-4-(3-hydroxy-3-methylbutanamido)-2-O-methyl-β-D-
glucopyranosyl-(1?3)-?-L-rhamnopyranoside (11): The glucoside 10 (20 mg, 51.1 µmol) was 
dissolved in DMF (4 mL) and 3-hydroxy-3-methylbutyric acid (12 mg, 102 µmol) in 0.5 mL of 
DMF were added. HATU (37 mg, 97 µmol), followed by N,N,-diisopropylethylamine (26 mg, 33 
µL, 201 mmol) was added yielding a slightly yellow solution. The mixture is stirred at room 
temperature for 2 h. All volatiles were removed in vacuo. The residue was purified by column 
chromatography using silica gel (dichloromethane/methanol 4:1) and further purified by using a 
reverse phase column C 18 silica gel (MeOH/H2O). The product containing fractions were 
combined and concentrated affording 21 mg (84%) of a colorless solid: [α]D = −50.0 (c = 0.5, 
CHCl3). IR (thin film, CHCl3): 3429, 3008, 2928, 1663, 1520, 1383, 1075 cm−1. 1H NMR (CD3OD, 
300 MHz): δ = 1.20 (d, J = 6.0 Hz, 3H), 1.25−1.28 (m, 9H), 1.66−1.73 (m, 2H), 2.11−2.18 (m, 2H), 
2.36 (d, J = 3.0 Hz, 2H), 3.02 (t, J = 8.4 Hz, 1H), 3.34−3.45 (m, 2H), 3.50−3.76 (m, 8H), 3.97−3.99 
(m, 1H), 4.59 (d, J = 8.1 Hz, 1H), 4.87 (s, 1H), 4.95−5.05 (m, 2H), 5.79−5.88 (m, 1H) ppm. 13C 
NMR (CD3OD, 75 MHz): δ = 17.7, 18.2, 29.3, 29.4, 29.6, 31.2, 57.7, 60.8, 67.5, 69.6, 70.3, 71.7, 
72.6, 74.6, 81.3, 85.1, 101.0, 105.2, 114.9, 138.8, 174.0 ppm. MALDI-HRMS: m/z [M + Na]+ calc. 
514.2623, obsd. 514.2629. 
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Scheme 1. Synthesis of anthrose 6 
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Scheme 2. Synthesis of disaccharide 11 
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1H NMR (CDCl3, 300 MHz) spectrum of compound 6 
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1H NMR (CD3OD, 300 MHz) spectrum of compound 11 
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8.1 General Discussion  
 
8.1.1 Malaria Control, a Changing Concept from Prevalence-based to Disease-based 
 Vaccines 
 
 In ancient times malaria was understood as God’s punishment for human sins. The idea that 
the environment could affect human health by means of miasms associated with swamps was also 
applied to malaria. In the age of Renaissance the concept of contagion was introduced, which was 
later on replaced by that of infectious agents. In the 20th century a better understanding of the 
pathological aspects of the disease allowed to consider severe malaria as an immune 
endotheliopathy. At present a novel concept about malaria is assumed: malaria as the result of 
disequilibrium of the system ‘human-plasmodium-mosquito’ (1). If this system is maintained in 
equilibrium, malaria does not ensue, and the result is asymptomatic plasmodium infection. 
Epidemiological studies show that asymptomatic malaria infections outnumber the symptomatic 
cases. These observations lead to the conclusion that the state of equilibrium or adaptation is the 
rule in human host-plasmodium relationships. Clinical manifestations, particularly the rare 
occurrence of severe and complicated forms of malaria, can be considered as a stage before 
equilibrium is reached or is lost either due to an overgrowth of the parasite and/or to dysfunction of 
the immune system (1).   
 The currently available strategies for malaria control rely on destruction by fighting malaria 
parasites with drugs and the anopheline vectors with insecticides (2, 3). This combined approach 
proved remarkably effective in Europe and North America, whereas malaria continues to represent 
a huge burden in sub-Saharan Africa, Asia and South and Central America mainly due to drug-
resistant parasites and insecticide resistant vectors (4). Pyrethroid-treated bednets are the mainstay 
of malaria control programs. Pyrethroids are highly effective insecticides showing low mammalian 
toxicity levels and currently the only class of insecticide available for use on bednets (5). Therefore 
the emergence of pyrethroid resistance threatens the successful use of insecticide-treated materials 
(6, 7). Resistance of plasmodium to antimalarial therapy has been described in endemic areas as a 
consequence of drug pressure (8). There is no doubt that the speed drug resistance occurs is far 
faster than that new antimalarial drugs are developed. It is possibly considered unreasonable to base 
malaria control on the destruction of plasmodia and mosquitoes, species extremely much older and, 
therefore, more selected and adaptable, than human beings (1). 
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 An effective malaria vaccine is not yet available, in part because of the high antigenic and 
biological complexity of the parasite; the lack of adequate models for the infection; the insufficient 
understanding of anti-plasmodial immunity; the unavailability of reliable parameters and tests for 
assessing protective immunity; the difficulty of identifying, selecting and producing the appropriate 
protective antigens from a parasite with a genome of well over five thousand genes (9); the frequent 
need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or 
delivery systems; and the genetic restriction of immune responses of the target-population (1, 10). 
 The traditional approach to develop malaria vaccines has focused on targeting one of the 
different stages of parasite development, whether the pre-erythrocytic, the intra-erythrocytic or the 
sexual stage. Pre-erythrocytic vaccine strategies aim to generate antibodies able to neutralize 
sporozoites and prevent them from invading hepatocytes, as well as to elicit a cell-mediated 
immune response able to interfere with the intra-hepatic schizogony. Asexual blood-stage vaccine 
strategies aim to elicit antibodies that will inactivate merozoites and target malarial antigens 
expressed on the RBC surface through antibody-dependent cellular cytotoxicity and complement 
lysis; and also are meant to elicit T cell responses able to inhibit the development of the parasite in 
RBCs (10). Transmission-blocking vaccines are aimed to induce antibodies against the sexual stage 
antigens in order to prevent the development of infectious sporozoites in the salivary glands of the 
mosquitoes (11). They are intended to protect communities from infection, not individuals from 
disease.  
 The usually expected outcome of malaria vaccines has been the reduction of local malaria 
prevalence. Therefore, first attempts in malaria vaccine development aimed at sterile protection 
from infection, which can only be achieved with a pre-erythrocytic vaccine. Indeed, irradiated 
sporozoites (12) and the RTS,S/AS02A (13) vaccine, which consists of a P. falciparum CSP 
polypeptide fused to the recombinant S antigen of hepatitis B virus, succeeded in conferring sterile 
protection to immunized volunteers experimentally infected after vaccination. However, the 
feasibility of a sporozoite vaccine remains doubtful and RTS,S/AS02A failed to show sterile 
protection in the field (14). One objection raised against sporozoite, liver-stage and sexual stage 
vaccines is that by interrupting transmission and preventing blood-stage infection, they may 
paradoxically prevent the acquisition of immunity in naive children or allow the waning of acquired 
immunity in adults, leading to more severe malaria once breakthrough infections establish (15).  
 Therefore the expected outcome of modern malaria vaccine development has shifted from 
protecting against the parasite to surviving with the parasite but without experiencing the noxious 
effects it can cause. The aim of such an anti-disease vaccine would be to prevent both parasite 
overgrowth and the over-stimulation of the immune system, the two causes of mortality in malaria. 
Blood-stage antigens and parasite toxins may represent the key components of an effective anti-
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disease vaccine that permits the establishment of the natural equilibrium in the ‘human-
plasmodium-mosquito’ system.  
 Asexual blood-stage vaccines are aimed to primarily protect against severe malaria disease, 
and not against infection, on the assumption that inhibition of parasite invasion cycles will lead to 
reduced parasite burden and decreased morbidity and mortality (16). Nonetheless, an alternative 
view is that reducing the replication of bloodstage parasites will not necessarily reduce morbidity or 
mortality, because host immune responses, which can be non-linear with respect to parasite 
densities, are important determinants of these events (17). Merozoite surface proteins are a major 
focus of research for blood-stage vaccines and the favoured candidates for future trials are MSP1 
and AMA1. Other merozoite proteins (MSP3, MSP4, MSP5, RAP2, D13 and GLURP) are at an 
earlier stage along the vaccine development path (1, 18).  
 As noted, the primary objective of a malaria vaccine is to reduce morbidity and mortality. 
Therefore, the novel concept of developing an anti-toxic vaccine is justified on the extensive 
evidence that malaria morbidity and fatalities have a toxic basis. However, it has been argued that 
anti-toxic vaccines might aggravate disease by inhibiting the acute-phase responses that limit 
parasite replication (19). Putative malaria toxins include GPI (sect. 1.2.2), haemozoin (an insoluble 
digestion product of trophozoites comprising detoxified haemoglobin, as well as remnants of host 
and parasite membranes) and anti-malaria IgE-antigen complexes (20-22). Anti-GPI antibodies 
have been proposed as mediators of anti-disease immunity and it is controversially debated, whether 
GPI could be a suitable component of a malaria vaccine (23).  
 
8.1.2 A Dualistic Approach to study the Relevance of Anti-GPI Immune Response for 
 Protection against Malaria  
 
 The pathological significance of GPIs has to be confirmed by studies of pathophysiology 
and natural immunity using more accurate analysis. The carbohydrate microarray based on 
synthetic PfGPI glycans developed in this thesis represented a dualistic device to test the hypothesis 
that this molecule is causally involved in malaria pathogenesis: natural immunity was analysed with 
the array by assessing levels and fine specificities of anti-GPI antibodies in healthy and malaria 
exposed individuals. In addition the microarray served as immunoassay for the selection of GPI 
specific B cells. The generated monoclonal anti-GPI antibodies also emerged as a dualistic tool to 
experimentally investigate the potential of anti-GPI antibodies as vaccine component and to study 
the GPI-anchored proteome of Apicomplexa species. 
 Understanding the relationship between GPI structures and anti-GPI antibody-binding 
activities is needed for a rational design of GPI-based vaccine candidates. The high throughput 
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serum screening strategy revealed a structure-dependent binding of anti-GPI antibodies to the GPI 
fragments. Anti-Man3 GPI response was associated with malaria-exposure whereas anti-Man4 GPI 
response was also observed with malaria-unexposed Caucasians. This indicates that immune 
responses against GPI or GPI-crossreactive carbohydrate antigens of non-malarial pathogens 
contribute to the overall anti-GPI antibody repertoire. Our data demonstrate, that results of 
serological analysis obtained with GPI isolated from P. falciparum parasites would critically 
depend on the ratio of Man3 to Man4 GPI in the antigen preparations used. In serological studies 
performed with purified GPI people who were not exposed to the malaria parasite were reported to 
completely lack anti-GPI antibodies (25). Epitope specificities of naturally occurring anti-GPI 
antibodies were also analysed with purified Man4 GPI, Man3 GPI and GPIs lacking a fatty acid 
substituent (26). In contrast to our results these studies showed a dual requirement of the glycan and 
lipid moieties of GPIs for antibody binding and, an absence of GPI specific antibodies in sera from 
healthy U.S. controls even when using Man4 GPI coated ELISA plates. Assuming that the 
preparations used were pure and free from contamination, these findings could indicate that the 
coating of purified material in ELISA plates may result in a conformation of the GPI molecule 
where the access of anti-GPI antibodies directed only to the glycan moiety is hindered. Thus, while 
the microarray is limited in measuring immunoglobulins specific for glycans, the ELISA coated 
with purified GPIs may be unable to detect this sub-population of anti-GPI antibodies due to 
coating-related conformational problems or sterical hindrance by lipids.  
 Serum anti-GPI antibodies from healthy individuals living in the same malaria endemic area 
displayed highly diverse fine specificity patterns in synthetic-GPI microarray analysis, but the 
individual response patterns were strikingly stable. This finding is highly reminiscent to the 
observation, that antibody responses to polymorphic malaria protein antigens tend to have a fixed 
specificity that is unaffected by exposure to novel allelic types  (27, 28).  A comparable clonal 
imprinting mechanism on basis of an “original antigenic sin” (29) may also be operative, when the 
immune system is confronted with pathogens that express GPIs with different substitutions. 
 By comparing  the levels and fine specificities of anti-GPI responses in healthy and diseased 
individuals the microarray-based approach identified glucosamine-inositol and glucosamine-inositol 
moieties coupled with one or two mannose sugars as relevant epitopes of anti-GPI antibodies that 
might be involved in protection against severe malaria. In our dualistic approach, the generated anti-
GPI monoclonal antibodies (mAbs) with different antigen binding patterns resulted in a convergent 
finding: strong cross-reactivity with parasite-derived GPIs in IFA and Western blotting was only 
obtained with antibodies that also bound strongly to the glucosamine-inositol moieties without 
mannose residues. Thus, glucosamine-inositol moieties coupled with one or two mannose sugars 
may be the functional relevant epitopes accessible for protective anti-GPI antibodies, resulting in 
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effective anti-GPI neutralizing activity. These defined structural requirements for the binding of 
naturally and experimentally elicited anti-GPI antibodies should be considered in a rational design 
of GPI-based vaccine candidates. Finally, given the conservation in the core structure of GPIs 
across eukaryotes, it would be important for anti-GPI vaccination to avoid inducing autoimmune 
responses.     
 
8.1.3 Lack of Reliable Surrogate Markers of Protection along the Malaria Vaccine 
 Development Path 
 
 Malaria vaccine development is roughly divided in research and development, preclinical 
profiling and clinical development phases. The first two phases include measuring vaccine induced 
antibody titers and fine-specificities in preclinical models (e.g. by ELISA, IFA and Western blot) 
and correlating these qualities with some biologically relevant functional activity (verified in vitro 
and in vivo in murine models). Subsequently identified antigens targeted by potentially protective 
immune mechanisms are evaluated in non-human primate or other animal models for their safety, 
immunogenicity and efficacy. Even though some of the here described anti-GPI mAbs bound to 
parasite GPI and had accordingly to the serological array study the specificity (reactivity with GPI 1 
to 3) predicted to be relevant for protection against severe disease, they failed to confer protection 
in functional assays; including in vitro parasite growth inhibition assays (GIAs), toxin neutralization 
assays (not shown) and passive protection experiments in animal infection models.  
 GIAs are currently the gold standard for in vitro activity of anti-malaria blood stage specific 
antibody responses and are explored to select antigens as candidates for preclinical development 
(30). GIAs with blood-stage parasites cultured in human red blood cells compare invasion and 
growth of parasites in the absence and presence of immunoglobulins. However, GIAs are very 
fragile test systems, hard to reproduce and therefore results have to be interpreted carefully. The 
correlation of in vitro growth inhibitory activities of antibodies with their potential protective 
capacity in vivo remains to be demonstrated. 
 TNF-α output by macrophages is used as a biochemical marker of malaria toxin activity in 
vitro. In toxin neutralization assays mouse macrophages or human peripheral blood monocytes are 
incubated with purified P. falciparum GPIs or total parasite lysates in the presence or absence of 
anti-GPI antibodies. Afterwards the culture supernatants are collected and TNF-α is measured by 
ELISA. A monoclonal antibody (23) to P. falciparum derived GPIs as well as sera from human 
patients infected with both P. falciparum und P. vivax (31) have been reported to neutralize the 
TNF-α-inducing activity of whole parasite extracts in vitro. However, like other investigators (20, 
J.B. de Souza et al., unpublished data) we could not confirm these findings in toxin-neutralisation 
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assays. The inconsistent results of this assay using extracted GPI suggest the existence of other 
parasite derived potent toxins in crude extracts or that not all anti-GPI antibodies are able to 
neutralize GPI activity in vitro. Analogous to the GIA, these assays are of limited predictive value. 
 The study of malaria vaccines is aided by the existence of experimental animal models, 
although rodent models are not available for infection with P. falciparum. The murine P. berghei 
ANKA (Antwerpen-Kasapa) strain is considered as a good pre-clinical model of severe disease 
(15). While many of the P. falciparum vaccine candidates are either not present or antigenically 
different in this species, we could evaluate GPI and the D13 protein in this model. Active and 
passive immunizations that targeted the conserved PbD13 N`-terminus failed to confer significant 
protection (data not shown). However, murine malaria is different from human malaria, and the 
mechanisms of immunity acting in such models may have no relevance for humans (32). Mice and 
rabbits represent good models to study the safety and immunogenicity of candidate vaccines but 
may fail to answer questions about protective efficacy (33). 
 The New World monkeys Aotus and Saimiri are the primate models used for preclinical 
trials of malaria vaccine efficacy, mainly because they can develop reproducible infections by both 
P. falciparum and P. vivax (34). Besides that these parasites have to be adapted to the artificial non-
human hosts for successful infection, the primate animal models are difficult to access. While their 
usefulness in evaluating immunogenicity, safety and efficacy of potential candidates is well 
established and widely accepted, their predictive value for selection of protective vaccine 
candidates remains unclear (32). 
 This lack of reliable surrogate markers of protection poses a major problem for the screening 
and evaluation of malaria vaccine candidates. It is important to know that data supporting the 
current vaccine candidates rely on the above in vitro and in vivo approaches and on epidemiological 
associations between protection and antigen recognition by exposed individuals. Consequently 
vaccine candidates that show promise in a given model might fail in humans or worse, experimental 
results may lead to the rejection of vaccine candidates that would be effective in humans (32).
 Once formulations and protocols have been defined and preclinical safety studies have been 
performed, candidates can be forwarded to human phase I clinical trials to evaluate safety, 
immunogenicity and the types of immune response elicited in non-immune volunteers living 
outside endemic areas. In phase IIa sporozoite challenge trials vaccine efficacy is evaluated as the 
ability to avoid or delay infection. Owing to ethical requirements, the trial end point is reached as 
soon as blood-stage parasites are detected. This is a limitation for evaluating blood-stage and anti-
toxic vaccines, which may be effective in reducing parasite burden and toxin neutralisation but only 
after allowing a limited growth. Nonetheless, a recent study showed evidence of vaccine-induced 
blood-stage efficacy for the first time in a sporozoite challenge study (35). Volunteers vaccinated 
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with PEV3A, which included IRIV formulated peptides from both the pre-erythrocytic antigen CSP 
and the blood-stage antigen AMA-1, were not completely protected from malaria; but lower rates of 
parasite growth and the presence of morphologically abnormal parasites (crisis forms) were 
significantly observed in vaccinated volunteers.  
 The sporozoite vaccine RTS,S/AS02A and DNA-based heterologous prime-boost 
immunization strategies have shown some protection after experimental sporozoite challenge of 
non-immune volunteers but showed no or only limited efficacy in field trials (13, 14, 36, 37). The 
relevance of phase IIa challenge trials for predicting clinical efficacy thus has still to be 
demonstrated. Phase IIb trials target semi-immune volunteers from endemic areas and protection is 
assessed through the ability of vaccinated individuals to get no or less infections or to have longer 
intervals between infections, as compared with a control group (32). Therefore IIb trials are the 
generally accepted method of establishing proof of principle for blood-stage vaccines. Results on 
the efficacy of anti-toxin vaccine candidates would be obtained only very late in clinical 
development; in phase III trials the vaccine is delivered to children and infants of endemic regions 
and the end point may be a significant decrease in the incidence of clinical malaria or of severe 
disease in relation to a non-vaccinated population. Due to missing validated correlates of protection, 
the failures of the anti-GPI mAbs produced in this thesis in conferring protection in functional 
preclinical assays do not exclude synthetic GPI as a candidate for inclusion in an anti-disease 
vaccine.  
 
8.1.4 Synthetic Polysaccharide Antigens need Enhancement for Immunogenicity in Infants 
 
 B cell activation by protein antigens requires both binding of the antigen by the B cell 
antigen receptor and interaction with antigen-specific helper T cells. With these thymus-dependent 
antigens, an immune response can occur shortly after birth, affinity maturation of the B cell 
response takes place, immunologic memory occurs and there is a heterogeneous immunoglobulin 
response (38). Some non-protein antigens stimulate B cells in the absence of linked recognition by 
peptide-specific helper T cells. Thymus-independent (TI) antigens elicit only limited isotype 
switching and do not induce memory B cells. These antigens can be divided into two classes, TI-1 
or TI-2. TI-1 antigens, such as LPS, are potent B-cell mitogens, capable of non-specific, polyclonal 
activation of B cells. TI-2 antigens consist of molecules such as polysaccharides that have repetitive 
structures. Whereas TI-1 antigens can activate both immature and mature B cells, TI-2 antigens can 
activate only mature B cells (39). This might be why infants do not efficiently produce antibodies to 
polysaccharide antigens; most of their B cells are immature. 
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 Therefore the generation of a vaccine-induced anti-GPI antibody response in children less 
than 5 years of age, which is the highest priority for vaccination in malaria-endemic areas, is 
critically dependent on the development of an antigen delivery platform that converts 
oligosaccharides into T cell dependent antigens. Experience with Neisseria meningitidis, 
Haemophilus influenzae type b and Streptococcus pneumoniae capsule polysaccharide conjugate 
vaccines has demonstrated that immunogenicity of carbohydrate antigens can be greatly improved 
by chemical conjugation to a protein carrier, especially in infants (40). For the development of an 
anti-toxic vaccine for malaria, it was proposed to conjugate synthetic GPI glycan to an 
immunogenic carrier protein, either of parasite (e.g. candidate blood-stage vaccine antigens, such as 
MSP-1) or bacterial (e.g. tetanus toxoid, diphtheria toxoid) origin (15). In addition, the 
immunogenicity has to be enhanced by delivery of the conjugates with an immunological adjuvant. 
With few exceptions, alum remains the sole adjuvant approved for human use in the majority of 
countries worldwide. This adjuvant has been used in practical vaccination for more than 60 years 
and is generally recognized as safe and as stimulator of Th2 immunity (41). Since alum represents 
only a sub-optimal adjuvant for recombinant proteins, synthetic peptides and polysaccharide 
antigens (41, 42), there is a major need for a safe and efficacious adjuvant capable of boosting 
cellular plus humoral immunity. Recently, immunopotentiating reconstituted influenza virosomes 
(IRIV) were evaluated as synthetic carbohydrate antigen delivery system (43). A leishmanial 
lipophosphoglycan-related synthetic tetrasaccharide was coupled to phosphatidylethanolamine or to 
hemagglutinin and embedded into virosomes. These vaccine formulations elicited in mice T cell 
dependent anti-glycan antibody responses that cross-reacted with native carbohydrate antigens 
expressed by leishmania cells. Experience with two licensed vaccines based on virosomes has 
shown that the technology is very safe and immunogenic even in children and infants (44-46). 
Therefore virosomes may be suitable as universal antigen delivery platform for an effective multi-
valent anti-disease vaccine based on synthetic GPI in combination with synthetic blood-stage 
peptides or recombinant proteins.  
 
8.1.5 mAbs serve as “All-Rounder” Tools in Infectious Disease Research, Therapy and 
 Diagnostics 
  
 The antibodies produced in a natural immune response or after immunization are a mixture 
of molecules of different specificities and affinities. Heterogeneity results from the production of 
antibodies that bind to different epitopes on the immunizing antigen. The hybridoma technology has 
revolutionized the use of antibodies by providing a limitless supply of mAbs of a single and known 
specificity (47). Since each hybridoma is an immortalized clone derived from fusion of a myeloma 
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cell with a single B cell, all the antibody molecules it produces are identical in structure, including 
their antigen-binding site and isotype. The uniform characteristics of mAbs created an expanding 
role for these immunological reagents in vaccine research and development, therapy, and clinical 
diagnosis. 
 Within the framework of the present thesis, mAbs were generated to study P. falciparum 
and B. anthracis antigens, allowing the characterization of carbohydrate targets as candidates for 
diagnostic tests and vaccine design.  
 The ability to produce monoclonal antibodies allows backtracking from the desired antibody 
to its corresponding epitope. Immunization with the identified precise epitope may elicit similarly 
protective antibodies in the vaccinee. Such a reversed immunological approach is the first step in 
the rational design of a B cell epitope-based vaccine and was applied here with the generated anti-
GPI mAbs. In addition, the anti-GPI mAbs may in future be used in combination with 
immunological, cell biological and biochemical methods to identify and study the GPI-anchored 
proteome in different life stages of P. falciparum and other Apicomplexa species. The newly 
identified GPI-anchored proteins are likely to include proteins involved in attachment and invasion 
of host cells or immune evasion mechanisms. They may comprise promising targets for parasite 
inhibitory antibodies and therefore represent new vaccine candidates.  
 Serum-therapy was one of the first effective means of treating infectious diseases but its use 
declined rapidly after the introduction of antimicrobial chemotherapy (48). Antibody-based 
therapies are currently undergoing a renaissance: there are more than 18 antibodies licensed for 
therapeutic use in the clinical settings of oncology, chronic inflammatory diseases, transplantation, 
infectious diseases and cardiovascular medicine (49). While polyclonal reagents suffer from a lack 
of reproducibility, mouse monoclonal antibodies used in humans can generate complications 
because of the host response to the foreign antibodies. In addition mouse antibodies may show only 
limited interactions with other elements of the human immune system resulting in inefficient 
effector functions and a short half-life (49). Humanization of murine antibodies is therefore a 
standard step in the development of therapeutic mAbs. Passive immunization of patients with severe 
malaria by administration of anti-toxin (GPI) antibodies is a thinkable therapeutic strategy, which 
could profit from the ongoing technological advances, including the synthesis of mouse–human 
chimeric antibodies, the immortalization of human peripheral B cells, direct cloning of variable 
genes into phage expression libraries and the creation of transgenic mice that produce human 
antibodies (50, 51). Passive anti-GPI antibody therapy may provide immediate immunity by 
neutralizing the toxic activities of parasite GPI and thereby reducing the over-stimulation of the 
immune system. This therapeutic proposal avoids the concern that inhibition of GPI-mediated early 
pro-inflammatory cytokine responses, which limit parasite growth, may favor rises in parasitaemia 
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in actively vaccinated people. In support of this antibody-based therapy, antibodies specific for 
bacterial super-antigens improved the clinical outcomes in streptococcal toxic shock syndrome, 
which is similar to the Th1 cytokine-dominated inflammatory response to severe malaria (52, 53). 
The time to develop an anti-GPI antibody therapy may be considerably shorter than that needed to 
produce a vaccine for infants. A clear limitation is that antibody drugs are expensive, which defines 
their use in developing countries. But high costs can be offset by unlikely development of 
resistance, since parasite GPI are invariant and essential for surviving.   
 Antibodies have provided the basis for specific and reproducible immuno-assays for the 
diagnosis of infectious diseases (54, 55). The uniform characteristics of mAbs have had a profound 
impact in the field of diagnostics by vastly improving the sensitivity and specificity of immuno-
assays (56). Concerns with immunochemical techniques to detect B. anthracis endospores include 
problems with cross-reactivity and difficulties in obtaining species specific assays. mAbs generated 
against irradiated B. anthracis spores of the Ames and Sterne strains as well as against exosporium 
isolated from irradiated spores cross-reacted with B. thuringiensis and B. cereus spores (57). The 
majority of these mAbs were directed toward the protein component of the BclA glycoprotein. 
Because of specificity problems, as shown in this thesis, the development of an immuno-assay for 
detection of Anthrax spores based on anthrose is more difficult than anticipated (58). However, the 
mAbs specific for the synthetic anthrose-containing tetrasaccharide cross-reacted with spores of a 
panel of virulent B. anthracis strains covering a broad phylogenetic spectrum. The sensitivity of 
mAbs produced against the anthrose-rhamnose disaccharide (not shown) was even higher, since this 
mAbs detected also two unique Chadian isolates that represent a novel genetic lineage (Aβ) in the 
B. anthracis A cluster according to (59, 60). Biosafety containment requires an inactivation of 
spores containing probes by irradiation or thermal treatment. Interestingly the preparation of the 
Bacillus samples employed in this thesis, which included extensive boiling and filtration of loading-
buffer denaturised spores, did not destruct the epitopes recognized by the carbohydrate specific 
antibodies. This conservation of the antigen was not self-evident, since it was demonstrated that 
inactivation methods could affect the sensitivity of nucleic acid- and antibody-based assays for the 
detection of B. anthracis endospores (61). ELISA or related solid phase immunoassay formats may 
represent the most useful forms of immunochemical method for the detection of B. anthracis 
spores, based on their simplicity and ability to analyze large numbers of samples at a time. The 
high-sensitivity quality of the anti-tetrasaccharide and disaccharide mAbs makes these 
immunological reagents ideal tools as capture antibodies for ELISA. Such highly sensitive spore 
detection ELISAs would be plagued by false-positive results but would afford a quick exclusion of 
negative samples from further analysis. Subsequent confirmatory expensive and time-consuming 
diagnostic tests with high specificity, such as real-time PCR or standard culture methods that focus 
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on the vegetative form, are therefore minimized. Improvements concerning the specificity of the 
proposed ELISA could be achieved in combining the sensitive anti-carbohydrate capture antibodies 
with detection antibodies of other specificities directed against B. anthracis spore antigens and/or 
unique markers of its closest relatives for exclusions. However, for a first screening of samples, 
which are suspected to contain B. anthracis spores, high sensitivity for the non-vegetative form is 
required to avoid false-negative results to guarantee civil protection in case of terrorist acts. 
 The efficacy of protective-antigen cell free anthrax vaccines is not satisfactory when 
compared with the live attenuated spore vaccine (62, 63). This could be because protective-antigen-
based vaccines target toxaemia and not bacteraemia. It is well established that full protection 
against anthrax requires a multifactorial immune response. Bacillus spores persist in the host for 
days after entrance into the body (64). Vaccination and passive immunization studies suggest that 
spore-specific Abs make a contribution to protection (65-67) The identity of these potentially 
protective Abs and their targets have yet to be determined (57). Exosporium antigens are likely to 
be involved in the interaction of spores with the infected host. The entry of the spore into 
macrophages is a critical step for B. anthracis infection. Spores are able to escape from 
phagolysosomes, and can germinate and multiply within the macrophage cytoplasm. The unique 
anthrose sugar could be included in a vaccine designed to elicit an immune response to B. anthracis 
spores. However, mice vaccinated with conjugated anthrose-containing tetrasaccharide were not 
protected following spore challenge, rather the opposite was observed (J. Frey, personnel 
communication). This indicates that the induced anti-carbohydrate antibody response might rather 
favour spore uptake by phagocytic cells after engaging Fc-receptors than inhibit the germination of 
spores in host macrophages.  
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8.2 Conclusions 
 
 In this thesis we have explored the potential of synthetically produced carbohydrate antigens 
of infectious agents as candidates for diagnostic tests and vaccine design. We presented a versatile 
screening method based on microarrays of synthetic carbohydrates that differentiates between 
malaria dependent and malaria independent adaptive immune responses to GPI. Human sera from 
malaria-exposed and malaria-free subjects exhibited differential binding patterns against two 
structurally distinct GPI glycans of P. falciparum, (EtNH2)-Man4-GlcNH2-PI and (EtNH2)-Man3-
GlcNH2-PI. Array based serological studies supported the hypothesis that GPI is a target of clinical 
immunity and established a correlation between the presence of antibodies to certain structural 
elements of GPI and resistance to severe malaria. Adjuvanted synthetic oligosaccharide-protein 
conjugates promoted the generation of T cell dependent immune responses with different binding 
patterns against native carbohydrates, thereby representing ideal conditions for the generation of 
monoclonal antibodies. Anti-GPI mAbs emerged as a dualistic tool to experimentally investigate 
the role of GPI in malaria pathogenesis and to study the GPI-anchored proteome of Apicomplexa 
species. mAbs specific for anthrose-containing synthetic oligosaccharides generated in the 
framework of this thesis have potential as immuno-capturing components for a sensitive spore 
detection system. The consolidated findings obtained in this thesis demonstrated a great potential 
for synthetically produced oligosaccharides for bio-medical and research applications.   
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Abstract 
 
 A conserved protein of Plasmodium falciparum, designated parasite density controlled 
protein (PDCP; PF14_0652) with three tandemly arranged CCCH zinc finger motifs has been 
described by us. During screening of anti-PDCP mAb for parasite binding by indirect immuno-
fluorescence analyses, we observed that the relative fluorescence signal strength in individual 
schizonts was associated positively with the parasite-density of cultures employed for staining. The 
relative PDCP expression was then assessed in high (10 %) versus low (2 %) parasite density 
cultures by quantitative laser scanning confocal microscopy. Experiments showed that the relative 
fluorescence intensity at least doubled in high density compared with low density parasite cultures. 
Interestingly, when 2 % cultures were grown for 48 h in the presence of cell-free parasite 
conditioned medium and then analyzed by IFA, the fluorescence signal obtained resembled that of 
10 % cultures. Hence, soluble factor(s) in cultures of infected erythrocytes might mediate signal(s) 
resulting in up-regulation of PDCP expression. Therefore, a co-culture system was used whereby 
diffusible molecules of asexual blood stages can move freely between different parasite cultures 
separated by a semi-permeable membrane system. Co-culture of 2 % parasite cultures with 10 %, 
but not 2 % cultures or uninfected erythrocytes resulted in statistically significant increase of the 
mean of fluorescence intensity. No difference in PDCP mRNA levels was measured by Northern 
blot analysis and quantitative RT-PCR in the 2 % and 10 % parasite cultures indicative for post-
transcriptional regulation of PfD13 expression. The inhibition of asexual parasite growth by anti-
PDCP mAb in combination with evidence for regulation by parasite derived diffusible factors 
supports the hypothesis that PDCP might be involved in parasite growth regulation. 
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Introduction 
 
 The complex life cycle of Plasmodium falciparum, responsible for the most virulent form of 
malaria, requires specialized and regulated protein expression for the appropriate adaptation to both 
the mammalian host and insect vector. A search for transcription-associated proteins within the 
complete P. falciparum genome found that the parasite contained about a third of the number of 
proteins associated with the transcriptional process than present in genomes of free-living 
eukaryotes (Coulson et al., 2004) even though enzymes are found in equivalent abundance in 
malaria and yeast. Members of the CCCH-type zinc finger protein family are most prevalent within 
the P. falciparum genome when its abundance within the genome is normalized against the size of 
the genome providing further support for the hypothesis that protein levels in P. falciparum are 
controlled through post-transcriptional mechanisms (Coulson, Hall, and Ouzounis 2004). Post-
transcriptional protein expression regulation has been described for genes involved in sexual 
differentiation, mitochondrial RNA processing and the stability of RNAs encoding for surface 
antigens (Le Roch et al., 2004). CCCH-type zinc finger proteins were first identified in differential 
screens for mRNAs that are rapidly induced following growth factor treatment of mammalian cells 
with the best-studied member of this class represented by the mouse protein tristetraprolin 
(Blackshear et al., 2005). Proteins containing zinc finger domains of the C-x8-C-x5-C-x3-H-type 
include proteins of eukaryotes involved in cell cycle or growth phase-related regulation and 
germline specification (Caro et al., 2005; Lai et al., 2000; Paterou et al., 2006; Shimada et al., 
2006).  
 A conserved protein of P. falciparum, designated as parasite-density-controlled-protein 
(PDCP) (D13, PF14_0652) with three tandemly arranged CCCH zinc finger motifs has been 
described by us (Daubenberger et al., 2003). The protein was highly expressed during schizogony, 
declined rapidly in early ring stages and was undetectable in trophozoites assessed by immuno-
fluorescence analysis (IFA) and Western blot analysis. Interestingly, inclusion of certain anti-PDCP 
mAbs targeting the CCCH-type zinc finger motif into asexual blood-stage cultures resulted in 
considerable inhibitions of parasite growth (Daubenberger et al., 2003).  
 Cell-to-cell communications via signal molecules play essential roles in synchronisation of 
gene expression and functional coordination. Since the concentration of some signal molecule(s) is 
a reflection of the population size, the term “quorum sensing” (QS) has been adopted to describe 
that accumulation of signal molecules enables individual cells to perceive when a minimum 
population unit, the “quorum”, is reached. QS is achieved through the production, release, and 
subsequent detection of and response to threshold concentrations of signal molecules and is well 
described in a wide variety of Gram positive and Gram negative bacteria (Bassler 2002). In recent 
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years evidence for QS has been also accumulating in eukaryotes. In Histoplasma capsulatum is has 
been shown that the yeast form produces some unique cell-wall polysaccharides (e.g. a-1,3-glucan) 
in a density-dependent fashion. If the fresh medium is supplemented with filtrate from a stationary-
phase yeast culture, the cells continue to produce the a-1,3-glucan (Kugler et al., 2000). A similar 
density-dependent phenomenon has been described in Ceratocystis ulmi, the dimorphic fungus that 
causes Dutch Elm disease. Ceratocystis ulmi develop as budding yeast when inoculated at high 
density and as filamentous mycelia when inoculated at low density (Hornby et al., 2004). It has long 
been documented that Candida albicans hyphal formation is suppressed at high cell densities and 
by supernatants from stationary-phase Candida albicans cultures. The factors in these fungal 
cultures that represses hyphal development have been identified as farnesol and farnescoid acid 
(Hornby et al., 2001; Oh et al., 2001). In Saccharomyces cerevisiae, phenylethanol and tryptophol 
were identified as QS molecules mediating the induction of filamentous growth (Chen and Fink 
2006). Proteins mediating QS in Dictyostelium discoideum, include a 80-kDa glycoprotein, a 450-
kDa protein complex and countin 2 (Brock et al., 2003; Chen et al., 2005; Kolbinger et al., 2005). In 
this study we provide first time evidence that PDCP expression is density-dependent regulated in 
asexual blood stage cultures. 
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Materials and methods 
 
 Parasite culture. P. falciparum (K1 and 3D7) were maintained in human A+ erythrocytes at 
5% hematocrit in RPMI 1640 supplemented with 25 mM HEPES, 24 mM NaHCO3, 50 mg/l 
hypoxanthin and 0.5 % Albumax (complete culture medium). Highly synchronized ring stage 
parasite cultures were prepared by 5% (wt/vol) sorbitol treatment (twice at a time interval of 10 
hours). The synchronized cultures were appropriately diluted into parallel cultures so that after a 
single 48 h cultivation period the cultures reached 2 % and 10 % parasite densities, respectively. 
Synchronization and parasite density were regularly confirmed by Giemsa staining.  
 
 Establishment of anti-PDCP mAb and indirect immuno-fluorescence analysis. A range of 
anti-PDCP mAb directed against the N-terminal 158 amino acids were established as described 
(Daubenberger et al., 2003). All hybridoma cultures were first screened in ELISA for specificity to 
the recombinant PDCP used for immunisation. Positive cultures were cloned twice, retested in 
ELISA for specific mAb production and expanded. Multi-test immuno-fluorescence microscopy 
slides (Flow Laboratories, Switzerland) were pre-treated with 0.01 % (w/v) poly-L-lysine (Sigma) 
for 30 min at room temperature and washed. Freshly isolated infected erythrocytes were washed 
and mixed with two volumes of a solution containing 4 % para-formaldehyde and 0.1 % Triton X-
100. Droplets of 30 microl cell suspension were added to each well and incubated for 30 min at 
room temperature. Cells were blocked with blocking solution containing 100 mg/ml fatty acid-free 
bovine serum albumin in PBS. Cells were incubated with relevant mAb for 1 h. After several 
washing steps with blocking solution, cells were incubated with cyanine-dye-conjugated affinity-
pure F(ab)2 fragment goat anti-mouse Ig heavy chain antibodies (Jackson Immuno Research 
Laboratories, West Grove, Pa.) diluted in blocking solution containing 0.01 mg/ml Hoechst dye no. 
33256 (Sigma). Antibody binding and DNA staining were assessed by fluorescence microscopy on 
a Leitz Dialux 20 fluorescence microscope and documented with a Leica DC 200 digital camera 
system. Magnification was 50 x and exposure time 0.4 sec and 1.2 sec for staining with Hoechst or 
antibody, respectively.  
 For relative quantification of the difference in PDCP expression by IFA, five images per 
slide from parasite cultures were recorded with the confocal laser scanning microscope (Leica TCS 
SP2 AOBS). Optical sections at interval of z µm were recorded using a HCX-PL APO CS 40x 1.25 
OIL immersion objective. All instrument settings (illumination, PMT, magnification, speed, 
averaging) were selected to collect fluorescence signal in the effective dynamic range of the PMT 
and kept constant throughout the whole experiment to allow for intensity comparison. Background 
signal was determined measuring mean intensity in cells incubated with the secondary Ab alone. 
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Images analysis was performed using Imaris Software (Bitplane, Switzerland). The mean Cy3 
fluorescence emission signal intensity was quantified for each cell using the “spot function” of 
Imaris. Mean fluorescence intensity values obtained from cells stained with the identical mAb but 
grown under different parasite densities were compared statistically using the Students t-test using 
the STATA program. 
 
 Cell free conditioned medium preparation and parasite co-culture experiments. 
Supernatant from P. falciparum (K1) high density parasite cultures (about 10 %) and uninfected 
RBC cultures cultivated similarly were collected. These supernatants were concentrated (25 fold) 
by Vivaspin 15R (Vivascience) with molecular weight cut offs of 30 kDa, dialyzed against 
complete culture medium and stored at +4 °C and are designated as cell free CM. Highly 
synchronized ring stage parasite cultures were treated with 1:100 and 1:1000 dilutions of the CM 
for 48 h. Cultures were harvested at late schizont stage and used for indirect immuno-fluorescence 
analysis and Northern blot analyses.  
 For the experimental co-culture system, parasites were synchronized by sorbitol treatment 
and then triplicate 0.4-mL test cultures were set up in Nunc (Roskilde, Denmark) 10-mm tissue 
culture insert wells with a 0.2-µm pore Anopore membrane base (SPI Supplies, West Chester, PA) 
at 2 % parasitemia. Each group of three wells was supported within a 20-mL environmental culture 
with parasitemia of 2 %, 10 % and RBC only in a 140-mm diameter petri dish. Molecules were thus 
free to diffuse between environmental and test cultures, while the membrane contained the cells and 
parasites. Containment of merozoites was confirmed by absence of parasites within the RBC culture 
dish after co-culture with asexually replicating parasites. Co-culture cultures were harvested after 48 
h for IFA and parasite growth was monitored by Giemsa staining (Dyer and Day 2003).  
 
 Northern blot analysis. Templates to prepare specific probes were generated by polymerase 
chain reaction (PCR) on K1 cDNA (Daubenberger et al., 2000) with PDCP specific primer pair 5-
CAACAAAATGGTTTATGCCACAC-3 and 5-GAGAAGCGACAACATAATACAACTA-3 
yielding a 560 bp fragment. PCR products were purified using NucleoSpin columns (Macherey-
Nagel, Oesingen, Switzerland) and labeled using [a-32P]dCTP and the HighPrime system (Roche 
Diagnostics, Rotkreuz, Switzerland). Northern blotting was done essentially as described. Total 
RNA was prepared using TRIzol reagent (Invitrogen) and separated on 1 % agarose gels containing 
5 mM guanidinium isothiocyanate. Equal loading (~5 µg/lane) and quality of RNA were analysed 
visually under UV light and documented. The gel was then treated for 15 min in 0.05 M NaOH and 
in 10× SSC for 10 min; RNA was transferred to Hybond XL membranes (Amersham Biosciences, 
Dübendorf, Switzerland) over night by capillary transfer. Hybridization was carried out at 42°C in 
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UltraHyb (Ambion, Lugano, Switzerland) overnight. Filters were washed 2 x 5 min with 2 x 
SSC/0.1% SDS and 2 x 10 min with 0.1 x SSC/0.1% SDS at 42°C. Autoradiography was conducted 
at - 70°C by using a Transcreen HE enhancer and MS films (Eastman Kodak, Rochester, NY) 
(Daubenberger et al., 2003). 
 
 Quantitative real time-PCR. 20 ml cultures each with parasitemias of 2 % and 10 % were 
exposed to 0.05 % saponin in phosphate-buffered saline to lyse the erythrocytes. Parasites were 
pelleted and used for RNA extraction using the RNeasy mini kit (Qiagen). Total RNA extracted was 
eluted from the column in 50 ml of RNase free water. 10 ml was used for cDNA synthesis using the 
QuantiTect Reverse Transcription kit (Qiagen). The gene-specific oligo-nucleotide pairs used for 
PDCP (forward: 5- ATGGTTTATGCCACACTTTTGAGTG-3 and reverse: 5-
GATCTAGTTGTATTATGTTGTCGCT-3) and 18S rRNA (SSU) of P. falciparum (forward: 5-
CATTCGTATTCAGATGTCAGAGGTG-3 and reverse: 5- 
CGTTCGTTATCGGAATTAACCAGAC-3) resulted in the amplification of PCR products of 565 
and 482 base pairs, respectively (Nirmalan et al., 2002). To control for genomic DNA 
contamination, oligo-nucleotide pairs covering the intron sequence of glyceraldehyde-3-phosphate 
dehydrogenase (forward: 5- GAGCAGCCTTTGGAAGGAAAGATATC-3 and reverse: 5- 
TAAATGGGTCGTTAATAGCAACTACTTC-3) (Daubenberger et al., 2000) were employed. PCR 
was carried out in a volume of 100 µl and contained 5 U of Taq polymerase, 100 µM each dNTP, 
200 ng of each primer pair, 2.5 mM MgCl2. Cycling parameters were as follows: a pre-cycle at 95 
°C for 5 min was flowed by 30 cycles of 95 °C for 30 s, 30 s at 50 °C and 72 °C for 2 min with a 
final cycle of 72 °C for 10 min. Ten replicates of PCR reaction tubes for each amplification of 18S 
rRNA and PDCP were set up with cDNA of each culture and transferred into the PCR apparatus. 
Removal of individual PCR tubes was carried out at two-cycle intervals at the end of elongation 
phase without cycling disruption starting at cycle 10 up to cycle 30. Samples of each individual 
experiment were amplified in the same PCR apparatus and analysed on the same 1 % agarose gel. 
Molecular weight marker used was the 1 Kb plus DNA ladder (Invitrogen). Comparison of data 
among different samples and experiments was carried out by normalizing to the transcript levels of 
asexual 18S rRNA of P. falciparum. This procedure obviated the need to quantify scares total RNA 
samples before reverse transcription and to control for reverse transcriptase efficiency.  
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Results 
 
 Comparison of tandem CCCH-type zinc finger proteins in Apicomplexan parasites. We 
searched for PDCP orthologs using the public sequence data bases of twelve Apicomplexan 
parasites genomes including Cryptosporidium hominis, C. parvum, P. berghei, P. chabaudi, P. 
falciparum, P. knowlesi, P. yoelii, P. vivax, Theileria annulata, T. parva, Toxoplasma gondii and 
Eimeria tenella. The alignment of the deduced amino acid sequences of the N-terminal 145 amino 
acid residues of the PDCP orthologs is given in Figure 1. The three tandemly arranged CCCH-type 
zinc finger motifs are boxed with the conserved cysteine and histidine amino acid residues marked 
with stars. The first CCCH-type zinc finger motif follows the described C-x8-C-x5-C-x3-H-type in 
E. tenella and T. gondii, while the motif in the other organisms is arranged as C-x7-C-x6-C-x3-H. 
The second motif shows a C-x15-18-C-x5-C-x3-H spacing and the third motif the C-x7-8-x4-C-x3-
H spacing pattern. In addition, many other residues are strictly conserved, including a RFRTK motif 
immediately preceding the first CCCH zinc finger motif. Within the 16 amino acid spacer located 
between the second and third zinc finger motif, 50% of the amino acid residues are conserved 
amongst these twelve apicomplexan species. Analyzing the nucleotide sequences of these PDCP 
orthologs for synonymous versus non-synonymous base exchanges indicated that a strong purifying 
selection pressure is operating resulting in high preservation of amino acid residues 
(http://selecton.bioinfo.tau.ac.il) (Doron-Faigenboim et al., 2005).  
 
 Conditioned medium of high density parasite cultures induces PDCP up-regulation. 
While screening a panel of anti-PDCP mAb in IFA with synchronized schizont stages of P. 
falciparum, we observed inconsistent staining results. Therefore, schizonts of strains K1 and 3D7 
were synchronized twice and then cultivated either at 2 % or 10 % parasite density, followed by 
parallel conducted IFA. Results with mAb D13.3 and D13.31 are shown in Figure 2A. Cells derived 
from cultures with 2 % and 10 % parasitemia are depicted in the first and forth row, respectively. 
Results of DNA control staining are given in the first and third column while the results of the 
staining with D13.3 and D13.31 are presented in the second and forth columns, respectively. 
Fluorescence intensities in individual schizonts at 10 % parasitemia cultures seemed to be higher 
compared with cells derived from 2 % cultures. This increased strength of the fluorescent signal 
was particularly evident in IFA using mAb D13.31 where in 2 % cultures, no fluorescence signal 
was detectable while cells derived from 10 % cultures were recognized (Figure 2A).  
 Next we addressed the question whether soluble factors accumulating in high-density 
parasite cultures might be responsible for changes of PDCP expression. Cell-free CM of high 
density (10 %) cultures of P. falciparum were sampled, concentrated and the 2 % parasite cultures 
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were treated with 1:100 and 1:1000 dilutions of the CM for 48 h starting with the ring stage. The 
IFA was conducted simultaneously with treated and untreated 2 % and 10 % cultures. In 2 % 
cultures exposed to 1:100 and 1:1000 diluted CM, enhanced fluorescence levels when compared to 
untreated 2 % cultures stained in parallel appeared (Figure 2A, second and third row). Supernatants 
of uninfected RBC suspensions did not influence PDCP expression levels (data not shown).  
 To quantify the observed differences in the immuno-fluorescence signal, schizonts were 
grown again at 2 % and 10 % densities and stained with mAb D13.44 and D13.26. Samples were 
analyzed by confocal laser scanning microscope followed by image analysis using the Imaris 
software for measurement of mean average fluorescence intensities. The results shown in Figure 2B 
demonstrated that a statistically significant difference in PDCP expression is seen between cells 
grown at 2 % and 10 % densities (p < 0.001). 
 For confirmation that a diffusible factor might mediate changes in PCDP expression, an 
experimental co-culture system was used where molecules of asexual blood stage cultures move 
freely between parasite cultures but are un-permeable for cells. Co-culture of 2 % parasite cultures 
with 10 % but not with 2 % cultures resulted in increased fluorescence signals (Figure 3A). As 
shown in Figure 3B, parasite cultures grown in vicinity of 10 % cultures had significantly higher 
mean fluorescence intensities compared to identical cultures grown in the neighbourhood of 2 % 
cultures (p < 0.001) (Figure 3B).  
 To exclude the possibility that PDCP up-regulation resulted merely from cellular responses 
to nutrients depletion or waste accumulation in the high density cultures, parasite growth was 
assessed by 3[H]-Hypoxanthin incorporations assays. No difference in 2 % cultures grown in the 
presence or absence of CM preparations used in the IFA experiments was observed (data not 
shown). It is well known that in standard cultures of malaria parasites growth is limited to 
parasitemia of 10 % – 15 % of erythrocytes. Hence at 2 % and 10 %, the parasite cultures have not 
reached yet their maximum density and no signs of cell degradation could be detected by Giemsa 
staining of culture smears (data not shown).  
 
 Evidence for post-transcriptional regulation of PDCP expression. To relate the increase in 
PDCP protein expression to chances in mRNA levels, Northern blot analysis was conducted with 
identical samples shown in Figure 2A. Total RNA was extracted from cultures and equal amounts 
of total RNA was loaded from each sample as evidenced by the ethidium-bromide stained agarose 
gels before transfer to Hybond-N membranes. The unique signals obtained after hybridisation with 
PDCP-specific radioactively labelled probes were comparable between the lanes loaded with 
mRNA derived from 2 %, 10% and schizont cultures treated with 1:100 dilution of CM, 
respectively (Figure 3A). As a second approach for analysis of changes in PDCP specific mRNA a 
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quantitative RT-PCR was conducted. This quantitative RT-PCR is based on the observation that the 
abundance of a given template sequence shows a reverse linear relationship with the cycle number 
at which the amplification product is first detected above the baseline level (the threshold cycle). 
The RT-PCR amplification products of the 18S rRNA from cDNAs derived from 2 % and 10 % 
cultures became visible at cycles 20 and 16, respectively. The RT-PCR products of PDCP amplified 
from the identical cDNAs appeared at cycles 26 and 24, respectively (Figure 3B). Hence, in relation 
to the threshold detection of 18S rRNA, significant changes in PDCP mRNA levels in 10 % versus 
2 % cultures was not found. 
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Discussion 
 
 In the current study we provide to our knowledge the first report of parasite density-
dependent regulation of a CCCH-type zinc finger protein in P. falciparum asexual blood stage. 
CCCH-type zinc finger proteins (http://www.ebi.ac.uk/interpro; IPR000571) that posses the 
characteristic C-x8-10-C-x5-C-x3-H sequence of the prototype CCCH-type zinc finger domain 
were first identified in differential screens for mRNA that is rapidly induced following growth 
factor treatment of mammalian cells. The best-studied member of this protein class is represented 
by the mouse protein tristetraprolin (TTP) (Blackshear 2002). TTP can shuttle between the nucleus 
and cytoplasm and the best-documented function of the protein is its ability to bind to AU-rich 
elements in certain mRNA molecules and to destabilize those mRNA, apparently by initiating a de-
adenylation process (Lai, Carballo, Thorn, Kennington, and Blackshear 2000; Phillips et al., 2002). 
Knockout mice lacking TTP show chronically over-expressed tumour necrosis alpha protein and 
granulocyte macrophage-colony stimulating factor levels due to stabilization their encoding 
mRNAs in macrophages derived from TTP-deficient mice (Taylor et al., 1996). In Caenorhabditis 
elegans, CCCH-type zinc finger proteins have been shown to be involved in the differentiation of 
germ cells during embryonic development and function via temporal and spatial regulation of 
maternal mRNA at levels of transcription, mRNA processing, RNA localization and translation 
(Mathesius et al., 2003; Shimada, Yokosawa, and Kawahara 2006; Shimada et al., 2002). 
 In Trypanosomes, the paucity of known transcriptional control and the poly-cistronic 
organization of the genome make post-transcriptional mechanisms the most important level for gene 
regulation (Clayton 2002). RNAi mediated knockdown and genetic ablation of one of these zinc 
finger proteins, TbZFP1, severely compromised the differentiation from bloodstream to pro-cyclic 
forms in Trypanosoma brucei (Hendriks et al., 2001; Hendriks and Matthews 2005). The authors 
speculate that TbZFP1 influences the differentiation through stabilizing or destabilizing mRNA 
with AU-rich elements or through modulating their cellular location or capacity for translation. A 
family of proteins characterized by their single zinc finger motif C-x7-8-C-x5-Cx3-H and small size 
(<150 amino acids with x representing any amino acid residue) has been demonstrated in 
Trypanosoma cruzi with TcZFP1 binding selectively to poly(C)homo-polymers in vitro (Morking et 
al., 2004). Interestingly, TcZFP1 and TcZFP2 interact with each other via the WW domain of 
TcZFP2 (Caro et al., 2005). 
 The co-regulation of PDCP mRNA expression with mRNA of proteins involved in host cell 
invasion (guilt by association (Le Roch et al., 2003)), in combination with results of the high 
throughput yeast two hybrid-system analysis of P. falciparum (LaCount et al., 2005) indicate that 
PDCP is involved in biological processes during schizont development, merozoite release or host 
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cell invasion. Orthologue sequences of PDCP with the conserved three tandemly arranged CCCH-
type zinc finger motives have been so far exclusively found in the genome sequences of the 
Apicomplexa C. hominis, C. parvum, E. tenella, P. berghei, P. chabaudi, P. knowlesi, P. vivax, P. 
yoelii, T. annulata, T. parva and T. gondii. Thus, members of this sub-family of CCCH-type zinc 
finger proteins might mediate conserved biological processes shared between these organisms.  
 The observed PDCP up-regulation could be explained as the result of diffusible, so far 
unknown factor(s) accumulating in high-density parasite cultures. This assumption was supported 
by the observations that the effect of CM on PDCP expression was concentration dependent and 
results of the two-chamber co-cultivation experiments. In P. falciparum, several independent 
observations and theoretical considerations support the possible involvement of diffusible 
molecules in cell-to-cell communication. Asexual bloodstream parasites responded to host-derived 
diffusible molecules (Lingnau et al., 1993; Maswoswe et al., 1985) and secreted a somatostatin-like 
hormone (Pan et al., 1987). Diffusible factors from log-phase asexual blood stages of P. falciparum 
stimulated their own growth and replication. The presence of the parasite was essential for growth 
regulation and the process was density-dependent (Dyer and Day 2003). Soluble factor(s) of 
unknown biochemical nature in parasite-CM stimulated gameto-cytogenesis in vitro (Coulson, Hall, 
and Ouzounis 2004). Monitoring of experimental human P. falciparum infections indicated the 
existence of a density-dependent stimulation mechanism of parasite growth in humans since 
parasite growth accelerated from logarithmic (days 1 – 4) to an above logarithmic rate (days 6 – 8) 
in malaria naïve subjects inoculated with an asexual blood-stage P. falciparum stabilate (Cheng et 
al., 1997). In studies of the longitudinal dynamics of multiple Plasmodium spp. infections in semi-
immune, asymptomtic children in Papua New Guinea, the total parasite density of Plasmodium spp. 
oscillated around a distinct threshold distinct from the fever threshold. The authors concluded that 
malaria parasitemia might be controlled in a density-dependent manner and that additionally cross-
species mechanisms of parasite density regulation might exist (Bruce et al., 2000b; Snounou 2004). 
Since it is well known that acquired immunity to Plasmodium infections is both species- and 
genotype-specific (Bruce et al., 2000a), a different mechanism could be responsible for the 
observed species-transcending nature of the density-dependent regulation. Whether the stable 
parasite density is driven by a host-derived, innate immune mechanism like nitric oxide production 
or by parasite-derived mechanisms remained so far unclear (Kwiatkowski 1995). Uncontrolled 
proliferation of P. falciparum asexual blood stages will result in host death, sometimes before the 
parasite can be transferred to the insect vector. Hence, one could hypothesize that the parasite might 
not rely exclusively on the host immune system to control its growth. The asexually proliferating 
parasite could regulate its density directly by (i) the rate of cell division; (ii) the rate of RBC 
invasion and (iii) the rate of cell death (Deponte and Becker 2004). Assuming that parasite derived 
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mechanisms limit the density of the parasites, then the questions arise like (i) what might be the 
physiological substrate for this cell-to-cell communication, (ii) does it resemble the QS mechanisms 
described in other organisms and (iii) which proteins are regulated by these factor(s)?   
 In recent years, there have been several reports of QS-like phenomena in fungal species. 
Intriguingly, each of these cases involved a morphological transition from a filamentous, mycelial 
form to a yeast form, or vice versa. Whether this apparent theme represents the most common 
application of QS in eukaryotes, or the limited search for QS in eukaryotes, is not known. The 
characterisation of components of CM mediating PDCP up-regulation may lead to elucidation of 
possible mechanisms of cell-to-cell communication and development regulation in P. falciparum.  
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Figures 
 
Fig. 1. Multiple amino acid sequence alignment of N-terminus of PDCP orthologues with the 
three zinc finger motifs (CCCH type) boxed. Sequences were aligned using CLUSTAL W (1.83) 
and included  P. chabaudi (PC000922.02.0), P. yoelii (MALPY00805), P. berghei (AY293729), P. 
knowlesi (pkn2318a12.pk1), P. vivax (Pv117045), Theileria parva (TP01_0814), T. annulata 
(TA05800), Cryptosporidium parvum (EAK88000.1) and C. hominis (AAEL01000292). (*) 
conserved residues and positions of the conserved cysteine and histidine amino acid residues are 
boxed. Databases searched included http://www.sanger.ac.uk, http://www.tigr.org, 
http://www.ncbi.nlm.nih.gov and http://plasmodb.org (August 2007).  
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Fig. 2A. Co-cultivation of 2 % P. falciparum cultures with cell-free conditioned medium 
results in PDCP up-regulation. Synchronized schizonts grown to 2 % and 10 % densities were 
analyzed by IFA with mAb D13.3 and D13.31. In parallel, 2 % cultures that were incubated for 48 h 
(starting from ring stages) with 1:100 and 1:1000 final dilutions of conditioned medium were 
stained and analysed. In the negative control, the secondary antibody only was applied to 10% 
parasite cultures. Parasite DNA staining with Hoechst 33258 is given in blue.  
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Fig. 2B. Relative quantification of PDCP expression after cultivation of schizonts at different 
densities. Synchronized schizonts grown to 2 % (white bars) and 10 % (grey bars) densities were 
stained for PDCP expression using mAb D13.26 and D13.44. Cells were analyzed by laser scanning 
confocal microscopy as described in materials and methods. The average mean intensity values 
after subtracting the background signals (mean fluorescence intensity of cells incubated with 
secondary antibody only) for each cell population are shown. The difference in expression level of 
PDCP assessed with both mAb was statistically significant (p < 0.001). 
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Fig. 3A. Two-chamber co-cultivation of P. falciparum asexual blood stages. Synchronized 2 % 
P. falciparum cultures were either cultivated with 2 % parasites (I) in a co-cultivation chamber or 
(II) with 10 % parasite cultures for 48 h starting at ring stages. Cells were removed and stained with 
Hoechst 33258 (binding to parasite DNA) or subjected to IFA using mAb D13.44. 
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Fig. 3B. Relative quantification of PDCP after trans-well co-cultivation experiments. 
Synchronized schizonts were co-cultivated in a trans-well chamber at 2 % with parasite populations 
grown to 2 % (white bars) or 10 % densities (grey bars) at the end of the cultivation period. Cells 
were removed from culture and stained with mAb D13.26 and D13.44. Schizonts were analyzed by 
laser scanning confocal microscopy and the average mean intensity values after subtracting the 
background signals (mean fluorescence intensity of cells incubated with secondary antibody only) 
for each cell population are shown. The difference in expression level of PDCP assessed with both 
mAb was statistically significant (p < 0.001). 
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Fig. 4A. Analysis of PDCP mRNA expression levels by Northern blot analysis. Cultures given 
in Figure 2A were used for RNA extraction. Untreated 2 % cultures, cultures treated with 1:100 
dilutions of CM and 10 % parasite cultures are given in (A), (B) and (C), respectively. Equal 
amounts of extracted total RNA was separated by agarose gel electrophoresis (II) and then blotted 
onto nylon membrane and hybridized to [a-32P]-dCTP-labelled probe corresponding to the 5'-
terminal 422-bp fragment of PDCP (I). Size markers are given on the left.  
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Fig. 4B. Quantitative RT-PCR analyses of PDCP in 2 % and 10 % parasite cultures. RT-PCR 
products derived from 2 % (i), (ii) and 10 % (iii), (iv) P. falciparum cultures are shown. In (i) and 
(iii) 18S rRNA was amplified yielding an unique product of 482 base pairs,  while in (ii) and (iv) 
PDCP was amplified as a product of 565 base pairs. Lane numbers correspond to the cycle number 
at which the PCR tube was removed from the PCR machine. The underlined numeral marks the 
cycle number at which the RT-PCR products became observable in the 1 % agarose gel stained with 
ethidium bromide. Molecular weight marker (M) is given on the left.   
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